2001

MedMira Receives "Review Complete" Notification from U.S. Food and Drug Administration for Reveal(TM) HIV Test: PRNewswire - December 27, 2001; HALIFAX, NS, Dec. 27 /PRNewswire/ - MedMira announced today that it has received official notification from the U.S. Food and Drug Administration ( FDA ) that it has completed its review on the Pre-Market Approval application for the MedMira Reveal(TM) HIV Test. The FDA has no further questions in relation to the pre-c
Doctors Sue NIH Over Controversial Cat Experiments: PRNewswire - December 27, 2001; WASHINGTON, Dec. 27 /PRNewswire/ -- The Physicians Committee for Responsible Medicine (PCRM) filed a lawsuit today against the federal National Institutes of Health (NIH) for concealing information about a controversial experiment involving live cats at Ohio State University (OSU) in Columbus. The experiments, conducte
AIDS Activist Larry Kramer Recovering Following Liver Transplant Surgery; Transplant Brings Focus to Issue of Co-Infection in Patients with HIV: PRNewswire - December 24, 2001; PITTSBURGH -- Larry Kramer, acclaimed writer and renowned AIDS activist, underwent liver transplant surgery on Dec. 21 at the University of Pittsburgh Medical Center (UPMC). Kramer, who has human immunodeficiency virus (HIV), needed the life-saving transplant because of end-stage liver failure caused by hepatitis B.
Visible Genetics' Trugene Genotyping Technology Effective for Hepatitis B and C: PRNewswire - December 19, 2001; TORONTO, Dec. 19 /PRNewswire/ -- Visible Genetics Inc. (VGI, Nasdaq: VGIN) today presented results of comparative studies using its TRUGENE(TM) Hepatitis B virus (HBV) and Hepatitis C virus (HCV) genotyping tests at the international HEP-DART meeting in Hawaii. The results of one study demonstrated that the TRUGENE HBV
Studies Presented by Tibotec-Virco at ICAAC Highlight Promising Results in the Development of New HIV Therapeutic Compounds and the Increasing Importance of Resistance Testing: PRNewswire - December 18, 2001; CHICAGO, Dec. 18 /PRNewswire/ -- Significant progress in the discovery and development of novel HIV therapeutics as well as the relevance of resistance testing systems in HIV management were highlighted by Tibotec-Virco scientists at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). The
Female Health Company Announces Agreement: Total Access Group Gets Regional Exclusivity for Public Sector Sales: PRNewswire - December 18, 2001; CHICAGO, Dec. 18 /PRNewswire/ -- The Female Health Company (OTC Bulletin Board: FHCO) and Total Access Group (TAG) announced the appointment of Total Access Group as an exclusive distributor for Public Sector sales in 15 states in the western U.S. The objective is to increase access of FC to women most in need in areas
New Protease Inhibitor Atazanavir Combined With Saquinavir Once-Daily Is Effective and Safe In Protease Inhibitor Experienced Patients First Atazanavir Data in Experienced Patients; Beneficial Effects on Lipid Profiles: PRNewswire - December 18, 2001; CHICAGO, Dec. 18 /PRNewswire/ -- New data shows that the investigational protease inhibitor atazanavir can be used safely and effectively with saquinavir as part of a combination regimen in protease inhibitor-experienced HIV infected individuals, and that this regimen is similar in efficacy to one that includes
New Data Show Trugene(TM) HIV Resistance Test May Be Useful in 'Early Failures' and Before Treatment Is Started: PRNewswire - December 18, 2001; TORONTO, Dec. 18 /PRNewswire/ -- Visible Genetics Inc., (Nasdaq: VGIN) (VGI) announced that data presented today at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Chicago indicate that Visible Genetics TRUGENE(TM) HIV-1 Genotyping Test can be used to detect HIV drug resistance even
Boehringer Ingelheim Presents Late-Breaking Data on Tipranavir, First Non-Peptidic Protease Inhibitor (NPPI): PRNewswire - December 18, 2001; CHICAGO, Dec. 18 /PRNewswire/ -- Data presented today demonstrate the antiretroviral activity of tipranavir in HIV-positive patients whose first protease inhibitor (PI)-containing regimen was failing. Tipranavir is the first non-peptidic protease inhibitor (NPPI) in development for the treatment of HIV-1 infection.
ViroLogic Announces New Study with Phenosense(TM) HIV Reveals Higher Than Expected Rate of HIV Drug Resistance In United States: Widespread Drug Resistance Supports Need for More Drug Resistance Testing: PRNewswire - December 18, 2001; SOUTH SAN FRANCISCO, Calif. and CHICAGO, Dec. 18 /PRNewswire/ -- ViroLogic, Inc. (Nasdaq: VLGC) announced today that the first national assessment of HIV drug resistance has revealed that 78 percent of HIV patients with measurable levels of virus in their blood are infected with an HIV strain that is resistant to one o
FDA Completes IND Review for Tibotec-Virco's Candidate Anti-HIV Drug, TMC125: Tibotec-Virco To Initiate Phase I Clinical Trial in the U.S.: PRNewswire - December 18, 2001; MECHELEN, Belgium , Dec. 18 /PRNewswire/ -- Tibotec-Virco announced that the U.S. Food and Drug Administration ( FDA ) has completed its review of the company s Investigational New Drug application (IND) for its candidate drug. TMC125 is a novel next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI).
Encouraging Resistance Data in Anti-Retroviral Naive Patients Extended To Two Years For Abbott Laboratories' Kaletra (lopinavir/ritonavir) - Additional Kaletra Clinical Trials to Study Resistance Profile Underway -: PRNewswire- -December 18, 2001; CHICAGO, Dec. 18 /PRNewswire/ -- Data presented today at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy in Chicago shows drug resistance has yet to emerge in naive patients who have been taking Kaletra for 96 weeks. The study of patients new to HIV therapy showed that of those who experienced
Progenics' Experimental Drug, PRO 140, Provided Complete and Sustained Control Of HIV Infection In Vivo - Company's HIV Entry Inhibitors PRO 542 and PRO 140 Featured In Keynote Session At Major Scientific Conference -: PRNewswire - December 18, 2001; CHICAGO, Dec. 18 /PRNewswire / -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) reported that repeated doses of its experimental drug, PRO 140, reduced and then maintained viral loads at undetectable levels for the duration of therapy in a well-recognized animal model of HIV (human immunodeficiency virus) infection. S
New Study Suggests Suppressive Therapy With VALTREX(R) (Valacyclovir Hydrochloride) Caplets Once-A-Day Can Significantly Reduce Genital Herpes Outbreaks by Nearly 80 Percent Compared to Episodic Therapy: PRNewswire - December 17, 2001; CHICAGO, Dec. 17 /PRNewswire/ -- New research presented today at ICAAC suggests that managing recurrent genital herpes with VALTREX caplets for suppressive therapy -- treating daily before symptoms ever appear -- is significantly more effective at reducing the number of genital herpes recurrences or outbreaks than tr
Cangene files for anti-Hepatitis B product approval in Canada: PRNewswire - December 17, 2001; TORONTO/WINNIPEG, Dec. 17 /PRNewswire/ - Cangene Corporation (TSE:CNJ) announces that it has filed a New Drug Submission for its anti-Hepatitis B hyperimmune in Canada . The submission follows a U.S. licensing application filed earlier this year, and seeks Health Canada (Health Products and Food Branch) approval for us
Novirio Pharmaceuticals Announces Results From First Human Study of LdT for the Treatment of Hepatitis B Infection - Phase I/II Data Presented at the Interscience Conference On Antimicrobial Agents and Chemotherapy (ICAAC) -: PRNewswire - December 17, 2001; CHICAGO, Dec. 17 /PRNewswire/ -- Novirio Pharmaceuticals yesterday announced at the 41st ICAAC Conference in Chicago results from the first human study of LdT, the company s new treatment for chronic hepatitis B virus (HBV) infection. Study results indicate rapid and profound reduction of hepatitis B virus replication
VaxGen to Present at Bay Area Biotech/Healthcare Forum on January 12, 2002: PRNewswire - December 17, 2001; BRISBANE, Calif., Dec. 17 /PRNewswire/ -- VaxGen , Inc. (Nasdaq: VXGN) will be among the companies featured at the Informed Investors Bay Area Biotech/Healthcare Forum on Saturday, January 12, 2002. The presentation will take place at 10:00 a.m. (PST) at the Radisson Hotel Berkeley Marina, 200 Marina Blvd., Berkeley, C
Achillion Pharmaceuticals Presents Phase 1 Data of ACH-126,443 at the 41st Annual ICAAC Conference - Lead Compound for the Treatment of Chronic Hepatitis B and HIV Infections: PRNewswire - December 17, 2001; NEW HAVEN, Conn., Dec. 17 /PRNewswire/ -- Achillion Pharmaceuticals, a privately held pharmaceutical company focused on the discovery, development and commercialization of innovative anti-infective agents, presented Sunday at the 41st annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Achi
Study Compares PROCRIT(R) (Epoetin alfa) Once-Weekly vs. Three-Times-Weekly Dosing in Anemic HIV-Positive Patients on Antiretroviral Therapy: PRNewswire - December 17, 2001; CHICAGO, Ill., Dec. 17 /PRNewswire/ -- The results of an interim analysis of an open-label study to assess the effect of once-weekly (QW) dosing of PROCRIT(R) (Epoetin alfa) versus three-times-weekly (TIW) dosing in HIV- positive patients receiving antiretroviral therapy were presented today at the 41st annual meeting
amfAR Grantee Dr. Richard Kornbluth Receives GlaxoSmithKline Award for Breakthrough Idea in HIV/AIDS Treatment: PRNewswire - December 17, 2001; NEW YORK, Dec. 17 /PRNewswire/ -- On December 14, 2001, American Foundation for AIDS Research (amfAR) grantee, Richard Kornbluth, M.D., Ph.D., received a GlaxoSmithKline Drug Discovery and Development Award for developing a test to measure HIV integration, or the means by which HIV inserts itself into the genes of cell
Dynacare Offers Breakthrough Test to Help Doctors Find Better Treatment Options for HIV Patients: New Test Identifies Each Patient's Specific Type of HIV Infection; Leads To More Effective Drug Therapy Program: PRNewswire - December 17, 2001; DALLAS, Dec. 17 /PRNewswire/ -- Dynacare Inc. (Nasdaq: DNCR; Toronto: DNA) announced today that it is now offering a new genotyping test to help doctors find better treatment options for their patients affected with the human immunodeficiency virus (HIV). The test, TRUGENE (TM) HIV-1 Genotyping Test, is manufactured by
University of Pittsburgh and Pittsburgh VA Receive $8 Million To Study Alcohol and HIV Interactions: PRNewswire - December 17, 2001; PITTSBURGH, Dec. 17 /PRNewswire/ -- Alcohol is the most common drug of abuse among people infected with HIV. To study how alcohol use and abuse interacts with HIV infection and treatment, the University of Pittsburgh and the Pittsburgh Veterans Administration Medical Center have received an $8 million grant from the Na
Celebrities Join AIDS Project Los Angeles and Soolip Paperie & Press For Holiday Card Campaign: Peri Gilpin, Sean Hayes, Imitation of Christ, Betsey Johnson, Lucy Liu, Valerie Rae Miller, Meryl Streep and Hilary Swank Donate Designs: PRNewswire - December 14, 2001; LOS ANGELES, Dec. 14 /PRNewswire/ -- Peri Gilpin, Sean Hayes, Imitation of Christ, Betsey Johnson, Lucy Liu, Valerie Rae Miller, Meryl Streep and Hilary Swank designed the artwork for AIDS Project Los Angeles (APLA) 2001 holiday card campaign. Created through a partnership with Soolip Paperie & Press, the holiday c
Emerging Company Report; Patented HIV Treatment Showing No Side Effects in Trials: PRNewswire - December 14, 2001; HOLLYWOOD, Calif., Dec. 14 /PRNewswire/ -- Emerging Company Report is the nationally syndicated television program profiling emerging-growth companies ( http://www.emergingcompany.com ), featuring informative interviews with the CEOs, insights into their operations and outlooks for their futures. Free information packa
$250,000 in Unrestricted Grants From GlaxoSmithKline Support Breakthroughs In HIV/AIDS Treatment: PRNewswire - December 14, 2001; RESEARCH TRIANGLE PARK, N.C., Dec. 14 /PRNewswire/ -- A program awarding $250,000 in unrestricted grants to support innovations in the treatment or prevention of HIV-1 was announced today by GlaxoSmithKline (GSK). The GSK Drug Discovery and Development Award 2001 honors three researchers for their groundbreaking work t
Antiviral Summit to Feature New Section on Latest Vaccine Research, March 13-14, Princeton NJ: PRNewswire - December 13, 2001; PRINCETON, N.J., Dec. 13 /PRNewswire/ -- The world of antiviral researchers and clinical experts from the pharma & biotech industry will be convening in Princeton, NJ to attend, speak, & exhibit at the 3rd International Antiviral & Vaccine Discovery & Development Summit announces Strategic Research Inst
New Partnership to Accelerate AIDS Vaccine Testing, Equip Developing Countries for Trials: International AIDS Vaccine Initiative Opens Central Laboratory With Imperial College and Chelsea and Westminster Hospital: PRNewswire - December 13, 2001; LONDON, Dec. 13 /PRNewswire/ -- A new international public-private partnership will help ensure that promising candidates for a vaccine to prevent AIDS advance rapidly through human testing and that developing countries -- particularly in Africa and Asia -- have the supplies and training needed to conduct their own vac
MAC Cosmetics Announces Elton John, Mary J. Blige and Shirley Manson as the New Spokespeople for VIVA GLAM IV Lipstick and the MAC AIDS Fund: PRNewswire - December 13, 2001; NEW YORK, Dec. 13 /PRNewswire/ -- MAC Cosmetics, the rule-breaking professional cosmetics company, announced today music legend and outspoken AIDS activist Elton John, Grammy Award winner Mary J. Blige and rock icon Shirley Manson of the band Garbage have been named the spokespeople for VIVA GLAM IV lipstick. Since its
AIDS ReSearch Alliance of America Announces Landmark Agreement to Share Drug Revenues With Samoan Village Healers - Promising Rain Forest-Derived Anti-AIDS Compound Is First Ever Licensed by National Cancer Institute to a Non-Profit Research Institution: PRNewswire - December 13, 2001; WEST HOLLYWOOD, Calif., Dec. 13 /PRNewswire/ -- AIDS ReSearch Alliance of America (ARA) today announced a landmark agreement to return 20 percent of any commercial revenues from an experimental but promising anti-HIV compound called prostratin to the people of Samoa who helped American resea
ViroLogic Announces Schedule of Presentations at the 41st Interscience Conference on Antimicrobial Agents and ChemotherapyCompany to Hold Conference Call to Discuss Impact of Latebreaker Study Results: PRNewswire - December 12, 2001; SOUTH SAN FRANCISCO, Calif., Dec. 12 /PRNewswire/ -- ViroLogic, Inc. (Nasdaq: VLGC) today announced the presentation of four abstracts including one latebreaker at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) taking place at the McCormick Place Lakeside Center from December 16-19, 2
Protein Sciences Announces Contact With The National Institute of Allergy and Infectious Diseases for Production of New HIV/AIDS Vaccines: Over $2 Million in Funding Already Approved and up to $76 Million Could Be Accessed: PRNewswire - December 12, 2001; MERIDEN, Conn., Dec. 12 /PRNewswire/ -- Protein Sciences Corporation (PSC) announced today that it has signed a contract with the National Institute of Allergy and Infections Diseases (NIAID) that provides for up to $76 million in funding through mid-2006 for development and production of antigens for new vaccines for
Gold Fields Signs Landmark Agreements on HIV/AIDS in the Workplace and Competencies and Job Grading With Unions and Associations: PRNewswire - December 12, 2001; JOHANNESBURG, South Africa , Dec. 12 /PRNewswire/ -- Gold Fields Limited today signed landmark agreements on HIV/AIDS in the Workplace and Competencies and Job Grading with Unions and Associations representative of Gold Fields employees. The agreement on HIV/AIDS In The Workplace, which is a comprehensive response to H
WDI Expands Distribution and Sales in South Africa: Provides Healthcare Screening for Private Sector Companies: PRNewswire - December 11, 2001; MIAMI LAKES, Fla., Dec. 11 /PRNewswire/ -- World Diagnostics, Inc. (WDI), http://www.worlddiagnostics.com, a global provider of medical diagnostic tests and specialized laboratory products for the international marketplace, announced today that its local distributor in Durbin has concluded agreements with AFROX, NAMPAK
Kaiser Family Foundation Survey: More Young People Going Online for Health Information Than to Shop, Check Sports Scores or Chat: Many Teen Health Seekers Blocked by Filtering Technology, but Two-Thirds Support It in Schools and Libraries: PRNewswire - December 11, 2001; NEW YORK, Dec. 11 /PRNewswire/ -- A new national survey by the Kaiser Family Foundation finds teens and young adults (ages 15-24) are not only going online to shop, talk to friends, or download music, but also to look up information about health issues from diabetes to AIDS. Two out of three young people (68%) have use
Gen-Probe and Chiron Settle Contractual Dispute: PRNewswire - December 11, 2001; SAN DIEGO, Dec. 11 /PRNewswire/ -- Gen-Probe Incorporated announced today that it and Chiron Corporation (Nasdaq: CHIR) have reached a negotiated resolution of all contractual disputes which were proceeding towards arbitration. This resolution was reached prior to the commencement of formal arbitration proceedings, whi
Hopkins Report: Youth Crucial to Stopping HIV/AIDS: PRNewswire - December 10, 2001; BALTIMORE, Dec. 10 /PRNewswire/ -- To stop the HIV/AIDS epidemic from becoming a catastrophe, prevention strategies must do much more to reach young people right away, according to a new report from the Johns Hopkins University Bloomberg School of Public Health. The Hopkins call for a youth-centered strategy follows gr
MedMira Amends Treatment Investigational Device Exemption: PRNewswire - December 7, 2001; HALIFAX, Dec. 7 /PRNewswire/ - MedMira announced it is in the process of filing an amendment to its current Food and Drug Administration ( FDA ) approved Treatment Investigational Device Exemption ( TIDE ) to include rapid HIV screening prior to smallpox vaccination. Increasing fear of bioterrorist actions involving th
Elizabeth Glaser Pediatric AIDS Foundation's Global Program to Prevent Mother-to-Child Transmission of HIV to Serve as Pilot Sites For New Initiative to Treat Women and Children With HIV/AIDS: PRNewswire - December 7, 2001; Elizabeth Glaser Pediatric AIDS Foundation Congratulates the Private Foundations for Their Unprecedented Collaboration and Expected $100 Million Commitment to MTCT-Plus WASHINGTON, Dec. 7 /PRNewswire/ -- The Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) commends the private foundations expected to commit $100 mill
ViroLogic Announces Distribution Agreement with Esoterix for HIV Phenotypic Drug Resistance Testing: Leading Laboratory Service To Offer ViroLogic's HIV Phenotypic Line of Tests: PRNewswire - December 6, 2001; SOUTH SAN FRANCISCO, Calif., Dec. 6 /PRNewswire/ -- ViroLogic, Inc. (Nasdaq: VLGC) today announced the Company has signed a distribution and marketing agreement with Esoterix Inc., a leading, privately held laboratory services company. ViroLogic will be the preferred provider of HIV phenotypic drug resistance testing f
CEL-SCI Corporation Announces Publication of Promising Preclinical Results: PRNewswire - December 5, 2001; VIENNA, Va., Dec. 5 /PRNewswire/ -- CEL-SCI CORPORATION (Amex: CVM) announces the peer-reviewed publication of important work in VACCINE (19(32) 4750-9). In the article, the researchers demonstrated that animals given CEL-SCI s experimental L.E.A.P.S. based HIV vaccine agent, showed strong evidence supporting the induc
Alicia Keyes, Gwen Stefani, Eve, *NSYNC and Other AAAW Supporters Put Global AIDS Pandemic as a #1 Priority for US Politicians at the Billboard Awards: PRNewswire - December 4, 2001; LAS VEGAS, Dec. 4 /PRNewswire/ -- Hot on the heels of its award for Best Collaboration at the VH1 Awards, Artists Against AIDS Worldwide is taking its call for urgent action to The Billboard Bash and Music Awards, to mark World AIDS Day. The message to the general public and politicians is clear: We have the know-how a
Lannett Company Receives FDA Approval for Isoniazid 300 mg Tablets: Used to treat Tuberculosis and as a preventative therapy for HIV: PRNewswire - December 4, 2001; PHILADELPHIA, Dec. 4 /PRNewswire/ -- Lannett Company, Inc. (OTC Bulletin Board: LANN), a manufacturer of pharmaceutical products, announced that the Food and Drug Administration has re-approved its Abbreviated New Drug Application (ANDA) for Isoniazid 300 mg tablets, which is an antibacterial drug used for Tuberculosis
Antibacterial, Antifungal, & Antiviral Drug Discovery Conferences To Take Place March 11-14, 2002 in Princeton, NJ: PRNewswire - December 3, 2001; PRINCETON, N.J., Dec. 3 /PRNewswire/ -- The World Antibacterial, Antifungal, & Antiviral research communities will convene in Princeton, NJ this coming March to attend the 7th Antibacterial Drug Discovery & Development Summit on March 11-12, and the 6th Antifungal Drug Discovery & Development Summit and 3rd
Pennsylvania Gov. Schweiker Administration Adds HIV Drug To Special Pharmaceutical Benefits Program: PRNewswire - December 3, 2001; HARRISBURG, Pa., Dec. 3 /PRNewswire/ -- On behalf of Pennsylvania Gov. Mark Schweiker, Public Welfare Secretary Feather O. Houstoun today announced the addition of Viread ( tenofovir disoproxil fumarate) to the HIV/AIDS drug formulary of the state s Special Pharmaceutical Benefits Program (SPBP
HUD Awards $6 Million to Assist People and Families Living With HIV/AIDS: PRNewswire - December 3, 2001; WASHINGTON, Dec. 3 /PRNewswire/ -- More than a thousand persons living with HIV/AIDS and their families will receive critically needed housing assistance and supportive services as a result of grants announced today by Housing and Urban Development Secretary Mel Martinez. The grants are part of HUD s Housing Opportunit
Black Media Launch Task Force to Respond to AIDS: AAAPTI Also Launches 'Heroes in the Struggle' Photo Exhibit: PRNewswire - December 1, 2001; LOS ANGELES, Dec. 1 /PRNewswire/ -- In an unprecedented commitment to the fight against AIDS, executives from the nation s leading black media companies today announced the formation of the Black Media Task Force on AIDS, a collaborative effort to increase AIDS awareness among the African-American community, and fight
Fusebox Launches Web Site Designed to Help Save the World's Youth: PRNewswire - November 30, 2001; NEW YORK, Nov. 30 /PRNewswire/ -- Fusebox has just launched a website for YouthAIDS (http://www.youthaids.org), a global initiative of Population Services International (PSI) to raise funds and awareness to stop the spread of HIV/AIDS among young people. Through education and the promotion and sale of affordable male a
Haiti: Inter-American Development Bank Continues to Block Health Loans - Approves Grant to NGO for HIV/AIDS: PRNewswire - November 30, 2001; WASHINGTON, Nov. 30 /PRNewswire/ -- Yesterday the Inter-American Development Bank approved a $1 million grant to the Pan American Health Organization (PAHO) for technical assistance to Haiti in the area of HIV/AIDS. On its face this grant would seem like the proper response to a growing and dramatic health crisis, but
World AIDS Day Announcement: The Balm In Gilead Launches International Program to Engage Churches in Six African Countries in Addressing AIDS: Nation's Only AIDS Organization Targeting Black Churches Now Expands Its Work To Churches in Sub-Saharan Africa: PRNewswire - November 30, 2001; NEW YORK, Nov. 30 /PRNewswire/ -- For World AIDS Day 2001, The Balm In Gilead, the nation s only organization dedicated exclusively to empowering churches to address HIV/AIDS in the Black community, announces the launch of its new international faith-based initiative. With funding from the Centers for Disease Control a
New Database on HIV/AIDS Nutrition with Soy Now Available on Internet: Soybean Farmers Offer Information in Conjunction with World AIDS Day: PRNewswire - November 30, 2001; ST. LOUIS, Nov. 30 /PRNewswire/ -- America s soybean growers are launching a new searchable database that will provide a rapid way to evaluate nutrition research and programs using soy for those living with HIV/AIDS. The database includes an annotated listing of citations. It can be searched at the website for the Worl
CONTINUOUS PROGRESS TO ADDRESS THE AIDS EPIDEMIC: Axios Celebrates World AIDS Day with Boehringer Ingelheim as Ukraine Becomes the First Country in Eastern Europe to Join the VIRAMUNE� Donation Program: PRNewswire - November 30, 2001; Dublin, Ireland , 30 November 2001 - On World AIDS Day 2001, Axios International reports on the successful progress of its partnership with Boehringer Ingelheim to address the HIV/AIDS epidemic in the developing world. The latest shipment of VIRAMUNE� was handed over to the
Stressgen announces robust HPV data from multiple Phase II clinical trials: Aggregate Data Support Broad Activity of HspE7 in Sexually Transmitted Diseases Caused by Human Papillomavirus: PRNewswire - November 29, 2001; VICTORIA, BC, Nov. 29 /PRNewswire/ - Stressgen Biotechnologies Corporation (TSE: SSB) announced the latest results compiled from six data sets from five key phase II clinical trials involving its lead fusion product, HspE7, a novel immunotherapeutic for the treatment of diseases caused by the human papillomavirus (HPV)
New TB Drugs Needed Alongside Antiretrovirals: Joint Approach of HIV and TB a 'Must,' As TB is Number 1 Killer of AIDS Patients: PRNewswire - November 29, 2001; NEW YORK, Nov. 29 /PRNewswire/ -- Fighting the converging epidemics of HIV/AIDS and tuberculosis (TB) will require improved anti-TB drugs as well as wide access to antiretrovirals, with an integrated approach to treating both diseases, according to the Global Alliance for TB Drug Development, a public-private partnersh
Female Health Signs Agreement for India: Major Marketer Plans to Register and Market Female Condom: PRNewswire - November 29, 2001; CHICAGO, Nov. 29 /PRNewswire/ -- The Female Health Company (OTC Bulletin Board: FHCO) today announced that it signed an agreement with Hindustan Latex Limited (HLL), India s largest male condom manufacturer. HLL also manufactures and markets a wide range of hormonal contraceptives. The agreement was signed in London, a
NIH Grant Helps Population Council Advance Promising HIV/AIDS Prevention Research: Support for 'Novel Anti-HIV Carrageenan-based Microbicides' Research May Result in More Options for Women to Protect Themselves From Infections: PRNewswire - November 29, 2001; NEW YORK, Nov. 29 /PRNewswire/ -- The U.S. National Institute of Child Health and Human Development (NICHD) has awarded a grant of $6.8 million to the Population Council to further its research on a promising HIV/AIDS prevention product. The funding is aimed at developing improved second-generation microbicides and at
Epimmune and Bavarian Nordic Combine Technologies to Develop HIV Vaccine: PRNewswire - November 29, 2001; SAN DIEGO and COPENHAGEN, Denmark , Nov. 29 /PRNewswire/ -- Epimmune Inc. (Nasdaq: EPMN) and Bavarian Nordic A/S (Copenhagen: BAVA), announced today that they have entered into a collaboration agreement to combine their technologies to develop vaccines for the treatment or prevention of HIV infection.
PAMBEC Laboratories Inc. Unveils New Anti-AIDS Drug: PRNewswire - November 29, 2001; FORT COLLINS, Colo., Nov. 29 /PRNewswire/ -- PAMBEC Laboratories Inc., of Loveland, Colorado today announced the release of a new Anti-AIDS drug AIDFAREL(TM) using a new drug technology invented by the company. This new technology shows great promise in permanently stopping the human immunodeficiency virus-1 (HIV-1), w
Artist Unveils Giant Painting on World AIDS Day for Children: Nearly an Acre in Size, the 41,400 Sq Ft Painting To Be Sold in Pieces for Charities: PRNewswire - November 28, 2001; RALEIGH, N.C., Nov. 28 /PRNewswire/ -- After five long years of planning and painting, international artist Eric Waugh will unveil Hero: The World s Largest Painting by One Artist for the first and only time on World AIDS Day, Dec. 1, 2001, to raise $4 million for Camp Heartland, a national non profit organization dedi
New AIDS Orphans Assistance Database (AOAD) Launched Before World AIDS Day 2001: PRNewswire - November 28, 2001; WASHINGTON, Nov. 28 /PRNewswire/ -- The Association Francois-Xavier Bagnoud (AFXB) and the World Bank Early Child Development Team announced today the launch of the revised AIDS Orphans Assistance Database (AOAD). The purpose of the AOAD is to facilitate communication among organizations and individuals worldwide which
World AIDS Day At The United Nations, November 30: `I Care ... Do You?' Highlights The Role of Volunteerism In Addressing the Epidemic: PRNewswire - November 28, 2001; UNITED NATIONS, Nov. 28 /PRNewswire/-- The United Nations Department of Public Information (DPI) and the Joint United Nations Program on HIV/AIDS ( UNAIDS ) are organizing an observance of World AIDS Day on 30 November 2001, 10:00 a.m. to 1:00 p.m. The town-hall meeting, I Care ... Do You?, will focus on the initiativ
New VA Research Looks at Alcohol and HIV Interaction: PRNewswire - November 27, 2001; WASHINGTON, Nov. 27 /PRNewswire/ -- Six medical centers of the Department of Veterans Affairs (VA) are joining forces in a major study to look at how excessive drinking impacts aging veterans with and without HIV (Human Immunodeficiency Virus) infection. Funded by the National Institute on Alcohol Abuse and Alcoholism
Americans are the World's Top Lovers... About 124 Times Each Year; The Fall 2001 Durex(R) Global Sex Survey Reveals That Americans are Having More Sex But Also Taking Risks: PRNewswire - November 27, 2001; ATLANTA, Nov. 27 /PRNewswire/ -- Americans are having sex more often, an average of 124 times per year, than people living anywhere else in the world according to this year s Global Sex Survey by Durex(R). And, the survey found that Americans have more partners, an average of 14.3, beating out the other world-leaders,
bioMerieux Receives PMA Approval for HIV-1 Viral Load Assay To Aid in Prognosis and Therapeutic Monitoring: PRNewswire - November 26, 2001; DURHAM, N.C., Nov. 26 /PRNewswire/ -- bioMerieux, Inc. has received Premarket Approval (PMA) from the United States Food and Drug Administration ( FDA ) for its NucliSens(R) HIV-1 QT quantitative viral load assay. Using the firm s proprietary Nucleic Acid Sequence-Based Amplification (NASBA) technology, the test identi
New Clinic to Offer Patient Tailored HIV Therapy; Minnesota Comprehensive Care Center Announces Grand Opening: PRNewswire - November 26, 2001; ROSEVILLE, Minn., Nov. 26 /PRNewswire/ -- Minnesota Comprehensive Care Center is celebrating its grand opening with an open house on Friday, November 30, from 3:00 p.m. to 7:00 p.m. Speakers include: Dr. Ron Falcon, Director, Minnesota Comprehensive Care Center and pioneer in patient tailored HIV therapy; Dr. Keith Hen
International AIDS Treatment Advocates Convene in Canada: Historic Conference Brings Together HIV/AIDS Treatment Experts From U.S., Canada, Mexico & Eastern Europe: PRNewswire - November 21, 2001; WASHINGTON, Nov. 21 /PRNewswire/ -- AIDS activists and workers from across North America will convene in Vancouver from December 2-5 for the 2001 North American AIDS Treatment Action Forum (NATAF). NATAF will bring together individuals from the United States , Canada , Mexico
WDI Receives Certification for Key Diagnostic Tests in Uganda -- Paves Way for Growth in Sales --: PRNewswire - November 20, 2001; MIAMI LAKES, Fla., Nov. 20 /PRNewswire/ -- World Diagnostics, Inc. (OTC Bulletin Board: WDGI) (WDI), http://www.worlddiagnostics.com, a global provider of medical diagnostic tests and specialized laboratory products for the international marketplace, announced today that it has received certification for its rapid HIV,
Atrix Submits Investigational New Drug Application to Test Oral Interferon In HIV-Related Condition: PRNewswire - November 19, 2001; FORT COLLINS, Colo., Nov. 19 /PRNewswire/ -- Atrix Laboratories, Inc. (Nasdaq: ATRX) announced today that the company has submitted an Investigational New Drug application (INDA) to the U.S. Food and Drug Administration ( FDA ) to proceed into human clinical studies with a low dose oral interferon-alpha product for the
Endocrine Disorders Complicate Treatment for HIV Infection, Says American Association of Clinical Endocrinologists: PRNewswire - November 16, 2001; JACKSONVILLE, Fla., Nov. 16 /PRNewswire/ -- A new study, which may be found at http://www.aace.com/pub/ep/EP00111.pdf, indicates that a combination of chronic diseases is now a major problem in the treatment of many patients with HIV infection, and that some of these diseases are going untreated. A study entitled Syndr
ViroLogic Launches First Combination HIV Drug Resistance Test to Provide Phenotypic and Genotypic Information on a Single Report: PRNewswire - November 15, 2001; SOUTH SAN FRANCISCO, Calif., Nov. 15 /PRNewswire/ -- ViroLogic, Inc. (Nasdaq: VLGC) today announced that the Company has launched PhenoSense GT(TM), the first HIV drug resistance test to provide doctors with a single report on a patient s drug resistance profile using phenotypic test results supplemented by genotypic i
Progenics Awarded $1.2 Million for Development of Innovative HIV Therapies: PRNewswire - November 15, 2001; TARRYTOWN, N.Y., Nov. 15 /PRNewswire/ -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that it had been awarded approximately $1.2 million from the National Institutes of Health (NIH) for the development of novel inhibitors of HIV (human immunodeficiency virus) entry and infection. Entry inhibitors are
PhRMA: WTO Doha Declaration Reaffirms Value of Intellectual Property Protection: PRNewswire - November 14, 2001; WASHINGTON, Nov. 14 /PRNewswire/ -- America s pharmaceutical industry recognizes the importance of the political statement reached in Doha that explicitly maintains TRIPS Agreement rights and obligations reaffirming that intellectual property protection promotes public health by encouraging the discovery and developmen
VaxGen to Present at Informed Investors Virtual Biotechnology Stocks Forum on Nov. 17: PRNewswire - November 14, 2001; BRISBANE, Calif., Nov. 14 /PRNewswire/ -- VaxGen , Inc. (Nasdaq: VXGN) will be among the companies featured during the Informed Investors Virtual Biotechnology Stocks Forum on Saturday, Nov. 17. Lance Ignon, VaxGen s vice president of corporate communications, will present a company overview and respond to questions vi
World Diagnostics, Inc. Opens New Office in Brazil: Registers WDI Products for Sale to Brazilian Government Agencies: PRNewswire - November 13, 2001; MIAMI LAKES, Fla., Nov. 13 /PRNewswire/ -- World Diagnostics, Inc. (OTC Bulletin Board: WDGI), http://www.worlddiagnostics.com, an emerging global provider of medical diagnostic tests and specialized laboratory products for the international marketplace, announced today that it has established an office of World Diagno
Genelabs Technologies, Inc. Reports Third Quarter and Nine Month 2001 Financial Results: PRNewswire - November 13, 2001; REDWOOD CITY, Calif., Nov. 13 /PRNewswire/ -- Genelabs Technologies, Inc. (Nasdaq: GNLB) today reported revenues of $1.1 million and a net loss of $3.0 million, or $0.06 per share, for the quarter ended September 30, 2001, compared with revenues of $1.6 million and a net loss of $2.7 million, or $0.06 per share, for th
BioMedicines Presents Promising Results from Phase II Trials Of Omega Interferon for the Treatment of Hepatitis C: PRNewswire - November 12, 2001; DALLAS, Nov. 12 /PRNewswire/ -- BioMedicines, Inc. today announced positive results from two Phase II clinical trials employing the company s omega interferon for the treatment of patients chronically infected with the hepatitis C virus (HCV). The results from clinical trials conducted at the Scripps Institute in the
Malaria Parasites Cleared in Patients With Hollis-Eden Pharmaceuticals Immune Regulating Hormone: Company Presents Clinical Trial Results At 50th American Society of Tropical Medicine and Hygiene: PRNewswire - November 12, 2001; SAN DIEGO, Nov. 12 /PRNewswire/ -- Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH) today announced preliminary results from a Phase II study treating Plasmodium falciparum malaria-infected patients in Thailand with the Company s lead investigational drug candidate, HE2000, an immune regulating hormone. Within the 7-d
Schering-Plough Reports Results of Clinical Studies of PEG-INTRON(TM) And REBETOL(R) Combination Therapy For Hepatitis C at American Association for the Study of Liver Diseases Meeting: Data Presented On Wide Variety Of Patient Populations: PRNewswire - November 12, 2001; DALLAS, Nov. 12 /PRNewswire/ -- Schering-Plough Corporation (NYSE: SGP) today reported results of several clinical studies presented here at the 52nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) on PEG-INTRON(TM) (peginterferon alfa-2b) Powder for Injection in combination with REBE
HUD Awards Nearly $200 Million to Florida: PRNewswire - November 9, 2001; WASHINGTON, Nov. 9 /PRNewswire/ -- Housing and Urban Development Secretary Mel Martinez today announced communities across Florida will receive nearly $200 million in federal assistance to stimulate local economies, promote affordable housing and help the homeless and persons living with AIDS. These grants do so much g
Statement by Alan F. Holmer, President of Pharmaceutical Research And Manufacturers of America, on the Opening of the World Trade Organization Ministerial on American Pharmaceutical Companies' Commitment To Better Access to New Medicines: PRNewswire - November 9, 2001; WASHINGTON, Nov. 9 /PRNewswire/ -- The following is a statement by Alan F. Holmer, President of Pharmaceutical Research and Manufacturers of America: At the occasion of the World Trade Organization (WTO) Ministerial in Doha, Qatar , leading American research-based pharmaceutical companies take this opportunity to reaff
Empire Health Resources Announces Failure to Consummate Strategic Alliance with Hemispherx Biopharma: PRNewswire - November 9, 2001; NEW YORK, Nov. 9 /PRNewswire/ -- Empire Medical Resources, Inc., a privately held healthcare management firm, announced today that it has never entered an agreement regarding a strategic partnership with Hemispherx Biopharma, Inc. (Amex: HEB), a biopharmaceutical company specializing in the development of nucleic acids
Hollis-Eden Pharmaceuticals Presents Anti-Inflammatory Effects Of Immune Regulating Hormones: PRNewswire - November 8, 2001; SAN DIEGO, Nov. 8 /PRNewswire/ -- Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH) today announced data from three separate presentations at the Cytokine Odyssey 2001 meeting held this week in Maui, Hawaii. The presentations include clinical results with the Company s lead immune regulating hormone, HE2000, indicating
Christians and Aids: Christians From Six Continents to Meet in Washington, D.C., February 17-21 for Prescription for Hope Conference on Response to the AIDS Pandemic: PRNewswire - November 7, 2001; BOONE, N.C., Nov. 7 /PRNewswire/ -- Seeking a coordinated response to the international HIV/AIDS crisis, Christians from six continents will meet in Washington, D.C. Feb. 17-21, 2002, for an international Christian conference on HIV/AIDS, called Prescription for Hope. The conference is sponsored by international relief
New Hepatitis C Research Reported at Major Medical Meeting; Thirteen Abstracts on PEGASYS(R) (peginterferon alfa-2a) to be Presented: PRNewswire - November 7, 2001; DALLAS, Nov. 7 /PRNewswire/ -- PEGASYS (peginterferon alfa-2a) -- Roche s once-weekly, pegylated form of interferon that is being investigated for the treatment of hepatitis C -- will be the subject of 13 oral presentations and poster sessions at The American Association for the Study of Liver Disease (AASLD) meeting i
amfAR Founding Chairman Dr. Mathilde Krim to Receive The Africa-America Institute's Individual Vision and Achievement Award: PRNewswire - November 7, 2001; NEW YORK, Nov. 7 /PRNewswire/ -- On Tuesday, November 13, Dr. Mathilde Krim, Founding Chairman and Chairman of the Board of the American Foundation for AIDS Research (amfAR), will receive the Africa-America Institute s Award for Individual Vision and Achievement in New York City. Dr. Krim, who is a Life Trustee of the
AnorMED announces AMD-3100 mobilizes stem cells: Study Results to be Presented at Upcoming American Society of Hematology:Meeting December 10th 2001, Orlando Florida: PRNewswire - November 7, 2001; VANCOUVER, BC, Nov. 7 /PRNewswire/ - AnorMED Inc. (TSE: AOM ) announced today that results from a Phase I study in healthy volunteers demonstrate that its drug candidate AMD-3100, a CXCR4 chemokine inhibitor, rapidly mobilizes hematopoietic progenitor cells (stem cells) which are the precursors of mature blood cells ou
Skaggs Design Teams Up With AIDS Project Los Angeles to Raise Funds And Awareness Over the Holiday Season: PRNewswire - November 6, 2001; SAN FRANCISCO, Nov. 6 /PRNewswire/ -- Since 1982, the Los Angeles AIDS Project has been at the heart of AIDS and HIV awareness, contributing millions of dollars to developing educational outreach programs and direct support services to men, women and children living with HIV and AIDS. To continue its role in raising aw
Schweiker Administration Adds Schizophrenia Drug To Pharmaceutical Benefits Program: Five Medications for Schizophrenia Now Covered: PRNewswire - November 6, 2001; HARRISBURG, Pa., Nov. 6 /PRNewswire/ -- On behalf of Pennsylvania Gov. Mark Schweiker, Department of Public Welfare (DPW) Secretary Feather O. Houstoun today announced the addition of Geodon (ziprasidone), an atypical anti-psychotic medication used to treat schizophrenia, to the state s Special Pharmaceutical Benefits
ViroLogic Announces Third Quarter 2001 Financial Results:Patient Testing Business Continues to Grow Steadily; Third Quarter Revenue Temporarily Affected by Tragic Events of September 11th and Variability Of Clinical Trial Timing: PRNewswire - November 6, 2001; SOUTH SAN FRANCISCO, Calif., Nov. 6 /PRNewswire/ -- ViroLogic, Inc. (Nasdaq: VLGC) today reported financial results for the third quarter ended September 30, 2001. The Company reported revenue of $4.4 million for the quarter, an increase of 134 percent over revenue of $1.9 million for the same period in 2000. Third qua
NeoGenesis and Immusol Form HIV Drug Development Joint Venture: PRNewswire - November 6, 2001; SAN DIEGO and CAMBRIDGE, Mass., Nov. 6 /PRNewswire/ -- Immusol, Inc. and NeoGenesis Pharmaceuticals, Inc., a privately held biotechnology company, today announced that they will collaborate to discover small molecule drug candidates for the treatment of HIV. The agreement will bring together Immusol s well-established
Vical to Receive $3 Million Milestone Payment; Merck Advances HIV Vaccine Testing: PRNewswire - November 5, 2001; SAN DIEGO, Nov. 5 /PRNewswire/ -- Vical Incorporated (Nasdaq: VICL) announced today that it has received a $3-million payment from Merck & Co. , Inc. (NYSE: MRK), which has begun human testing of a prime-boost vaccine regimen that employs Vical s patented naked DNA non-viral gene delivery technology to combat human
Alexion Pharmaceuticals Acquires Worldwide Rights Related to Novel Immune System Targets - Monoclonal Antibodies Block Fundamental Human Immune System Components: PRNewswire - November 5, 2001; CHESHIRE, Conn., and NIJMEGEN, Netherlands , Nov. 5 /PRNewswire/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that it has acquired exclusive worldwide commercial rights related to newly discovered cell surface proteins, DC-SIGN, found exclusively on human dendritic cells and a related receptor, L-SIG
Viracept(R) Combination Therapy Demonstrates Durable Response Following Switch From An NNRTI-Based Regimen: Treatment Failure and Tolerability Cited Most Often as Reason for Switch from NNRTI -: PRNewswire - November 2, 2001; ATHENS, Greece , Nov. 2 /PRNewswire/ -- Agouron Pharmaceuticals, Inc. reported that VIRACEPT(R) (nelfinavir mesylate) provided a durable HIV viral load suppression, as well as an increase in CD4 cells, based on a multi-center, retrospective chart review of 234 patients living with HIV.
VIRACEPT(R) Combination Therapy Continues to Demonstrate Long Term Durability in Combating HIV After Four Years: PRNewswire - November 2, 2001; ATHENS, Greece , Nov. 2 /PRNewswire/ -- Agouron Pharmaceuticals, Inc. presented data from the long-term extension (LTE) phase of its pivotal study 511, examining immunologic reconstitution, efficacy and safety of VIRACEPT(R) (nelfinavir mesylate) in combination with
American Medical Laboratories Offers State-of-the-Art HIV Resistance Testing; Patient Care for HIV-Infected Individuals is Enhanced Significantly: PRNewswire - November 2, 2001; CHANTILLY, Va., Nov. 2 /PRNewswire/ -- American Medical Laboratories, Inc. (AML) announced today that it entered into an agreement with Virco Lab, Inc. of Rockville, MD to provide HIV Resistance Testing in addition to AML s HIV-1 Genotyping. AML will be able to offer clinicians Virco s VirtualPhenotype(TM) test and Vir
VaxGen to Present Progress Updates in Seattle, New York, and West Palm Beach, Nov. 5-7: PRNewswire - November 1, 2001; BRISBANE, Calif., Nov. 1 /PRNewswire/ -- Senior executives of VaxGen , Inc. (Nasdaq: VXGN) will present updates to the investment communities in Seattle, New York, and West Palm Beach, Fla., during the week of Nov. 5, 2001. Donald P. Francis, M.D., D.Sc., president, and Lance K. Gordon, Ph.D., chief executive officer,
Covering the West Hollywood Halloween Carnaval? Consider Dropping by 'Out' Boutique for Some B-Roll of the Bruce Willis Items: Last Minute Halloween Costume? Consider Bidding on a Leather Varsity Jacket, Other Clothing & Furnishings from Hollywood Actor Bruce Willis: PRNewswire - October 31, 2001; WEST HOLLYWOOD, Calif., Oct. 31 -- Clothing and personal items donated by Hollywood film star Bruce Willis to AIDS Healthcare Foundation (AHF) will be sold today Halloween night during a special holiday silent auction at AHF s Out (Out of The Closet store) at 8861 Santa Monica Boulevard in West Hollywood. The silent au
Once-Daily Zerit (stavudine) QD Capsules Safe and Effective: PRNewswire - October 31, 2001; ATHENS, Greece , Oct. 31 /PRNewswire/ -- Data presented today at the 8th European Conference on Clinical Aspects and Treatment of HIV Infection show that a new once-daily Zerit ( stavudine or
Twice-Daily HIV Regimen With FORTOVASE(R) and Mini-Dose Ritonavir Evaluated In Independent Clinical Studies - Less Frequent Dosing Offers Potential to Improve Adherence -: PRNewswire - October 31, 2001; ATHENS, Greece , Oct. 31 /PRNewswire/ -- New data were released today from two independently conducted clinical studies evaluating a twice-daily HIV treatment regimen of Roche s protease inhibitor FORTOVASE(R) in combination with mini-dose ritonavir .
Artists Against AIDS Worldwide's New Superstar Version of Marvin Gaye's 'What's Going On' In Stores Tuesday, October 30: Proceeds to Support AIDS Charities & Sept 11 Victims Relief Fund: PRNewswire - October 30, 2001; LOS ANGELES, Oct. 30 /PRNewswire/ -- Artists Against AIDS Worldwide s new, all-star version of Marvin Gaye s 1971 hit What s Going On, featuring Christina Aguilera, Backstreet Boys, Mary J. Blige, Bono, Destiny s Child, Sean P. Diddy Combs, Fred Durst (of Limp Bizkit), Nelly Furtado, Marvin Gaye III, Nona Gaye, Darren
Potential Once-Daily Anti-HIV Combination of SUSTIVA(R)+VIDEX(R)+FTC Demonstrates Strong Antiviral and Immunologic Effects in Pilot Study Through 96 Weeks: Pharmacokinetic Data from Study Support Once-Daily Dosing for This Regimen: PRNewswire - October 30, 2001; WILMINGTON, Del., Oct. 30 /PRNewswire/ -- Data presented today at the 8th European Conference on Clinical Aspects and Treatment of HIV Infection (ECCATHI) in Athens, Greece suggest that the once-daily protease inhibitor-sparing regimen of Bristol-Myers Squibb s (NYSE: BMY) SUSTIVA(R) (
Dr. Edmund Tramont, Director of the Division of AIDS at NIAID/NIH, Presents Significant Clinical Data With CEL-SCI Drug in HIV-Infected Women With Human Papilloma Virus (HPV) Induced Cervical Dysplasia: PRNewswire - October 30, 2001; VIENNA, Va., Oct. 30 /PRNewswire/ -- CEL-SCI CORPORATION (Amex: CVM) announced today the presentation of additional new clinical data for CEL-SCI s immunotherapy drug, Multikine(TM), at the 40th Annual ACOG (American College of Obstetricians and Gynecologists) Meeting of the Armed Forces District in Norfolk, Virginia.
VaxGen's AIDS Vaccine Clears 6th Safety Review; N. American/European Study Scheduled to Conclude in One Year: PRNewswire - October 29, 2001; BRISBANE, Calif., Oct. 29 /PRNewswire/ -- The independent board that oversees the world s only final-stage clinical trials of an AIDS vaccine has once again indicated that the vaccine appears safe and that the trials are being conducted appropriately, VaxGen , Inc. (Nasdaq: VXGN) announced today. In its sixth revie
Two Protease Inhibitor-Switch Studies Show Longer Virologic Response in Patients Switching to a Regimen Containing SUSTIVA(R): PRNewswire - October 29, 2001; WILMINGTON, Del., Oct. 29 /PRNewswire/ -- Data presented today at the 8th European Conference on Clinical Aspects and Treatment of HIV Infection (ECCATHI) in Athens, Greece show that patients who substituted Bristol-Myers Squibb s (NYSE: BMY) anti-HIV drug SUSTIVA(R) (
Atazanavir Demonstrates Antiviral Efficacy and a Favorable Lipid Profile at 48 Weeks: PRNewswire - October 29, 2001; ATHENS, Greece - Data shows that a regimen containing the novel and potent investigational protease inhibitor, atazanavir, given once daily as part of a highly active antiretroviral therapy (HAART) regimen is associated with significantly lower concentrations in total cholesterol, fasting LDL cholesterol and fasting tr
96-Week VIRAMUNE(R) (nevirapine) Study Results Presented At Major European AIDS Conference - Two Studies Examine Lipoprotein Profiles in Patients Taking VIRAMUNE: Boehringer Ingelheim Pharmaceuticals, Inc.; ATHENS, Greece , - Findings from two studies presented at the 8th European Conference on Clinical Aspects and Treatment of HIV Infection demonstrate that HIV-positive individuals taking a VIRAMUNE(R) ( nevirapine )-based anti-HIV treatment combination were observed to hav
International Organizations Join in Unprecedented Collaboration to Assist Africa's Children Orphaned by AIDS: PRnewswire - October 29, 2001; WASHINGTON and SEATTLE, Oct. 29 /PRNewswire/ -- Five leading international humanitarian organizations today announced they have joined to launch the Hope for African Children Initiative, an unprecedented collaboration that will address the enormous challenges faced by children whose lives have been devastated by the AI
Data Suggest SUSTIVA(R) May Have Greater Potency and Durability Than Viramune(R) in HIV Positive Treatment-Naive Patients: PRnewswire - October 29, 2001; WILMINGTON, Del., - Data presented today at the 8th European Conference on Clinical Aspects and Treatment of HIV Infection (ECCATHI) in Athens, Greece suggest that a regimen containing Bristol-Myers Squibb s (NYSE: BMY) anti-HIV drug SUSTIVA(R) ( efavirenz ) i
TMC125 Demonstrates Strong Antiviral Effect in HIV; First Clinical Results In Short-Term Study Are Promising: PRnewswire - October 29, 2001; ATHENS, Greece , - Data presented today at the 8th European Conference on Clinical Aspects and Treatment of HIV Infection (ECCATH) demonstrate an average reduction in the amount of HIV in patients plasma (viral load) of 99% after one week of treatment using Tibotec-Virco s novel, new candidate drug TMC125, a potent non
Simplification of HIV Treatment Schedules: Study Examines Once-Daily FORTOVASE(R) in Co-Infected Patients With HIV And Hepatitis C Receiving Methadone: Second Study Explores Changes in Drug Costs for 15 Patients Who Switched To Once-Daily FORTOVASE: PRNewswire - October 29, 2001; SAN FRANCISCO, Oct. 29 /PRNewswire/ -- Data from a retrospective review of patients co-infected with HIV and hepatitis C virus (HCV) receiving methadone indicate that a once-daily dose of Roche s protease inhibitor, FORTOVASE(R) (saquinavir), in combination with a mini-dose of the protease inhibitor
U.S. FDA Approves Gilead Sciences' Anti-HIV Drug Viread(TM): PRNewswie - October 29, 2001; FOSTER CITY, Calif., Oct. 29 /PRNewswire/ -- Gilead Sciences (Nasdaq: GILD) announced that it received U.S. Food and Drug Administration ( FDA ) approval on Friday, October 26, for its antiretroviral agent Viread (TM) (tenofovir disoproxil fumarate) for the treatment of human immunodefici
VA Establishes New Hepatitis C and HIV Field Office: PRnewswire - October 26, 2001; WASHINGTON, Oct. 26 /PRNewswire/ -- To better address the needs of nearly 100,000 veterans infected with hepatitis C or HIV, the Department of Veterans Affairs (VA) recently established a new field office in West Haven, Conn., that will provide front-line perspective to the national program. Dr. Michael Rigsby, an infe
New Strategy Doubles Efficacy of Hepatitis C Treatment In Patients Co-infected with HIV: Co-infection a Focus at Infectious Diseases Society of America Annual Meeting: PRNewswire - October 26, 2001; SAN FRANCISCO, Oct. 26 /PRNewswire/ -- Daily administration of interferon alfa-2b in combination with ribavirin for the treatment of the hepatitis C virus (HCV) is more than twice as effective as the standard treatment regimen (three injections interferon/week plus ribavirin) at suppressing hepatitis C viral levels in
Trinity Medical Group USA Announces Publication of REMUNE(R) Study Results at 132 Weeks: PRNewswire - October 26, 2001; RANCHO SANTA MARGARITA, Calif., Oct. 26 /PRNewswire/ -- Trinity Medical Group USA, Inc. (OTC Bulletin Board: TMGU) today announces the publication of follow-up results of a human clinical study of an Immune-Based Therapy for the treatment of HIV, REMUNE(R), at 5 sites in Thailand . The study results, together with pre
Progenics Enters Collaboration With Formatech to Develop Improved Dosing Formulations For Investigational HIV Drug Pro 542- Collaboration Leverages New Efficacy Data in HIV Animal Model: PRNewswire - October 26, 2001; SAN FRANCISCO, Oct. 26 /PRNewswire/ -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) announced the initiation of a collaboration with Formatech, Inc., Andover, MA, to develop improved product formulations for PRO 542, an investigational drug currently in Phase II clinical testing for the treatment of HIV (human immuno
Visible Genetics' TRUGENE(TM) HIV-1 Genotyping Kit To Be Used in a GlaxoSmithKline Sponsored Clinical Trial: PRNewswire - October 25, 2001; TORONTO, Oct. 25 /PRNewswire/ -- Visible Genetics Inc. (Nasdaq: VGIN) ( VGI ) announced today that Visible Genetics TRUGENE(TM) HIV-1 Genotyping Kit will be used to provide genotypic information on all patients enrolled in a large-scale Phase III clinical trial sponsored by GlaxoSmithKline (NYSE: GSK) for a new HIV
The Month-Long 102.9 WMGK Rock Art Show and Silent Auction Opens to the Public On Friday, November 16 and Will Benefit the Elizabeth Glaser Pediatric AIDS Foundation: PRNewswire - October 24, 2001; PHILADELPHIA, Oct. 24 /PRNewswire/ -- WMGK (102.9FM/Philadelphia) will showcase a never-before-seen collection of original art and lithographs, as well as handwritten, autographed song lyrics from popular music s greatest songwriters at the second annual 102.9 WMGK Rock Art Show to benefit the Elizabeth Glaser Pediatri
FDA Approves Investigational Device Exemption For Efoora HIV Rapid Test: PRNewswire - October 24, 2001; BUFFALO GROVE, Ill., Oct. 24 /PRNewswire/ -- Efoora, Inc. announced today that the Center for Biologics Evaluation and Research (CBER) of the U.S. Food & Drug Administration has granted an Investigational Device Exemption (IDE) for Efoora s HIV Rapid Test. The IDE will allow the Efoora HIV Rapid test to be used in
Bio-Rad Grants HIV-2 License to Genelabs Diagnostics: Settlement Agreement Allows Continued Sales of Confirmatory HIV Tests: PRNewswire - October 24, 2001; HERCULES, Calif., and SINGAPORE, Oct. 24 /PRNewswire/ -- Bio-Rad Laboratories, Inc. (Amex: BIO.A and BIO.B) and Genelabs Diagnostics Pte. Ltd. announced today that they have reached an agreement that allows Genelabs Diagnostics to continue to manufacture and sell the company s HIV-2 Western Blot 1.2 and HIV Blot 2.2 We
National Institute of Health Utilizes Bioject'S Needle-Free Injection System For Its DNA AIDS Vaccine Study: The First Volunteer of a Planned 20 Patient Cohort Injected: PRNewswire - October 23, 2001; PORTLAND, Ore., Oct. 23 /PRNewswire/ -- Bioject Medical Technologies, Inc. (Nasdaq: BJCT), a leading developer of needle-free drug delivery systems, today announced that the Biojector(R) 2000 (B-2000) is the delivery device being used by the Dale and Betty Bumpers Vaccine Research Center (VRC) for the human clinical te
Phase I Clinical Trial to Commence on SLIL Cancer Drug, SL11047: PRNewswire - October 23, 2001; MADISON, Wis., Oct. 23 /PRNewswire/ -- SLIL Biomedical Corp. announced that the FDA has completed its review of the Investigational New Drug application (IND) for SLIL s candidate drug, SL11047. Phase I human clinical trials with the drug will now commence. The Phase I clinical study, aimed at AIDS-lymphoma patients, w
The National AIDS Treatment Advocacy Project Announces 'A Day For Women': PRNewswire - October 22, 2001; NEW YORK, Oct. 22 /PRNewswire/ -- HIV is a growing problem for women in the United States . Infection rates among women continue to steadily increase. Among women of color, the rate of new infections is disproportionately increasing compared to other groups. HIV treatment and care is different for women than it is for
Walkers Raise $2.5 Million at AIDS Walk Los Angeles, Sunday, October 21: PRNewswire - October 21, 2001; LOS ANGELES, Oct. 21 /PRNewswire/ -- More than 20,000 people turned out for AIDS Walk Los Angeles on Sunday, October 21. Together, they raised $2.5 million in a showing of this community s continued and determined support for the work of APLA, according to Craig Miller, the event s long time producer. Mayor James Hahn,
VaxGen Obtains Land in South Korea for Manufacturing Facility: PRNewswire - October 19, 2001; BRISBANE, Calif., Oct. 19 /PRNewswire/ -- VaxGen , Inc. (Nasdaq: VXGN) and the city of Incheon, South Korea , announced the signing of an agreement today that provides VaxGen land on which to construct a facility to manufacture the company s AIDS vaccine.
Oxfam Lauds U.S. Effort in Making Anti-Anthrax Medicine Available: PRNewswire - October 17, 2001; WASHINGTON, Oct. 17 /PRNewswire/ -- Oxfam America is lauding recent efforts by the U.S. Government to provide a much-needed antibiotic. The Government is asking Bayer Corporation to relax its patent on the anti-anthrax medicine, Cipro (ciprofloxacin). Oxfam America s Senior Policy Adviser, Severina Rivera, praised the
ViroLogic Announces Broadened Agreement With Roche and Trimeris for Use of Its HIV Drug Resistance Testing Technology: PRNewswire - October 16, 2001; SOUTH SAN FRANCISCO, Calif., Oct. 16 /PRNewswire/ -- ViroLogic, Inc. today announced that the Company signed an expanded agreement with Hoffmann-La Roche , Inc. and Trimeris, Inc. to use ViroLogic s proprietary HIV resistance testing technology in the development of T-20 and T-1249, the first and most advanced members
Mixed 2001 Legislative Session Frustrates AIDS Activists; AIDS Project Los Angeles Plans Aggressive Strategy for Future: PRNewswire - October 15, 2001; LOS ANGELES, Oct. 15 /PRNewswire/ -- Activists are stunned by a legislative session that saw fewer than expected advances in the area of HIV/ AIDS policy and diminishing support from Governor Gray Davis for prevention and education efforts. Despite his previous record, this year Governor Davis became the first Californ
Roche Molecular Systems International Blood Screening Business News: French Health Ministry and Japanese Red Cross Select Roche PCR Technology: PRNewswire - October 13, 2001; PLEASANTON, Calif., Oct. 13/PRNewswire/ -- Roche Diagnostics announced today that it was recently awarded substantial blood-screening business in France and Japan to screen the blood supply and to help prevent the transfusion of blood infected with certain viruses. FRENCH HEALTH MINISTRY AWARDS BLOOD SCREENING CONT
California Governor Acts on Two AHF-Sponsored Bills to Advance HIV Care: PRNewswire - October 12, 2001; LOS ANGELES, Oct. 12 /PRNewswire/ -- Two AIDS Healthcare Foundation (AHF) sponsored bills aimed at improving access to HIV/AIDS care for California managed care plan enrollees were acted on yesterday by California Governor Gray Davis. Assembly Bill 937 (Koretz, D-West Hollywood/Cedillo, D-Los Angeles) -- a bill to ensu
ViroLogic Announces Nearly All State Medicaid Programs Now Cover Its HIV Drug Resistance Assays: Company Plans to Launch Novel Resistance Assay Later This Year: PRNewswire - October 12, 2001; SOUTH SAN FRANCISCO, Calif., Oct. 12 /PRNewswire/ -- ViroLogic, Inc. today announced that 44 out of 50 U.S. state Medicaid programs, including California, New York, Illinois and Pennsylvania, now have coverage policies enabling reimbursement of the company s PhenoSense(TM) and GeneSeq(TM) HIV drug resistance assays. At
Decision Resources Report Forecasts Substantial Market Opportunities for Therapies to Treat Hepatitis B and C Viruses: PRNewswire - October 11, 2001; WALTHAM, Mass., Oct. 11 /PRNewswire/ -- The Prevention and Treatment of Select Viral Infections is a forthcoming DR Report from Decision Resources that evaluates the current and future status of therapeutic and prophylactic drugs and vaccines in development for six major viruses: human immunodeficiency virus (HIV), hep
Bruce Brochtrup, Wilson Cruz, Eric McCormack and Ming-Na to Host AIDS Walk Los Angeles Sunday, October 21: PRNewswire - October 11, 2001; New Post-Walk Entertainment Featuring Singer Songwriter From Ally McBeal, Vonda Shepard! New Location! New Route! AIDS Walk Begins at the Pacific Design Center in West Hollywood Proceeds Benefit AIDS Project Los Angeles and Other AIDS Service Organizations Across LA County LOS ANGELES, Oct. 11 /PRNewswire/ -- Thousands
PowderJect Awarded $1 Million U.S. Government Funding to Support Development of HIV DNA Vaccine: PRNewswire - Ocotber 11, 2001; OXFORD, England and MADISON, Wis., Oct. 11 /PRNewswire/ -- PowderJect Pharmaceuticals Plc (London: PJP), the rapidly growing specialty vaccines company, and its wholly owned subsidiary PowderJect Vaccines Inc, today announced that in association with the University of Pittsburgh the company has been awarded $1 million
Fundraiser Goes to the Net: Denver Chapter of Cable Positive Uses Internet To Expand Charity Efforts: Via the Web, People Can Get Event Information, Bid on Silent Auction Items And Get a Copy of the Words to All the Event's Song Parodies: PRNewswire - October 10, 2001; DENVER, Oct. 10 /PRNewswire/ -- The Denver chapter of Cable Positive has turned to the Internet to spread the word about its upcoming musical parody and raise funds to assist those infected with HIV and AIDS. The chapter has unveiled a temporary Web presence that provides an opportunity to bid in a Silent Auction, buy
amfAR Symposium to Focus on Women and HIV/AIDS: HIV Infection Now the Fifth Leading Cause of Death for Women in the United States: PRNewswire - October 10, 2001; NEW YORK, Oct. 10 /PRNewswire/ -- Women now account for more than 25 percent of AIDS cases in the United States , a percentage that has tripled since the epidemic first began 20 years ago. To help address this alarming situation, the American Foundation for AIDS Research (amfAR) will host a day-long medical symposium e
Cambridge Antibody Technology Announces Product Development Alliance With Merck & Co., Inc.: Collaborative program to develop novel drugs for the prevention and treatment of HIV-mediated infectious disease: PRNewswire - October 10, 2001; MELBOURN, England, Oct. 10 /PRNewswire/ -- Cambridge Antibody Technology announces today that it has entered into a collaboration and license agreement with Merck & Co. , Inc. for the research and development of products specific for a key target involved in disease mediated by HIV. Under the terms of the five-y
Celebrities Join AIDS Project Los Angeles and Soolip Paperie & Press For Holiday Card Campaign: Peri Gilpin, Sean Hayes, Imitation of Christ, Betsey Johnson, Lucy Liu, Valerie Rae Miller, Meryl Streep and Hilary Swank Donate Designs: PRNewswire - October 9, 2001; LOS ANGELES, Oct. 9 /PRNewswire/ -- Peri Gilpin, Sean Hayes, Imitation of Christ, Betsey Johnson, Lucy Liu, Valerie Rae Miller, Meryl Streep and Hilary Swank designed the artwork for AIDS Project Los Angeles (APLA) 2001 holiday card campaign. Created through a partnership with Soolip Paperie & Press, the holiday ca
European Humanitarian Group Orders Rapid HIV Tests From BICO Subsidiary - Rapid HIV Detection Corporation: PRNewswire - October 9, 2001; PITTSBURGH, Oct. 9 /PRNewswire/ -- The world appears to be gravitating toward Pittsburgh-based BICO, Inc. and their subsidiary, Rapid HIV Detection Corp. One week after Walter Reed Army Institute of Research placed their second order of InstantScreen(TM) Rapid HIV tests, an order for 1,000 tests has come from a Europea
Multikine(TM) Demonstrates Excellent Clinical Responses in HIV-Infected Women With Human Papilloma Virus (HPV) Induced Cervical Dysplasia: PRNewswire - October 9, 2001; * Elimination of HPV-induced cervical dysplasia demonstrated in majority of treated patients. * Presentation at the Annual Meeting of the International Society for Interferon and Cytokine Research in Cleveland, Ohio by scientists from the Institute of Human Virology and CEL-SCI suggests a potentially effective new trea
ViroLogic to Present at UBS Warburg LLC Global Life Sciences Conference Next Week in New York: PRNewswire - October 4, 2001; SOUTH SAN FRANCISCO, Calif., Oct. 4 /PRNewswire/ -- ViroLogic, Inc. announced today that the company will present at the UBS Warburg Global Life Sciences Conference on Friday, October 12, 2001 at 8:00 a.m. EDT. Bill Young, ViroLogic s chairman and chief executive officer will update members of the investment community
Regent Group, Inc. Announces That Co-discoverer of AIDS Virus Joins Research Consultant Team: PRNewswire - October 4, 2001; BERNARDSVILLE, N.J., Oct. 4 /PRNewswire/ -- Regent Group, Inc. announced today that Dr. Luc Montagnier, the world renowned virologist and co-discoverer of the virus that causes AIDS, has joined the research team of Millennium Biotechnologies, Inc., its wholly owned subsidiary. Dr. Montagnier will be responsible for ove
Visible Genetics' to Present at UBS Warburg LLC Global Life Sciences Conference: VGI Also Presenting at European Investor Conference: PRNewswire - October 4, 2001; TORONTO, Oct. 4 /PRNewswire/ -- Visible Genetics Inc. (VGI) announced today that Richard T. Daly, President and CEO of Visible Genetics will be presenting at the UBS Warburg Global Healthcare Conference being held next week in New York from October 8 to 12. Mr. Daly will give his presentation at 2:20 PM on Wednesday Oc
TherImmune Awarded $4.5 M for HIV Vaccine Development Services: PRNewswire - October 4, 2001; GAITHERSBURG, Md., Oct. 4 /PRNewswire/ -- TherImmune Research Corporation is pleased to announce its recent award of a 3-year $4.5 M HIV Vaccine Development Task Order awarded under their National Institute of Allergy and Infectious Diseases (NIAID) Indefinite Delivery - Indefinite Quantity Contract (IDIQ). The company
Scott Evertz, Director of the White House Office of National AIDS Policy, To Kick Off 11th Annual AIDS Arms LifeWalk in Dallas: PRNewswire - October 4, 2001; DALLAS, Oct. 4 /PRNewswire/ -- AIDS Arms, Inc., a Dallas-based agency providing both outpatient medical care and psychosocial services for persons diagnosed with HIV/AIDS, announced today that Scott Evertz, director of the White House Office of National AIDS policy, will kick off the eleventh annual AIDS Arms LifeWalk
Hollis-Eden Pharmaceuticals Cleared to Initiate Clinical Trial in Hepatitis B; The Company Initiates Dosing HE2000 in Malaria Patients: PRNewswire - October 4, 2001; SAN DIEGO, Oct. 4 /PRNewswire/ -- Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH) today announced that it has received approval to initiate a Phase II clinical trial in Hepatitis B (HBV) infected patients with the Company s lead investigational drug, HE2000, at Mt. Elizabeth Medical Centre in Singapore .
Myriad Genetics and University of Utah Publish Pioneering HIV Research in the Scientific Journal CELL: Scientists Identify Promising New Targets for HIV Drug Intervention: PRNewswire - Thursday October 4, 2001; SALT LAKE CITY, Oct. 4 /PRNewswire/ -- Myriad Genetics, Inc. (Nasdaq: MYGN - news) and the University of Utah today announced the publication of the results of pioneering research into molecular mechanisms essential for the lifecycle of the Human Immunodeficiency Virus, (HIV) the virus known to cause AIDS (Acquired Imm
Virco Signs Major HIV Resistance Testing Contracts With Pharmaceutical Companies: Contracts Confirm Virco as Partner of Choice for Development of New HIV Drugs: PRNewswire - October 4, 2001; MECHELEN, Belgium , Oct. 4 /PRNewswire/ -- Virco announced today that it has entered into a number of agreements to provide HIV drug resistance testing and other analytical services to pharmaceutical companies. The contracts, with a number of leading pharmaceutical companies including Dupont Pharmaceuticals, are the la
5,300 Signatures in Support of AIDS Bill Delivered to Governor: AB 937 (Koretz, D-West Hollywood/Cedillo, D-Los Angeles) Strongly Supported in San Francisco Chronicle Editorial Today: PRNewswire - October 3, 2001; LOS ANGELES, Oct. 3 /PRNewswire/ -- 5,300 signatures in support of Assembly Bill 937 (Koretz, D-West Hollywood/Cedillo, D-Los Angeles) -- a bill that would help ensure access to HIV specialists for California HMO members living with HIV/AIDS -- were delivered to Governor Gray Davis office yesterday. The signatures are
Maxygen Awarded $3.7 Million USAID Cooperative Grant to Develop Malaria Vaccine: PRNewswire - October 3, 2001; REDWOOD CITY, Calif., Oct. 3 /PRNewswire/ -- Maxygen, Inc. announced today that it had received a $3.7 million, three-year grant from the U.S. Agency for International Development (USAID) to support the research and development of a novel, broadly protective malaria vaccine. Under the terms of the agreement, Maxygen wi
VaxGen Awarded Second NIH Grant for Development of AIDS Vaccine for Africa, India and China: PRNewswire - October 3, 2001; BRISBANE, Calif., Oct. 3 /PRNewswire/ -- VaxGen , Inc. (Nasdaq: VXGN) announced today that it has been awarded the second part of a $1.1 million grant from the National Institutes of Health (NIH) to continue the development of a vaccine designed to prevent infection by HIV subtype C, the most widespread form of the vir
Visible Genetics Acquires Former Virco UK Laboratory: VGI Establishes Major Research Facility In Europe: PRNewswire - October 3, 2001; TORONTO, Oct. 3 /PRNewswire/ -- Visible Genetics Inc. today announced that it has acquired Virco s international research laboratory in Cambridge, UK together with substantially all the research staff of about 25 scientists. VGI will acquire the laboratory assets for US$829,000 and assume the lease for the 20,000 squar
Web's Premier HIV/AIDS Resource Launches Prescription Program Serving People With HIV: A Contrast With New Glaxo Prescription Drug Program: PRNewswire - October 3, 2001; NEW YORK, Oct. 3 /PRNewswire/ -- TheBody.com today launched BodyPlus, a new online prescription drug program for people with HIV. The program will provide significant discounts and embarrassment-free delivery, and envisions an unprecedented level of highly targeted patient education by using the company s award-winning
Tibotec-Virco Reorganizes HIV Diagnostics; Transfer of Activities to Belgium to Improve Effectiveness: PRNewswire - October 3, 2001; MECHELEN, Belgium , Oct. 3 /PRNewswire/ -- Following the recent announcement to re-focus core activities geographically, Tibotec-Virco today announced that it has relocated its HIV genotyping services and HIV diagnostics research from Cambridge, UK to the company s headquarters in Mechelen, Belgium. We are delight
Churches Gearing Up for 13th Annual Black Church Week of Prayer for the Healing of AIDS: PRNewswire - October 2, 2001; NEW YORK, Oct. 2 /PRNewswire/ -- Churches across the country are gearing up for the 13th annual Black Church Week of Prayer for the Healing of AIDS March 3-9, 2002. The week, organized by The Balm In Gilead, is a national campaign, which mobilizes Black churches to become centers for AIDS education and compassion. Sinc
Epimmune Provides Cancer Vaccine Program Update: PRNewsire - October 2, 2001; SAN DIEGO, Oct. 2 /PRNewswire/ -- Epimmune Inc. (Nasdaq: EPMN) today provided additional information on its cancer vaccine program including its initial vaccine candidate and clinical trial plans. Epimmune will move forward with a therapeutic lung cancer vaccine candidate and anticipates that it will file an Investigat
Amarillo Biosciences, Inc. Licenses Rights to Low Dose Oral Interferon For Orphan Drug Indications: PRNewsire - October 2, 2001; AMARILLO, Texas, Oct. 2 /PRNewswire/ -- Amarillo Biosciences, Inc. announces the company has signed a licensing agreement with Atrix Laboratories, Inc. (Nasdaq: ATRX) providing the rights to oral low-dose interferon-alpha for the treatment of Behcet s disease and oral papillomavirus warts in HIV-positive patients. The
BICO Receives Additional Order From Walter Reed For Rapid HIV Tests: PRNewswire - October 2, 2001; PITTSBURGH, Oct. 2 /PRNewswire/ -- BICO, Incorporated announced today that subsidiary Rapid HIV Detection Corp. has received an order for an additional 1,200 of its InstantScreen(R) Rapid HIV tests from Walter Reed Army Institute of Research in Washington, DC for use in scientific evaluation. In August, Walter Reed Ins
Final Preparations Made for AIDS Walk Michigan - City of Detroit; Record Numbers Anticipated for This Year's Walk: PRNewswire - September 28, 2001; DETROIT, Sept. 28 /PRNewswire/ -- Tomorrow morning the AIDS Memorial Quilt, on loan from its home in Atlanta, Georgia is unveiled at the Belle Isle Casino as part of AIDS Walk Michigan -- City of Detroit. The Quilt includes more than 30 quilt blocks that will be unpacked and put on display early in the morning in prepa
AIDS Walk Detroit Raises $340,000, Sets Records: 2001 Walk united and benefited many in Metro-Detroit: PRNewswire - September 28, 2001; ROYAL OAK, Mich., Sept. 28 /PRNewswire/ -- An estimated 16,000 people showed their American spirit on September 16 by raising a record $340,000 to help Metro-Detroiters whose lives have been affected by HIV and AIDS. The amount raised exceeded last year s record by more than $20,000 and brought the total raised by Step
VA Establishes New HIV Center: PRNewswire - September 28, 2001; WASHINGTON, Sept. 28 /PRNewswire/ -- In its continuing efforts to provide care to more than 20,000 veterans infected with HIV (Human Immunodeficiency Virus), the Department of Veterans Affairs (VA) has announced the creation of the Center of HIV Research Resources located at the Palo Alto Health Care System in Californ
FDA Grants Market Clearance of Visible Genetics' HIV Genotyping System: TRUGENE(TM) HIV-1 Genotyping Kit is First FDA Cleared DNA Sequence-Based Test For HIV Drug Resistance Testing: PRNewswire - September 26, 2001; TORONTO, Sept. 26 /PRNewswire/ -- Visible Genetics Inc. (Nasdaq: VGIN) (VGI) today received clearance from the U.S. Food and Drug Administration ( FDA ) to market its TRUGENE(TM) HIV-1 Genotyping Kit and OpenGene(TM) DNA Sequencing System for routine clinical use, becoming the first HIV drug resistance test to receive
AHF Inducts PacifiCare Into their AIDS Hall of Shame: California Managed Care Plan Cited for Failure to Refer Patients to AIDS Specialists & Pay for AIDS Care, Leading Opposition to Legislation That Would Improve Care for Californians Living with HIV/AIDS: Gov. Davis Urged to Sign AB 937 (Koretz, D, W. Hollywood) to Improve Access To AIDS Care: PRNewswire - September 26, 2001; LOS ANGELES, Sept. 26 /PRNewswire/ -- In a press conference today in front of AIDS Healthcare Foundation s (AHF s) administrative offices, AIDS medical providers and activists inducted PacifiCare of California into the AIDS Hall of Shame for their ongoing mismanagement of HIV/AIDS patients HMO specialty care and referr
New Study Proves - Ameda HygieniKit Protects Breast Milk From Bacteria and Viruses*: PRNewswire - September 26, 2001; LIBERTYVILLE, Ill., Sept. 26 /PRNewswire/ -- There is good news for mothers who rely on electric breast pumps to provide breast milk to their babies. The Food and Drug Administration ( FDA ) reviewed and cleared the claim that the patented silicone diaphragm used in the Ameda HygieniKit milk collection system creates a
amfAR's Founding Chairman Dr. Mathilde Krim to Receive Eleanor Roosevelt Val-Kill Medal: PRNewswire - September 26, 2001; NEW YORK, Sept. 26 /PRNewswire/ -- On Sunday, September 30, Dr. Mathilde Krim, Founding Chairman and Chairman of the Board of the American Foundation for AIDS Research (amfAR), will receive the Eleanor Roosevelt Val-Kill Medal in recognition of her leadership role in galvanizing the nation s research effort against HIV
Celebrities Join AIDS Project Los Angeles and Soolip Paperie & Press For Holiday Card Campaign: PRNewswire - September 25, 2001; Peri Gilpin, Sean Hayes, Imitation of Christ, Betsey Johnson, Lucy Liu, Valerie Rae Miller, Meryl Streep and Hilary Swank Donate Designs LOS ANGELES, Sept. 25 /PRNewswire/ -- Peri Gilpin, Sean Hayes, Imitation of Christ, Betsey Johnson, Lucy Liu, Valerie Rae Miller, Meryl Streep and Hilary Swank designed the artwork fo
20 Years, 22 Million Lives Lost to AIDS: Register Now to Walk, Run and Stroll in 15th Annual AIDSWalkPhilly2001 on Sunday, October 21: PRNewswire - September 25, 2001; PHILADELPHIA, Sept. 25 /PRNewswire/ -- 20 years after doctors reported that a strange and deadly new disease turned up in five gay men in Los Angeles, more than 22 million people worldwide have lost their lives to AIDS and that number increases daily. Area residents are encouraged to register to walk, run or stroll in
Conference to Explore Inextricable Connection Between Health, Law and Human Rights: PrNewswire - September 24, 2001; NEW YORK, Sept. 24 /PRNewswire/ -- The American Foundation for AIDS Research (amfAR) will sponsor a conference entitled Health, Law and Human Rights: Exploring the Connections from September 29 to October 1, 2001, in Philadelphia. Conference participants from around the world will discuss the use of law and human right
Prominent Physician Named Head of New South African AIDS Clinic; Ithembalabantu 'People's Hope' Clinic to Provide Antiretroviral Treatment: PRNewswire - September 24, 2001; LOS ANGELES, Sept. 24 /PRNewswire/ -- South Africa s newest HIV clinic, a joint effort between American and South African AIDS activists, will be headed by a South African physician with extensive experience in HIV/AIDS treatment. Dr. Lerato Mohapi, MBBCH, will oversee the treatment program as Medical Director of the I
CEL-SCI Corporation Announces Clinical Data To Be Presented in October at the Annual Meeting Of The International Society for Interferon and Cytokine Research: PRNewswire - September 24, 2001; Clinical Study of HIV-Infected Women With Human Papilloma Virus (HPV) Induced Cervical Dysplasia, the Precursor Stage Before the Development of Cervical Cancer. Dysplasia Is Usually Detected Through Pap Smear. Cervical Cancer Is The Second Leading Cause of Cancer Death in Women Worldwide. VIENNA, Va., Sept. 24 /PRNewsw
LabCorp's National Genetics Institute Receives FDA Approval for Nucleic Acid Tests for HCV and HIV-1: PRNewswire - September 21, 2001; BURLINGTON, N.C., Sept. 21 /PRNewswire/ -- Laboratory Corporation of America(R) Holdings (NYSE: LH) (LabCorp(R)) today announced that its National Genetics Institute Inc. (NGI) had its Biologics License Applications for the UltraQual(TM) HCV RT-PCR and UltraQual(TM) HIV-1 RT-PCR assays approved by the U. S. Food and Dr
ViroLogic Enters Agreement With Triangle Pharmaceuticals to Evaluate New HIV Drugs - PhenoSense(TM) Technology to Assess HIV Susceptibility To Investigational Compounds: PRNewswire - September 20, 2001; SOUTH SAN FRANCISCO, Calif., Sept. 20 /PRNewswire/ -- ViroLogic Inc. (Nasdaq: VLGC) today announced an agreement with Triangle Pharmaceuticals, Inc. (Nasdaq: VIRS), to assist in clinical evaluation of new anti-HIV agents in development at Triangle Pharmaceuticals. Triangle Pharmaceuticals will use ViroLogic s phenotypi
Myriad Genetics Reports Advanced Pre-Clinical Progress With Anti-HIV Drug - IND Filing for Human Clinical Trials Expected This Fiscal Year: PRNewswire - September 20, 2001; SALT LAKE CITY, Sept. 20 /PRNewswire/ -- Myriad Genetics, Inc. (Nasdaq: MYGN), today reported pre-clinical data on its lead Anti-HIV compound, MPI-49839. The drug addresses a novel mechanism in the viral-host interaction and holds the potential for an entirely new class of AIDS therapeutics. In pre-clinical tests, MPI-
Name Change Announced for Female Condom Product: PRNewswire - September 19, 2001; CHICAGO, Sept. 19 /PRNewswire/ -- The Female Health Company announced today the establishment of FC Female Condom(R) as the Company s worldwide trademark for its female condom. The Company has previously sold the female condom as REALITY to consumers in the US. According to the Company s President, Dr. Mary Ann Leeper,
CEL-SCI Corporation Announces Issuance of Three New U.S. Patents Covering HIV Immunotherapeutic Agents: PRNewswire - September 19, 2001; VIENNA, Va., Sept. 19 /PRNewswire/ -- CEL-SCI CORPORATION (Amex: CVM) announced today the issuance of three new U.S. patents, further expanding the patent protection related to its HIV-1 based therapeutic and preventive vaccines. These new patents expand the Company s intellectual property protection to the C strain (c
Want to Give Blood? First See If You Are Eligible Suggests the American Society of Clinical Pathologists: PRNewswire - September 18, 2001; CHICAGO, Sept. 18 /PRNewswire/ -- The American Society of Clinical Pathologists (ASCP) is urging potential blood donors to review their personal medical history and other factors before heading to the nearest blood collection center. Due to the overwhelming response, many collection centers are filled with potential do
Midwest AIDS Prevention Project: 'ARTWORKS FOR LIFE' Benefit, Saturday, September 22; A Portion of the Proceeds to Benefit the Red Cross: Detroit Artists Unite in the Fight Against AIDS: PRNewswire - September 18, 2001; FERNDALE, Mich., Sept. 18 /PRNewswire/ -- Over 150 of Detroit s most prominent artists will donate original pieces of art to be auctioned at the sixth annual ARTWORKS FOR LIFE. This exciting event will begin at 6:30 p.m. on Saturday, September 22, 2001 and will be held at the Edsel and Eleanor Ford House in Grosse Poin
From Ashes of Despair, a Ray of Hope and Determination from AIDS Community; 300+ Travel By Car, Train, Bus to Nation's Largest Conference in Show Of Compassion and Empathy for Those Impacted By Tragedy: PRNewswire - September 14, 2001; MIAMI BEACH, Fla., Sept. 14 /PRNewswire/ -- They came from as far away as Kenya and Micronesia , arriving in Miami Beach before this week s horrible tragedy. They drove, took the train and the bus from as far away as California when their flights were cancelled.
Real People. Real Stories. AIDS Walk Detroit; Redford Man Lost His Wife To AIDS - Walks So No One Else 'Loses Their Lori': PRNewswire - September 12, 2001; ROYAL OAK, Mich., Sept. 12 /PRNewswire/ -- AIDS Walk Detroit has hit the streets with its 2001 campaign, Real People. Real Stories. As part of this campaign, 6 area residents whose lives have been touched by HIV and AIDS are telling their stories in support of the September 16 Walk. They include Ken, of Redford, whose
New York Baby AIDS Law Continues to Show Great Success; All HIV-Exposed Babies Identified, 99.4% Receiving Medical Care: PRNewswire - September 11, 2001; ALBANY, N.Y., Sept. 11 /PRNewswire/ -- Rates of perinatal HIV transmission continue to drop in New York and nearly all HIV exposed babies born in the state are receiving medical care, according to new data from the New York State Department of Health AIDS Institute. One in ten HIV-positive pregnant women, however, only
IGEN Presents Four New High-Throughput Screening Tests: Integrase Test Successfully Accelerated Screening for Potential New AIDS Drugs: PRNewswire - September 11, 2001; GAITHERSBURG, Md., Sept. 11 /PRNewswire/ -- Scientists from IGEN International Inc. (Nasdaq: IGEN) are this week presenting recent research results from four new screening tests developed by IGEN to speed the discovery of new drugs. The presentations being made at the annual meeting of the Society for Biomolecular Scre
Hollis-Eden Presents Data Demonstrating HE2000 Regulates a Broad Array of Inflammatory Mediators Implicated in Disease Progression in HIV Patients: Findings Also Have Implications for Other Inflammatory Conditions: PRNewswire - September 10, 2001; SAN DIEGO, Sept. 10 /PRNewswire/ -- Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH) today announced presentation of additional clinical results from its South African studies of investigational drug candidate HE2000, an immune regulating hormone (IRH). Highlights from the results demonstrate that HE2000 administered t
Santana Band Co-Founder Gregg Rolie to Perform Santana Classics at Macy's And American Express Passport '01 Fundraisers in Los Angeles and San Francisco Benefitting HIV/AIDS Charities: PRNewswire - September 7, 2001; SAN FRANCISCO, Sept. 7 /PRNewswire/ -- Rock n Roll Hall of Famer and veteran keyboardist-vocalist-producer Gregg Rolie, co-founder of multi- platinum acts Santana and Journey, will perform at the Macy s and American Express Passport 01 galas in San Francisco (Fort Mason Center, September 12-13-14) and Los Angeles (Sant
Global Reporting Initiative Receives Nearly $1 Million From Bill and Melinda Gates Foundation for HIV Work: Grant Awarded to Develop Corporate HIV/AIDS Reporting Protocol: PRNewswire - September 7, 2001; BOSTON, Sept. 7 /PRNewswire/ -- The Global Reporting Initiative (GRI) announced today that it has received a $950,000 grant from the Bill and Melinda Gates Foundation to develop a corporate HIV/AIDS reporting protocol. The grant, which will be administered by the Coalition for Environmentally Responsible Economies (CER
Epimmune Provides HIV Vaccine Program Update: PRNewswire - September 7, 2001; SAN DIEGO, Sept. 7 /PRNewswire/ -- Epimmune Inc. (Nasdaq: EPMN), presenting at the AIDS Vaccine 2001 Conference in Philadelphia today, provided additional information on its HIV vaccine program including its initial vaccine candidate and clinical trial plans. Epimmune anticipates that it will file an Investigational Ne
CEL-SCI Corporation Reports Promising Preclinical Results With Potential HIV Immunotherapeutic Agent: PRNewswire - September 7, 2001; VIENNA, Va., Sept. 7 /PRNewswire/ -- CEL-SCI Corporation (Amex: CVM) announces today s presentation of a poster at the AIDS Vaccine 2001 Congress in Philadelphia, PA entitled C Clade HGP-30 {p17 aa 86-115} Based Peptide Conjugates as Potential Therapeutic and Prophylactic HIV-1 Vaccine Antigens. In it, strong evidence
Real People. Real Stories. AIDS Walk Detroit; Birmingham Teacher Walks For the Future of His Students: PRNewswire - September 7, 2001; ROYAL OAK, Mich., Sept. 7 /PRNewswire/ -- AIDS Walk Detroit has hit the streets with its 2001 campaign, Real People. Real Stories. As part of this campaign, 6 area residents whose lives have been touched by HIV and AIDS are telling their stories in support of the September 16 Walk. They include Jerry, a Birmingham educ
Myriad Genetics Discovers Novel Hepatitis 'C' Target; Drug Development Program Has Been Initiated: PRNewswire - September 6, 2001; SALT LAKE CITY, Sept. 6 /PRNewswire/ -- Myriad Genetics, Inc. has discovered a novel drug target for the treatment of human infection by the hepatitis C virus (HCV), and has initiated high-throughput screening with its ProTrap(TM) drug screening technology, the Company announced today. The HCV target was discovered usi
ViroLogic Announces New Technology to Advance AIDS Vaccine Development: Results Indicate New Assay Can Help Identify Effective Vaccine Candidates Faster and More Efficiently Than Current Methods: PRNewsire - September 6, 2001; PHILADELPHIA, Sept. 6 /PRNewswire/ -- ViroLogic, Inc. (Nasdaq: VLGC) announced today that an enhanced version of its PhenoSense(TM) HIV drug resistance assay can measure the potential effectiveness of AIDS vaccines in development faster, more efficiently and more consistently than currently used methods, according to r
First African Great Lakes AIDS Conference Organized and Sponsored By AHF Global Immunity, Community Health and Information Network (Chain), & Uganda Business Coalition on HIV/AIDS (UBC) Scheduled In Entebbe, Uganda, September 6 to 9, 2001: 20 African Countries Assemble to Attack Barriers to HIV/AIDS Treatment And Support * Ugandan President Museveni to Welcome Delegates*: PRNewswire - September 5, 2001; ENTEBBE, Uganda , Sept. 5 /PRNewswire/ -- AHF Global Immunity, an international initiative of AIDS Healthcare Foundation, together with its partners, the Uganda Business Coalition on HIV/AIDS (UBC) and Community Health And Information Network (CHAIN), are hosting the First African Great Lakes AIDS Conference in Entebbe
ViroLogic Awarded $1.2 Million Ryan White CARE Grant For HIV Drug Resistance Testing in District of Columbia: PRNewswire - September 5, 2001; SOUTH SAN FRANCISCO, Calif., Sept. 5 /PRNewswire/ -- ViroLogic, Inc. (Nasdaq: VLGC), announced today that the Company has been exclusively awarded a $1.2 million Ryan White CARE Grant for HIV drug resistance testing in the District of Columbia. The grant will provide testing access to low-income individuals in the D.C.
Challenge Sir Elton John and Help Fight the Battle Against: World-Renowned Musician Participates in MSN Money AIDS Market Challenge Benefiting Elton John AIDS Foundation to Increase Global Education About Life-Threatening Disease: PRNewswire - September 4, 2001; REDMOND, Wash., Sept. 4 /PRNewswire/ -- To raise funds for the prevention of and education about HIV/AIDS, Microsoft Corp. today announced the MSN(R) Money AIDS Market Challenge, featuring pop-music icon Sir Elton John. Consumers can log on to CNBC on MSN Money and learn how to improve their stock-picking skills while
Real People. Real Stories. AIDS Walk Detroit; Pontiac Woman Lost a Brother to AIDS; Her Mother Still Lives with HIV: PRNewswire - August 31, 2001; ROYAL OAK, Mich., Aug. 31 /PRNewswire/ -- AIDS Walk Detroit has hit the streets with its 2001 campaign, Real People. Real Stories. As part of this campaign, 6 area residents whose lives have been touched by HIV and AIDS are telling their stories in support of the September 16 Walk. They include, Melody, whose brother d
Data Safety Monitoring Board Finds Primary Endpoint Met From Phase II Clinical Trial of REMUNE(R): PRNewswire - August 30, 2001; CARLSBAD, Calif., Aug. 30 /PRNewswire/ -- As announced by The Immune Response Corporation (Nasdaq: IMNR) on July 11, 2001, it was anticipated that the independent Data Safety Monitoring Board (DSMB) would be meeting again to evaluate the results of the Phase II clinical trial (STIR 2102) completed in Spai
The Immune Response Corporation Announces Its Decision Not to Proceed With Agouron's REMUNE(R) Study 202: PRNewswire - August 30, 2001; CARLSBAD, Calif., Aug. 30 /PRNewswire/ -- The Immune Response Corporation announced today that after a thorough review of the available data, it has informed Agouron Pharmaceuticals, Inc. (a Pfizer Company (NYSE: PFE)), the Company s former corporate partner, of the Company s decision that it does not intend, and is no
Ugandan Government and International AIDS Vaccine Initiative Sign Agreement to Accelerate Testing of AIDS Vaccines: PRNewswire - August 30, 2001; KAMPALA, Uganda , Aug. 30 /PRNewswire/ -- The International AIDS Vaccine Initiative (IAVI) and the Government of the Republic of Uganda today signed a partnership agreement aimed at accelerating the development and testing of preventive AIDS vaccines for Uganda and the world. Uganda has been a leader in accelerating pr
Tickets Now on Sale for 'Positively Cable Aught One: The Technical Trials Of Our Sweet Cablene,' Presented by AT&T Broadband: A Benefit for Cable Positive and Denver's Rainbow House: 15 Colorado Cable All Stars Headline The 7th Annual Musical Fundraiser on October 18, 2001, in Denver: PRNewswire - August 29, 2001; DENVER, Aug. 29 /PRNewswire/ -- The work may be hard, but the laughter is cheap in the cable industry. That s reflected in prices for tickets that are now on sale for this year s Positively Cable Aught One: The Technical Trials of Our Sweet Cablene, the 7th annual musical parody fundraiser, scheduled for Thursday eveni
'Ithembalabantu!' (Zulu for 'People's Hope'); First International Partnership for HIV Treatment to Launch in South Africa: Global Immunity and the Network of AIDS Communities of South Africa (NetCom, SA) Open New AIDS Clinic Thursday August 30th: PRNewswire - August 29, 2001; U.S. Congresswomen Barbara Lee & Diane Watson, The Premiere of KwaZulu Natal Province AIDS Healthcare Foundation President Michael Weinstein to Officiate DURBAN, South Africa , Aug. 29 /PRNewswire/ -- A U.S. and South African partnership will launch a clinic to provide anti-viral HIV treatments Thursday in Durban.
Real People. Real Stories. AIDS Walk Detroit: Ten Years After Losing 2 Sons to AIDS, Waterford Woman Still Walks: PRNewswire - August 27, 2001; ROYAL OAK, Mich., Aug. 27 /PRNewswire/ -- AIDS Walk Detroit has hit the streets with its 2001 campaign, Real People. Real Stories. As part of this campaign, 6 area residents whose lives have been touched by HIV and AIDS are telling their stories in support of the September 16 Walk. They include Elsie, who lost 2 sons t
Three Rivers Pharmaceuticals Seeks Permission For Generic Treatment for Hepatitis C: PRNewswire - August 24, 2001; PITTSBURGH, Aug. 24 /PRNewswire/ -- Three Rivers Pharmaceuticals, LLC, a Pittsburgh-based and privately-owned company, has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food & Drug Administration ( FDA ) for permission to market the antiviral prescription drug ribavirin. Ribavirin in combinatio
Midwest AIDS Prevention Project: Detroit Artists Unite in the Fight Against AIDS At 'ARTWORKS FOR LIFE' Benefit, Saturday, September 22: PRNewswire - August 23, 2001; FERNDALE, Mich., Aug. 23 /PRNewswire/ -- Over 150 of Detroit s most prominent artists will donate original pieces of art to be auctioned at the sixth annual ARTWORKS FOR LIFE. This exciting event will begin at 6:30 p.m. on Saturday, September 22, 2001 and will be held at the Edsel and Eleanor Ford House in Grosse Point
Infectech Obtains Patent in Bacterial Genomics Combating Deadly Bacteria In Patients with AIDS and Cystic Fibrosis: PRNewswire - August 22, 2001; SHARON, Pa., Aug. 22 /PRNewswire/ -- Infectech, Inc., (National Quotation Bureau: IFEC) a biotechnology company, has received U.S. Patent number 6,277,562 on August 21, 2001 for A Method for Paraffinophilic Isolation and Identification From a Body Specimen. This patent covers a method for detecting and killing non-tube
Real People. Real Stories. AIDS Walk Detroit; Local Woman Walks to Educate Latino Community: PRNewswire - August 17, 2001; ROYAL OAK, Mich., Aug. 17 /PRNewswire/ -- AIDS Walk Detroit has hit the streets with its 2001 campaign, Real People. Real Stories. As part of this campaign, 6 area residents whose lives have been touched by HIV and AIDS are telling their stories in support of the September 16 Walk. They include Julia, a Latino woman, w
Samaritan Pharmaceuticals (SPHC) Completes Phase I/II Clinical Trial Of ANTICORT in Patients With HIV Infection: Milestone Clinical Trial for ANTICORT, If Results Significant, Could Be First Low Cost Drug for AIDS: PRNewswire - August 17, 2001; LAS VEGAS, Aug. 17 /PRNewswire/ -- Samaritan Pharmaceuticals, Inc. (OTC Bulletin Board: SPHC), a developer of innovative treatments for high cortisol diseases, today announced it has completed its Phase Ib/IIa, dose-escalating clinical human trial for safety, toxicity and efficacy of ANTICORT(TM) in patients with HIV i
nSight Tackles The Monster Challenge: nSight and the AIDS Action Committee Team Up for the Second Time and Launch MonsterChallenge.Org, an AAC Fundraising Event Web site --: PRNewswire - August 16, 2001; BURLINGTON, Mass., Aug. 16 /PRNewswire/ -- nSight, Inc., a recognized leader in print and interactive communications offering a unique combination of consulting, project management, training, and staffing services, and the AIDS Action Committee (AAC), invite you to visit http://www.monsterchallenge.org. This whimsical,
Noted HIV/AIDS Physician to Address National Association of Black Journalists (NABJ) During Annual Conference in Orlando, FL August 23, 2001 - 8:00 a.m. : BET's Ed Gordon Will Moderate Panel Discussion: PRNewswire - August 16, 2001; OAKLAND, Calif., Aug. 16 /PRNewswire/ -- How Can Journalists Impact The AIDS Crisis? Noted HIV/AIDS physician Dr. Robert Scott of Oakland, California will lead this panel discussion, joined by award winning journalist Renee Kemp, whose coverage of the 13th International AIDS Conference in Durban, South A
Medical Services Adds Saliva-Based Rapid Test Kit: PRNewswire - August 15, 2001; EDMONTON, Alberta, Aug. 15 /PRNewswire/ -- Medical Services International Inc. (Pink Sheets: MSITF) is pleased to announce that it has added a Saliva-based HIV test kit to its current inventory of rapid test kits. Rather than using the invasive procedure of obtaining whole blood, saliva is collected and mixed with a bu
Walter Reed Says Rapid HIV Test 100% Accurate: PRNewswire - August 14, 2001; ATLANTA, Aug. 14 /PRNewswire/ -- The test results of InstantScreen(R), a rapid HIV test kit, were presented at the 2001 National HIV Prevention Conference in Atlanta on Monday by representatives from Walter Reed Army Institute of Research. BICO, Inc. (OTC Bulletin Board: BIKO) subsidiary Rapid HIV Detection Corp. s Ins
AIDS Healthcare Foundation Alleges 'PACIFIC Doesn't CARE!' AIDS Healthcare Foundation Files Lawsuit Against PacifiCare Over Mismanagement Of AIDS Patients' HMO Specialty Referrals and Access to Appropriate Care: PRNewswire - August 13, 2001; LOS ANGELES, Aug. 13 /PRNewswire/ -- In a press conference set for 10:30 a.m. this morning, Monday, August 13th at AIDS Healthcare Foundation s HOLLYWOOD HEALTHCARE CENTER (on the campus of Queen of Angels Hospital in Hollywood, 1300 Vermont Avenue, LA, CA 90027, rear entrance) AIDS medical providers and activists will
Medical Services Completes Initial Order for Rapid Test Kits: PRNewswire - August 13, 2001; EDMONTON, Alberta, and CAPE TOWN, South Africa , Aug. 13 /PRNewswire/ -- Medical Services International Inc. (Pink Sheets: MSITF) is pleased to announce that it has signed an agreement to supply an initial order of 50,000 rapid test kits for both HIV and Tuberculosis (TB) to HIVE Exports (SA) (PTY) Ltd. of Cape Town, S
Kaiser Permanente Research Featured at CDC HIV Prevention Conference: Studies Find More Early Detection Needed, Barriers to Testing Can Be Reduced: PRNewswire - August 13, 2001; OAKLAND, Calif., Aug. 13 /PRNewswire/ -- Studies presented by researchers from Kaiser Permanente will be featured at the HIV Prevention Conference in Atlanta sponsored by the Centers for Disease Control and Prevention. One study will show that 40% of patients diagnosed with HIV have already progressed to AIDS before HI
Novel AIDS Research Suggests New Treatment Path; Stimulating Innate Human Immune System May Retard Disease Progression: PRNewswire - August 13, 2001; NEW YORK, Aug. 13 /PRNewswire/ -- Research published in the August issue of the peer-reviewed journal Experimental Hematology presents laboratory findings that could lead to an antibody-based medication that prevents or attenuates the progression of HIV to AIDS. This research advance is based on new insights into the e
Dixie Chicks to Perform at Gala Event to Benefit The Fight Against Pediatric Aids in Texas: PRNewswire - August 10, 2001; AUSTIN, Texas, Aug. 10 /PRNewswire/ -- Texas s most beloved chicks will come home next month to perform at the invitation only Texas Twilight Gala benefiting the Pediatric AIDS League of Texas, University of Houston Pediatric HIV Program and Pediatric AIDS Network of Dallas (PANDA). The Office of the Governor Texas Fil
Real People. Real Stories. AIDS Walk Detroit: Ferndale Man Walks in Memory of Lost Friends P: PRNewswire - August 10, 2001; ROYAL OAK, Mich., Aug. 10 /PRNewswire/ -- AIDS Walk Detroit has hit the streets with its 2001 campaign, Real People. Real Stories. As part of this campaign, 6 residents from across the Metro-Detroit area whose lives have been touched by HIV and AIDS are telling their stories in support of the September 16 Walk. They in
Study Published in the New England Journal of Medicine Demonstrates Durable Viral Load Suppression With Combination Regimen Containing SUSTIVA(TM) In Heavily Pre-Treated Patients: Four-Drug Regimen Containing SUSTIVA(TM)+Nelfinavir+NRTIs May Provide Effective New Option for Difficult to Treat Patients: PRNewswire - August 9, 2001; WILMINGTON, Del., Aug. 9 /PRNewswire/ -- Quadruple combination HIV therapy with DuPont Pharmaceuticals non-nucleoside reverse transcriptase inhibitor (NNRTI) SUSTIVA(TM) ( efavirenz ), plus nelfinavir and two nucleoside reverse transcriptase inhibitors (NRTIs), provides greater and more durable viral load suppression c
Effective Treatments Lacking for Most Desperate AIDS Patients; AIDS Researchers Issue Call to Action in New England Journal of Medicine: PRNewswire - August 8, 2001; PITTSBURGH -- New medications are urgently needed for individuals who have drug-resistant HIV, and academia, industry and government must work together to bring them into the clinic, urged AIDS researchers John Mellors, M.D., University of Pittsburgh, and Julio Montaner, M.D., University of British Columbia (UBC), in a
BICO Receives Order From Walter Reed for Rapid HIV Tests: PRNewswire - August 8, 2001; PITTSBURGH, Aug. 8 /PRNewswire/ -- BICO, Incorporated (OTC Bulletin Board: BIKO) announced today that subsidiary Rapid HIV Detection Corp. has received an order for 14,000 of its InstantScreen(R) Rapid HIV tests from Walter Reed Army Institute of Research for further evaluation by its HIV Research Program in Washington
The Journal of Immunology Publication Reports Power of Linkage Approach To Vaccination Over a Simple Combination of Antigen and Immunostimulatory Sequences in Mouse HIV Prophylaxis Model: PRNewswire - August 8, 2001; BERKELEY, Calif., Aug. 8 /PRNewswire/ -- Dynavax proprietary immunostimulatory DNA sequences (ISS) have been shown effective in producing potent immune responses in mice when linked to envelope protein gp120 antigen. This research appears in the August 1 issue of The Journal of Immunology. The Journal of Immunology stu
Sangamo BioSciences Reports Publication of Data in Nature Biotechnology And Methods in Enzymology: Enhanced Methods Developed to Engineer DNA-binding Proteins: PRNewswire - August 7, 2001; RICHMOND, Calif., Aug. 7 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced the publication of research data in Nature Biotechnology in an article entitled, A Rapid, Generally Applicable Method to Engineer Zinc Fingers Illustrated by Targeting the HIV-1 Promoter, and related work published in Meth
Contraceptive Effective Against HIV Transmission Found Safe in Recent Testing: PRNewswire - August 7, 2001; ROSEVILLE, Minn., Aug. 7 /PRNewswire/ -- In a paper published in the current issue of the Journal of Applied Toxicology, scientists at Parker Hughes Cancer Center reported that 5-bromo-6-methoxy-5,6,-dihydro-3 - azidothymidine-5 -(p-bromophenyl) methyoxyalaninyl phosphate (WHI-07), a potent dual-function contraceptive
AIDS Healthcare Foundation Celebrates First Anniversary of Oakland, CA Earvin 'Magic' Johnson, Jr. Clinic: Growing State-of-the-Art AIDS Healthcare Facility Offers Underserved Populations in Alameda County Improved Access to Quality Care, Services: PRNewswire - August 6, 2001; LOS ANGELES, Aug. 6 /PRNewswire/ -- AIDS HEALTHCARE FOUNDATION (AHF), the nation s largest HIV/AIDS medical care provider today celebrates the first anniversary of its state-of-the-art AIDS healthcare center serving Oakland and Alameda County. The center, which opened last July and now serves 125 patients, is officiall
Pittsburgh Firm Prepares to Set the Standard in Rapid HIV Testing: PRNewswire - August 6, 2001; PITTSBURGH, Aug. 6 /PRNewswire/ -- A new weapon in the battle against the worldwide AIDS epidemic is set to be unleashed. BICO, Incorporated (OTC Bulletin Board: BIKO) subsidiary Rapid HIV Detection Corp. (Rapid Corp.) has acquired the worldwide marketing rights for a new HIV diagnostic test known as InstantScreen(R).
New Survey Reveals Most People Living With HIV Experience Anemia, Yet Few Are Aware of Its Symptoms, Diagnosis and Treatment: Know Your Red Blood Cell Count! Campaign Seeks to Increase Awareness of 'Missing Marker' for HIV -: PRNewswire - August 6, 2001; RARITAN, N.J., Aug. 6 /PRNewswire/ -- Awareness of the symptoms, diagnosis and treatment of HIV-related anemia among people living with HIV remains alarmingly low according to the results of a first-of-its-kind survey of nearly 700 HIV-positive Americans. These results indicate that, as America enters its third decade
Quidel Receives Additional Patent Protection on LTF Technology; Patent Covers Use of Company Technology to Detect Vaginal Clue Cells: PRNewswire - August 2, 2001; SAN DIEGO, Aug. 2 /PRNewswire/ -- Quidel Corporation (Nasdaq: QDEL), a leading provider of point-of-care (POC) rapid diagnostic tests, today announced receipt of additional patent protection for its Layered Thin Film (LTF) Technology. The recently issued U.S. Patent, No. 6,200,817 B1, covers the use of proprietary Quid
Tanox to Initiate Phase I Clinical Trial of TNX-355 for HIV Infection: PRNewswire - August 1, 2001; HOUSTON, Aug. 1 /PRNewswire/ -- Tanox, Inc. (Nasdaq: TNOX) announced today that enrollment is now open in a Phase I clinical trial of a monoclonal antibody being developed for a new approach to the treatment of HIV. After review of the Investigational New Drug Application submitted by Tanox, the FDA indicat
AIDS Healthcare Foundation Announces the Opening Of The AHF Healthcare Center/New York: California-Based Provider to Join Forces With Dr. Jeffrey Greene, One of New York's Most Respected HIV/AIDS Specialists, In State-of-the-Art AIDS Healthcare Facility Offering Patients Improved Access to Quality HIV/AIDS Care, Services: PRNewswire - August 1, 2001; LOS ANGELES, Aug. 1 /PRNewswire/ -- AIDS Healthcare Foundation (AHF), the nation s largest HIV/AIDS medical care provider is pleased to announce a new venture in the fight against AIDS. AHF is partnering with Dr. Jeffrey Greene, one of New York City s most respected HIV/AIDS medical providers in a new state-of-the-art
New Health Site Helps Consumers Interpret Lab Test Results: 'Lab Tests Online' Only Testing Site Supported By Clinical Laboratory Community: PRNewsire - July 31, 2001; CHICAGO, July 31 /PRNewswire/ -- The most up-to-date information on PSA, HIV, pap smear, cholesterol, and dozens of other laboratory tests is now a few clicks away. Lab Tests Online (http://www.labtestsonline.org ), the only non- commercial medical testing site supported by the clinical laboratory community, provides h
Health and Health Care Issues Examined at Annual Joint Statistical Meetings: PRNewswire - July 31, 2001; ATLANTA, July 31 /PRNewswire/ -- At the Joint Statistical Meetings, August 5-9, 2001, in Atlanta, Georgia, statisticians and other biomedical researchers will present recent findings in clinical research, genetics, and health policy. Paper titles of selected sessions are below, and detailed descriptions including abstr
BICO Acquires Worldwide Marketing Rights for Rapid HIV Diagnostic Test: PRNewswire - July 31, 2001; PITTSBURGH, July 31 /PRNewswire/ -- BICO, Incorporated (OTC Bulletin Board: BIKO) today announced that it has acquired the exclusive worldwide marketing rights to a rapid HIV diagnostic test, known as InstantScreen(TM), which takes only 30 seconds to produce results. Instant Screen is currently being evaluated in the l
Trinity Medical Group USA Announces Filing of New Drug Application For HIV Treatment, REMUNE(TM), in Thailand: PRNewswire - July 30, 2001; RANCHO SANTA MARGARITA, Calif., July 30 /PRNewswire/ -- Trinity Medical Group USA, Inc. (OTC Bulletin Board: TMGU) today announced the filing of a New Drug Application (NDA) with the governing health authorities in Thailand for its HIV-1 Immunogen product, also known as REMUNE(TM). The NDA, which was filed by the Comp
AIDS Healthcare Foundation Ads Target HMO Neglect of AIDS Patients: PRNewswire - July 27, 2001; LOS ANGELES, July 27 /PRNewswire/ -- A public awareness ad campaign targeting HMO neglect of AIDS-affected Californians debuts this week in major gay media outlets throughout California. The print ads -- sponsored by Los Angeles-based AIDS Healthcare Foundation (AHF) -- urge HIV-infected HMO enrollees to report problem
Camp Arroyo gives terminally ill children a place to be: PRNewswire - July 27, 2001; Justino Aguila, Chronicle Staff Writer; Eleven-year-old Dillon Scheer has to deal with the knowledge that he s HIV-positive as well as endless amounts of medications - and occasional name- calling from some classmates. But at Camp Arroyo, he s free to be a kid. Camp was fun, Dillon said while playing video games in his home in Forestville in Sonoma County.
Notable Rock Musician Scores Greatest Hit By Coming Out at HRC's Annual Chicago Dinner: PRNewswire - July 27, 2001; WASHINGTON, July 27 /PRNewswire/ -- Rock musician and Chicago native Chuck Panozzo will celebrate a special homecoming tomorrow as he comes out as a gay man living with HIV at the Human Rights Campaign s annual Chicago dinner. Panozzo, founding member and bass player of the rock group Styx, said he elected to go public
AIDS Project Los Angeles Applauds Increased Funding for AIDS Drug Assistance Program; Questions Cuts in Education and Prevention Programs: PRNewswire - July 26, 2001; LOS ANGELES, July 26 /PRNewswire/ -- AIDS Project Los Angeles (APLA) applauds Governor Gray Davis for the augmentation of the AIDS Drug Assistance Program in California s FY 2001 - 2002 Budget. The cuts to HIV prevention and education programs, however, elicited harsh criticism. Though extremely pleased with the sought
VaxGen Receives NIH Funds for HIV Vaccine Research: PRNewswire - July 25, 2001; BRISBANE, Calif., July 25 /PRNewswire/ -- VaxGen , Inc. (Nasdaq: VXGN) today announced that it has finalized an agreement to collaborate with BBI Biotech, a wholly-owned subsidiary of Boston Biomedica, Inc. (Nasdaq: BBII), to collect, process, and store white blood cells and seminal plasma from participants in VaxGen s
Antigenics and Dr. Bruce Walker of Massachusetts General to Test Heat Shock Protein-Based Approach to HIV: PRNewswire - July 25, 2001; NEW YORK, July 25 /PRNewswire/ -- Antigenics Inc. (Nasdaq: AGEN) announced today that it has entered into a collaboration with Bruce D. Walker, M.D., director of the Partners AIDS Research Center at Massachusetts General Hospital and one of the world s leading immunologists in the field of HIV research. Dr. Walker s as
Educators Take Their Skills to Africa: PRNewswire - July 24, 2001; HIGH POINT, N.C., July 24 /PRNewswire/ -- Six teachers will share their knowledge and expertise with colleagues in rural South Africa through a unique partnership between two North Carolina companies. On Saturday, June 30, the team of educators departed from Raleigh. During a three-week trip to South Africa, the group
CEL-SCI Gives Update on Cervical Cancer Clinical Trial: PRNewswire - July 24, 2001; - Encouraging results seen in HIV-infected women with HPV induced cervical dysplasia, the stage preceding the development of cervical cancer. - Cervical cancer is on the Center for Disease Control and Prevention s list of AIDS-defining illnesses, and has been increasing among HIV-infected women. - Potential for
GSK and Shionogi to Enter Global Multi-Product Development And Commercialization Alliance; GSK-Shionogi Joint Venture to be Formed: PRNewswire - July 24, 2001; PHILADELPHIA, July 24 /PRNewswire/ -- Shionogi & Co., Ltd. and GlaxoSmithKline plc (GSK) (NYSE: GSK) today announce a plan to form a joint venture to develop and market several drugs in clinical trials, including new agents to fight against HIV and neurological disorders. Under the terms of a letter of intent, Shio
10,000 Physicians to Ask for Resignation of CDC Director, End of Cover-Up: PRNewswire - July 23, 2001; WASHINGTON, July 23 /PRNewswire/ -- At a press conference scheduled for Tuesday, July 24, in Washington DC, a coalition of physician members of Congress and medical groups representing 10,000 doctors will ask for the resignation of Dr. Jeffrey Koplan, the director of the Centers for Disease Control and Prevention (CDC)
Study Demonstrates SuperGen's Rubitecan Reduced Replication of HIV-1 in Human Lymphocytes by 95%, and Induced Apoptosis Within 24 Hours of Drug Treatment in Freshly Infected Human Lymphocytes: PRNewswire - July 23, 2001; DUBLIN, Calif., July 23 /PRNewswire/ -- SuperGen Inc. (Nasdaq: SUPG & SUPGZ) announced today that a study of rubitecan demonstrated the drug s ability to inhibit by greater than 95 percent the replication of HIV-1 in clinically relevant primary peripheral blood lymphocytes (PBLs). Equally important, the study showe
'Magic' Comes to Jacksonville!: AIDS Healthcare Foundation Announces the Opening of The Earvin 'Magic' Johnson, Jr. Clinic: PRnewswire - July 23, 2001; LOS ANGELES, July 23 /PRNewswire/ -- AIDS Healthcare Foundation (AHF), the nation s largest HIV/AIDS medical care provider is pleased to announce a new venture in the fight against AIDS. AHF will establish a state-of-the-art HIV/AIDS healthcare center serving the greater Jacksonville area (Duval County) and surrounding
G-8 Summit: Call for Leaders to Deliver on Commitments To Speed AIDS Vaccine Development: PRNewswire - July 20, 2001; NEW YORK, July 20 /PRNewswire/ -- In a briefing paper released today, IAVI urged G-8 leaders to translate past pledges into concrete action at this week s G-8 Summit, the first to include AIDS as a major agenda item. As far back as the Denver Summit in 1997, G-8 member countries have made commitments to fight against A
Physicians Consortium Says NIH Report Proves That Abstinence, Not Condoms, Must Be the Focus of Federal Health Efforts: PRNewswire - July 20, 2001; WASHINGTON, July 20 /PRNewswire/ -- Condoms, long the mainstay of the safe-sex public health model, do not protect against the spread of nearly all sexually transmitted diseases. This is the major finding of a benchmark report released on Friday by the U.S. Department of Health and Human Services (HHS). Clinical resear
AIDS Project Los Angeles Applauds Presidential Advisory Council on HIV/AIDS Recommendations to Bush Administration: PRNewswire - July 20, 2001; LOS ANGELES, July 20 /PRNewswire/ -- AIDS Project Los Angeles (APLA) fully supports the new recommendations made by the Presidential Advisory Council on HIV/AIDS to the Bush Administration. APLA urges President Bush to act on these recommendations and commit federal resources to both prevent new HIV infections and impr
Africa Expert Visits Denver: On July 30, Chris Conrad of CARE Will Visit Denver to Discuss the Fight Against HIV/AIDS: PRNewswire - July 17, 2001; SAN FRANCISCO, July 17 /PRNewswire/ -- Chris Conrad, a development veteran of more than 20 years, will visit Denver to provide a unique and largely untold aspect of the fight of AIDS in Africa. As CARE s regional director based in Johannesburg, South Africa , Conrad oversees self-help programs, including an innovative
PTC Therapeutics Awarded Second Phase I SBIR Grant To Develop Novel HIV Treatments: PRNewswire - July 17, 2001; SOUTH PLAINFIELD, N.J., July 17 /PRNewswire/ -- PTC Therapeutics announced today it has been awarded a second Phase I Small Business Innovation Research (SBIR) Grant from the National Institutes of Health. This grant will be used to advance PTC s RNA-based approach for developing novel drugs that target the mechanism t
amfAR Awards Over $3 million for New Research on HIV/AIDS-New Initiative Targets 'Orphan Genes' of AIDS Virus for Drug Development: PRNewswire - July 17, 2001; NEW YORK, July 17 /PRNewswire/ -- The American Foundation for AIDS Research (amfAR) today announced research awards totaling over $3 million for new projects to develop an AIDS vaccine, microbicides, new anti-HIV drugs, and methods of restoring immune function in people with HIV/AIDS. The Foundation awarded $500,000 as
University of Pittsburgh AIDS Researchers Receive Awards: PRNewswire - July 17, 2001; PITTSBURGH, July 17 /PRNewswire/ -- Two University of Pittsburgh AIDS researchers have received grants from the American Foundation for AIDS Research (amfAR) for work that is aimed at finding new approaches to combating the human immunodeficiency virus (HIV), the virus that leads to AIDS. Michael A. Parniak, Ph.D., pro
Jerusalem Global Ventures (InnoMed) Invests $1 Million in BioVirase: PRNewswire - July 16, 2001; JERUSALEM, July 16 /PRNewswire/ -- Dr. Dalia Megiddo, Managing Partner of InnoMed, the life sciences fund of Jerusalem Global Ventures, announced today that Jerusalem Global Ventures has invested $1 million in BioVirase (formerly Amidut). BioVirase has developed a test kit to measure the sensitivity of the HIV virus to
Consensus Pharmaceuticals Awarded Accelerated Phase I/II Grant to Advance Development of AIDS Treatment: PRNewswire - July 16, 2001; MEDFORD, Mass., July 16 /PRNewswire/ -- Privately-held Consensus Pharmaceuticals, Inc. announced today the award of a $1.05 MM Accelerated Phase I/II Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health in Bethesd
Visible Genetics Enters into Agreement With Abbott Laboratories: TRUGENE(TM) HIV-1 Genotyping Test to Be Used in Clinical Studies: PRNewswire - July 16, 2001; TORONTO, July 16 /PRNewswire/ -- Visible Genetics Inc. reported today that it has entered into an Agreement with Abbott Laboratories . Under the terms of the agreement Visible Genetics will assist Abbott Laboratories by providing HIV resistance testing in two clinical studies involving Abbott s protease inhibitor,
National AIDS Fund AmeriCorps Program Members Honored At MetLife Foundation Caring Counts Awards For Making a Difference in Fight Against HIV/AIDS; Actress/Activist Judith Light Hosts Awards: PRNewswire - July 13, 2001; WASHINGTON, July 13 /PRNewswire/ -- Thirty-three National AIDS Fund AmeriCorps Program members from across the nation were honored today at the 2001 MetLife Foundation Caring Counts Awards for their service efforts in the fight against HIV/AIDS. The work that the AmeriCorps members do is priceless in the fight against
Trinity Medical Group USA Announces Study Indicating No HIV Mutation Found in Patients Treated With REMUNE(TM) Up to 144 Weeks: PRNewswire - July 11, 2001; RANCHO SANTA MARGARITA, Calif., July 11 /PRNewswire/ -- Trinity Medical Group USA, Inc. (OTC Bulletin Board: TMGU) today announces the presentation of clinical studies showing that random genotype testing in patients using its immune-based therapy for HIV, REMUNE(TM), did not experience mutation of the virus. After 144
New Virological Findings From Phase II Clinical Trial of REMUNE(TM) Presented at the 1st International AIDS Society Conference On HIV Pathogenesis and Treatment: PRNewswire - July 11, 2001; CARLSBAD, Calif., July 11 /PRNewswire/ -- The Immune Response Corporation announced today that the principal investigator Professor Eduardo Fernandez-Cruz, M.D., Ph.D., presented new virological findings from the Phase II clinical trial (STIR 2102) completed in Spain with REMUNE(TM) (HIV-1 Immunogen), an investigationa
VIRACEPT(R) Combination Therapy as Initial HAART Demonstrates Long-Term Response: PRnewswire - July 11, 2001; BUENOS AIRES, Argentina , July 11 /PRNewswire/ -- Agouron Pharmaceuticals, Inc. reported that VIRACEPT provided durable and potent HIV viral load suppression, as well as an increase in CD4 cells based on a retrospective chart review of 1,309 people living with HIV, who received VIRACEPT(R) (nelfinavir mesylate) combina
Study Examines Impact of Long-Term Administration of T-20 on Daily Life: Eighty-Five Percent of Patients Report Subcutaneous Delivery Does Not Substantially Affect Daily Activities: PRNewswire - July 11, 2001; BUENOS AIRES (July 11, 2001) - Data evaluating patient acceptance of the subcutaneous administration of T-20, an investigational HIV fusion inhibitor being developed jointly by Roche and Trimeris (Nasdaq: TRMS), are being presented today at the First International AIDS Society (IAS) Conference on HIV Pathogenesis and T
Griffin Securities, Inc. Issues Special Industry Report on HIV/AIDS: PRNewswire - July 10, 2001; NEW YORK, July 10 /PRNewswire/ -- Griffin Securities, Inc. is a member of the National Association of Securities Dealers, CRD number 43229. Griffin Securities special industry report: HIV / AIDS: The Past and the Future provides an overview of the market s past, present and future treatment strategies and emerging tren
Largest Protease Inhibitor-Switch Study Shows Longer Virologic Response In Patients Who Switch to a Regimen Containing SUSTIVA(TM): PRNewswire - July 10, 2001; BUENOS AIRES, Argentina , July 10 /PRNewswire/ -- Data presented today at the 1st International AIDS Society (IAS) Conference on HIV Pathogenesis and Treatment here indicate that patients who substituted DuPont Pharmaceuticals anti-HIV drug SUSTIVA(TM) ( efavirenz ), a non-nucleoside
Interferon/Ribavirin Combination Therapy More Effective at Reducing Hepatitis C Viral Load in HIV-Infected Persons: PRNewswire - July 10, 2001; BUENOS AIRES, Argentina , July 10 /PRNewswire/ -- A clinical study has revealed that interferon/ribavirin combination therapy is more effective than interferon monotherapy at reducing hepatitis C viral load in HIV-infected persons in the first 12 weeks of treatment. The study also showed that combination therapy appear
Simple and Compact Ziagen/Combivir Regimen Results in Superior Efficacy Compared to Protease Inhibitor-Based Regimen for the Treatment of HIV: PRNewswire - July 10, 2001; BASINGSTOKE, England, July 10 /PRNewswire/ -- Shire Pharmaceuticals Group plc announces that new research findings were presented today regarding a Ziagen / Combivir regimen at the 1st International AIDS Society Conference on HIV Pathogenesis and Treatment.
New Data Show Once-Daily Videx EC Capsules Provide Safe, Effective and Convenient Treatment for HIV-Positive Patients: PRNewswire - July 10, 2001; BUENOS AIRES, Argentina , July 10 /PRNewswire/ -- Once-daily Videx EC (enteric-coated didanosine) as part of a triple drug regimen provides an effective, well-tolerated anti-HIV therapy with similar antiviral activity to an AZT /
Visible Genetics' Trugene HIV-1 Genotyping Test and Hardware Receive Canadian Regulatory Approval: PRNewswire - July 10, 2001; TORONTO, July 10 /PRNewswire/ -- Visible Genetics Inc. (Nasdaq: VGIN) (VGI) today announced that it has received licenses for its TRUGENE(TM) HIV-1 Genotyping Test and hardware from the Therapeutics Product Directorate (TPD) of Health Canada . In Canada, each individual component of the OpenGene system - the DNA sequen
Virco HIV Resistance Tests Can Predict Response to Therapy for Up to Two Years: PRNewswire - July 10, 2001; BUENOS AIRES, Argentina , July 10 /PRNewswire/ -- A study presented today at the 1st International AIDS Society Conference on HIV Pathogenesis and Treatment shows that Virco s resistance tests can predict clinical response to HIV treatment for up to two years. Patients who received three or more active drugs (as meas
New VIRAMUNE(R) (nevirapine) Data Presented at International AIDS Society Conference: Studies Examine Lipoprotein Profile in Patients Taking VIRAMUNE -: PRNewswire - July 10, 2001; BUENOS AIRES, July 10 /PRNewswire/ -- Preliminary findings from three studies presented this week at the first International AIDS Society Conference on HIV Pathogenesis and Treatment demonstrate that HIV-positive individuals taking a VIRAMUNE(R) ( nevirapine )-based anti-HIV treatment combination were observed to have
Virologic announces data showing new Phenosense assay 10 times more sensitive than other HIV drug resistance assays; Expands testing to new patients with low viral loads: PRNewswire - July 10, 2001; BUENOS AIRES, ARGENTINA & SOUTH SAN FRANCISCO, CA ViroLogic, Inc. (NASDAQ: VLGC) announced today that a new generation of its drug resistance assay, PhenoSense HIV, is nearly 10 times more sensitive than other commercially available drug resistance assays according to research presented at the International AIDS So
Results of Studies Comparing the Potency of Lamivudine (Epivir(R)) Vs. Emtricitabine Differ Depending on Cell Line Selected for In Vitro Testing: PRNewswire - July 9, 2001; AT A GLANCE -- Previous in vitro studies comparing the potency of Epivir and FTC may have been influenced by the cell lines used in testing. -- New research comparing the two drugs and using three different cell types shows varying results, based on the cell line. -- The drugs were essentially equivalent in in vitr
Three Year Durability of Response Data Shows SUSTIVA(TM) Provides Greater Viral Suppression Than Protease Inhibitor Therapy: PRNewswire - July 9, 2001; BUENOS AIRES, Argentina , July 9 /PRNewswire/ -- Data presented today at the 1st International AIDS Society (IAS) Conference on HIV Pathogenesis and Treatment here indicate that combination therapy with DuPont Pharmaceuticals anti-HIV drug SUSTIVA(TM) ( efavirenz ), a non-nucleoside re
Study Shows VIRAMUNE(R) (nevirapine) Treatment Combination As Effective as Protease-Inhibitor-Based Regimen in Suppressing HIV: PRNewswire - July 9, 2001; BUENOS AIRES, Argentina , July 9 /PRNewswire/ -- Final one-year results of the international COMBINE study show that an anti-HIV treatment regimen of VIRAMUNE(R) ( nevirapine ) plus Combivir (TM) ( 3TC
SUSTIVA(TM) Demonstrates Treatment Advantage Over Viramune(R) and Over Protease Inhibitors in HIV Positive Patients: PRNewswire - July 9, 2001; BUENOS AIRES, Argentina , July 9 /PRNewswire/ -- Data presented today at the 1st International AIDS Society (IAS) Conference on HIV Pathogenesis and Treatment here showed that HIV treatment-naive patients taking a combination HIV treatment regimen containing DuPont Pharmaceuticals anti-HIV drug SUSTIVA(TM) (
Agouron Pharmaceuticals, Inc. Terminates REMUNE(TM) Development Collaboration: PRNewswire - July 6, 2001; CARLSBAD, Calif., July 6 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced today it has received notification of the termination by Agouron Pharmaceuticals, Inc. (a Pfizer company) of the continued development and commercialization of REMUNE(TM) (HIV-1 Immunogen), an investigational immune-based
Developers of Technology That Increases Affect of Drugs For Hepatitis, HIV, Cancer, Other Uses, Form Spin-Off Company From Wake Forest University School of Medicine: PRNewswire - July 6, 2001; WINSTON-SALEM, N.C., July 6 /PRNewswire/ -- Buoyed by continued successes of a novel method for targeting drugs inside the body, Louis S. Kucera, Ph.D. has formed Kucera Pharmaceutical Co. as a spinoff from Wake Forest University School of Medicine and the University of North Carolina at Chapel Hill. The technique invo
Bristol-Myers Squibb Launches New Web Site: PRNewswire - July 5, 2001; PENNINGTON, N.J., July 5 /PRNewswire/ -- ZeritHCP.com, a new Web site designed as an online resource to provide healthcare professionals access to the most up-to-date information about Zerit(R) ( stavudine ), was recently launched. Zerit(R), a product of Bristol-Myers Squibb , is a medicatio
ViroLogic Assay Shows "Hypersusceptibility" to HIV Drugs Leads to Improved Patient Outcomes: PhenoSense HIV Only Assay Able to Measure Hypersusceptibility: PRNewswire - July 5, 2001; SOUTH SAN FRANCISCO, Calif., July 5 /PRNewswire/ -- ViroLogic, Inc. (Nasdaq: VLGC) announced today that a new study using its highly sensitive PhenoSense(TM) HIV drug resistance assay demonstrates that HIV patient outcomes can be significantly improved by the presence of enhanced susceptibility, or hypersusceptibility,
The co-discoverer of the AIDS virus, Professor Jean-Claude Chermann, becomes Chief Scientific Director of URRMA Biopharma, and Research and Development Director at URRMA R&D: PRNewswire - June 29, 2001; MONTREAL, June 29 /PRNewswire/ - At the head of the research Unit 322 at Inserm, Marseille, France , for 13 years, Professor Jean-Claude Chermann, becomes, as a full time and exclusive position, Chief Scientific Director of URRMA Biopharma, and also Research and Development Director of URRMA Biopharma s subsidiary - UR
Congresswoman Tubbs Jones Supports State of Emergency on AIDS Epidemic: PRNewswire - June 28, 2001; WASHINGTON, June 28 /PRNewswire/ -- Congresswoman Stephanie Tubbs Jones spoke at a press conference on June 28, 2001 requesting a state of emergency be declared regarding the AIDS epidemic in communities of color. The press conference was called in conjunction with the Congressional Black Caucus but was also attended b
IAVI Commends United Nations Declaration of Commitment to HIV/AIDS; However Some Crucial Issues Left Unaddressed: PRNewswire - June 27, 2001; NEW YORK, June 27 /PRNewswire/ -- Seth Berkley, M.D., President and CEO of the International AIDS Vaccine Initiative (IAVI), today issued the following statement in response to the UN General Assembly approval of a Declaration of Commitment to HIV/AIDS: The International AIDS Vaccines Initiative applauds the United Nat
FXB and Partners In Health (PIH) Announce Expansion of DOT-HAART Program to be Discussed at UN Church Center, June 27, 2001, 9am-noon: PRNewswire -June 27, 2001; UNITED NATIONS, June 27 /PRNewswire/ -- For more than a decade, the Association Francois-Xavier Bagnoud (FXB) has been expanding access to high-quality HIV/AIDS Care and Treatment in HIV-affected populations worldwide, including Africa. Now, with Partners In Health, FXB has developed novel HIV/AIDS treatment strategies
House Committee Approves Global AIDS Funds: Hyde: "AIDS Pandemic is One of the Great Moral Challenges Of Our Era, and Threatens the Stability of the Globe": PRNewswire - June 27, 2001; WASHINGTON, June 27 /PRNewswire/ -- A compromise international AIDS funding proposal authored by U.S. Rep. Henry J. Hyde (R-IL) was overwhelming approved today by the House International Relations Committee. The $1.36 billion proposal includes $750 million for an international AIDS trust fund, and was the result of suc
50 Volunteers Gather on HIV Testing Day: AIDS Walk Detroit Gears up for September 16 Walk: PRNewswire - June 27, 2001; ROYAL OAK, Mich., June 27 /PRNewswire/ -- In conjunction with National HIV Testing Day in Michigan, Steppin Out announced that more than 50 volunteers will gather at the Royal Oak Woman s Club on Fourth Street in Downtown Royal Oak at 6:30 p.m. on Wednesday, June 27, 2001 to help Steppin Out kick off its preparations f
Catholic Medical Mission Board and Boehringer Ingelheim Host Multi-Sector Reception on Collaborative HIV/AIDS Prevention and Care Strategies: PRNewswire - June 27, 2001; NEW YORK, June 27 /PRNewswire/ -- On June 24, 2001 U.N. General Assembly Special Session (UNGASS) delegate Catholic Medical Mission Board (CMMB) and Boehringer Ingelheim , one of the world s leading pharmaceutical companies, hosted a private reception at the UN Plaza Hotel that focused on multi-sector responses to the
ViroLogic Launches Phenosense.com to Facilitate HIV Drug Resistance Management and Insurance Reimbursement: PRNewswire - June 27, 2001; SOUTH SAN FRANCISCO, Calif., June 27 /PRNewswire/ -- ViroLogic, Inc. today announced the launch of PhenoSense.com (http://www.phenosense.com), an online resource that provides HIV patients and caregivers with up-to-date information on HIV drug resistance management and resistance testing insurance coverage. Drug resist
National HIV Testing Day: PRNewswire - June 27, 2001; WASHINGTON, June 27 /PRNewswire/ -- Today the National Association of People with AIDS (NAPWA) sponsors the seventh annual National HIV Testing Day. Federal and corporate partners join NAPWA in supporting more than 10,000 communities across the country as they organize local activities to encourage those at risk to get
Model Treatment Program Set to Combat AIDS in Poorest Nations; Community Based Organizations Provide Model for Provision of AIDS Treatment: PRNewswire - June 26, 2001; NEW YORK, June 26 /PRNewswire/ -- What began as a small crusade to provide HIV-positive patients with leftover and discarded treatments has grown into a full-scale program for providing treatments for people living with HIV/AIDS in 14 of the poorest African and Caribbean nations, according to AIDS Empowerment and Treat
Catholic Leaders at U.N. AIDS Conference Cite Church's Success at Delivering Care: PRNewswire - June 26, 2001; NEW YORK, June 26 /PRNewswire/ -- The churches of South Africa are emerging as the best network for the prevention and treatment of HIV-AIDS, said Sr. Allison Munro today as she participated in the first ever U.N. General Assembly Special Session (UNGASS) on HIV-AIDS. Sr. Munro represents the Southern African Catholic
Call for UN Meeting, Global Fund to Include Historic Commitment to Rapid, Worldwide ACCESS to AIDS Vaccines: White Paper released at UN Meeting details public sector actions to accelerate R&D and prepare for vaccine delivery. Individuals, Organizations from 145 nations launch global e-petition in support.: PRNewswire - June 26, 2001; NEW YORK, June 26 /PRNewswire/ -- As world leaders gather at the UN General Assembly Special Session on HIV/AIDS and continue discussions on a Global AIDS/Health Fund, the International AIDS Vaccine Initiative (IAVI) today called for an unequivocal firm, advance commitment to make AIDS vaccines available to all who nee
Cable Television Provides Close to 200 Hours of HIV/AIDS Programming To Support National HIV Testing Day (June 27): Cable Positive Unites Cable's Efforts Through Targeted Public Service Campaign To Reach More Than 70 Million American Households With the Messages of HIV/AIDS Prevention and Awareness: PRNewswire - June 26, 2001; NEW YORK, June 26 /PRNewswire/ -- Cable Positive, the national non-profit organization that galvanizes the cable industry s resources, access and influence in the fight against HIV/AIDS, has united the efforts of cable television to provide more than 70 million American households with close to 200 hours of HIV/AIDS pr
VaxGen's AIDS Vaccine for Developing World Shows Unexpected Activity: Results May Yield Vaccine With Broader Protection: PRNewswire - June 26, 2001; BRISBANE, Calif., June 26 /PRNewswire/ -- VaxGen , Inc. (Nasdaq: VXGN) presented laboratory data today at an international scientific conference indicating that antibodies to HIV subtype C (HIV-C) have an unexpected ability to bind to significant regions of another HIV subtype. The findings indicate that a vaccine that
Kimberly-Clark Donates $2.6 Million to Help Children Orphaned by AIDS; Largest-Ever Contribution to U.S. Fund for UNICEF's HIV/AIDS Programs: PRNewswire - June 25, 2001; NEW YORK, June 25 /PRNewswire/ -- The U.S. Fund for UNICEF (United Nations Children s Fund) today announced that the Kimberly-Clark Corporation has given $500,000, the first installment of a four-year $2.6 million grant, to UNICEF to help the more than 13 million children orphaned by AIDS worldwide. Children orphaned b
Major Study in Uganda to Identify Best Community-Based Approaches for HIV/AIDS Prevention: New Partnership Program Involving UNAIDS, UNICEF, Uganda AIDS Commission and Pfizer Foundation: PRNewswire - June 25, 2001; NEW YORK, June 25 /PRNewswire/ -- The Pfizer Foundation today announced that it will fund a study in Uganda to determine which preventive measures have been most effective in curbing HIV infection. The study will be conducted over 18 months and be done in collaboration with UNAIDS ,
BET Rap-It-Up Family Block Party Rallies the Washington Community in the Fight Against AIDS: Cable Network Launches Historic National Campaign to Raise Health Awareness and Encourage HIV Testing in Urban Communities Nationwide: PRNewswire - June 25, 2001; WASHINGTON, June 25 /PRNewswire/ -- Black America is under siege by the AIDS epidemic, with greater than 50 percent of new AIDS cases occurring among African-American men, women and children. To educate and protect African- American communities, Black Entertainment Television (BET) is partnering with local organization
Lopinavir Added to VirtualPhenotype(TM): PRNewswire - June 25, 2001; MECHELEN, Belgium , June 25 /PRNewswire/ -- Tibotec-Virco today announced that it has added the protease inhibitor (PI) lopinavir to its HIV drug resistance test the VirtualPhenotype(TM). The addition means that the VirtualPhenotype reports a quantitative prediction of the level of phenotypic resistance of HIV to all 1
Elizabeth Glaser Pediatric AIDS Foundation CEO to Join U.S. Delegation To United Nations General Assembly Special Session on HIV/AIDS: Foundation is One of Only Seven Non Governmental Organizations To Represent the United States in First-Ever United Nations Session Dedicated to Global Pandemic: PRnewswire - June 22, 2001; WASHINGTON, June 22 /PRNewswire/ -- Kate Carr, the CEO of the Elizabeth Glaser Pediatric AIDS Foundation, will be one of only seven leaders from Non Governmental Organizations representing the United States at the first-ever United Nations General Assembly Special Session on HIV/AIDS to be held June 25-27 in New York.
'National HIV Testing Day 2001' is Wednesday, June 27th: The Elizabeth Glaser Pediatric Aids Foundation Urges Women Of Childbearing Age and Their Partners to Get Tested: PRNewswire - June 21, 2001; SANTA MONICA, Calif., June 21 /PRNewswire/ -- The Elizabeth Glaser Pediatric AIDS Foundation urges all women of childbearing age and their partners to get tested for HIV on National HIV Testing Day 2001, Wednesday, June 27th. Women of childbearing age represent one of the fastest growing segments of the HIV positive po
UNAIDS Signs Up Coca-Cola in Battle Against AIDS: The Coca-Cola Africa Foundation Will Co-ordinate Local Support For AIDS Programs Across the Continent: PRNewswire - June 20, 2001; GENEVA, June 20 /PRNewswire/ -- UNAIDS today announced a partnership with The Coca-Cola Africa Foundation to bring new impetus to the battle against AIDS. Under the terms of the three-year agreement, the Foundation will co- ordinate the efforts of Coca-Cola Africa and its bottling partners across the continent to suppo
Bill & Melinda Gates Foundation Announces $100 Million Commitment to the Global Fund for AIDS and Health: PRNewswire - June 19, 2001; BRUSSELS, Belgium , June 19 /PRNewswire/ -- Signaling that stopping the transmission of AIDS is the foundation s top global health priority, the Bill & Melinda Gates Foundation today announced that it will commit $100 million to the Global Fund for AIDS and Health. The foundation used the occasion to call on other
Drug Manufacturers, GlaxoSmithKline, Pfizer, Johnson & Johnson, Aventis, Eli Lilly, Pharmacia Corporation, Confer With Multicultural Marketing Experts to Market Diabetes, Cardiovascular, HIV/AIDS and Other Products on June 25-26, Conference in Princeton, N: PRnewswire - June 18, 2001; NEW YORK, June 18 /PRNewswire/ -- Strategic Research Institute New York announces its Multicultural Pharmaceutical Marketing & PR conference on June 25-26, 2001 in Princeton, New Jersey. The program features major companies like Pfizer , GlaxoSmithKline , Johnson & John
Ichor Corporation Closes Private Placement to Fund Development of Innovative AIDS Vaccines and Therapeutics: PRNewswire - June 18, 2001; LYON, France , June 18 /PRNewswire/ -- Ichor Corporation announced today the successful completion of a US$2 million private financing from a consortium of investors advised by MFC Merchant Bank, Geneva, Switzerland . The funds will be used to support Ichor s continued research and development of novel AIDS vaccines an
Nautica Jeans Company Supports Love Heals, The Alison Gertz Foudation for AIDS Education: Saturday, June 23rd Luna Farm, Sagaponack, NY: PRNewswire - Monday 18 June, 2001; NEW YORK, June 18 /PRNewswire/ -- Nautica Jeans Company has partnered with Love Heals, The Alison Gertz Foundation for AIDS Education, for the 2nd Annual Mercedes-Benz Rocks Love Heals at Luna Farm to be held on Saturday, June 23rd. The event includes music, fashion and fun as The Go-Go s get the beat going with a live
Third National Women's Conference Continues to Promote Federal/Private Sector Partnerships: PRNewswire - June 15, 2001; ROCKVILLE, Md., June 15 /PRNewswire/ -- Representatives of 12 federal agencies will be engaged in an open dialogue with people from across the country on issues that impact women s health and well-being at the Third National Women s Conference to be held in Orlando, Florida, June 18-21. A Generational Journey: Women Ca
Clinical Data of REMUNE as Long Term Immune Based Therapy of HIV Patients Announced by Trinity Medical Group USA: PRNewswire - June 15, 2001; RANCHO SANTA MARGARITA, Calif., June 15 /PRNewswire/ -- Trinity Medical Group USA, Inc. (OTC Bulletin Board: TMGU) announced today the presentation of clinical data of HIV positive patients who have undergone treatment using its Immune Based REMUNE product. The presentation concludes that long term REMUNE treatment is
The Balm in Gilead to Host a Harlem Religious Service For the United Nations General Assembly Special Session on HIV/AIDS: PRNewswire - June 14, 2001; NEW YORK, June 14 /PRNewswire/ -- The United Nations General Assembly unprecedented Special Session on HIV/AIDS will feature a historic event hosted by The Balm In Gilead. A church worship service, themed Harlem Churches Unite in Praise and Worship for the Healing of AIDS, will be held Monday, June 25 at Harlem s Canaa
Bayer Acquires Rights to HIV Group O Immunoassay from Roche Diagnostics and Dade Behring: PRNewswire - June 14, 2001; TARRYTOWN, N.Y., June 14 /PRNewswire/ -- Bayer Corporation announced today that it has been granted a license under patent rights of Roche Diagnostics GmbH and Dade Behring, relating to the development, manufacture and marketing of immunoassays that detect exposure to HIV Group O infection. Bayer Diagnostics said this
Bayer Acquires Certain Rights to Infectious Disease Diagnostics from Ortho-Clinical Diagnostics and Chiron Corporation: PRNewswire - June 14, 2001; TARRYTOWN, N.Y., June 14 /PRNewswire/ -- Bayer Corporation today announced it has acquired certain development, manufacturing and sales agency rights for immunodiagnostic products for the detection of Hepatitis C (HCV) and HIV antibodies from Ortho-Clinical Diagnostics (Ortho), a subsidiary of Johnson
2001 AHF California Legislative Agenda Update: AIDS Healthcare California Legislation Clears Key Hurdles: PRNewswire - June 13, 2001; - Assembly Bill 937 (Koretz; Cedillo): Creates Fair HMO Rates For AIDS Specialists - Senate Bill 613 (Alarcon): Protects AIDS Patients Medi-Cal HMOs - AB 180 (Cedillo) Exempts Charity Thrift Store From State Sales Tax LOS ANGELES, June 13 /PRNewswire/ -- Three (3) key AIDS-related bills in the California Legislature cl
Globalvision Film on AIDS Hero Nkosi Johnson To Be Shown in an Africa-Wide Broadcast June 14, 2001: Documentary Collaboration with Videovision/South Africa Airs on MNET (Check Local Listings): PRNewswire - June 13, 2001; NEW YORK, June 13 /PRNewswire/ -- Last Saturday, more than five thousand people -- South Africans of all races -- paid tribute to the late Nkosi Johnson, a twelve-year-old AIDS orphan who spoke for children infected and affected by AIDS on a continent with more than 30 million HIV positive people. Less than a week late
ViroLogic Receives Broad Range of U.S. Patent Claims for Hepatitis B Drug Resistance Testing: PRNewswire - June 13, 2001; SOUTH SAN FRANCISCO, Calif., June 13 /PRNewswire/ -- ViroLogic, Inc. today announced the issuance of 42 separate claims in U.S. Patent No. 6,242,187 related to hepatitis B virus (HBV) drug resistance testing. The additional issued claims, which are assigned exclusively to ViroLogic, relate to anti-HBV drug susceptibili
Noted HIV/AIDS Physician to Address Black Publishers During Annual Conference In Atlanta June 14, 2001: PRNewswire - June 13, 2001; ATLANTA, June 13 /PRNewswire/ -- The National Newspaper Publishers Association (NNPA) and Agouron Pharmaceuticals, makers of Viracept (R), announced today that Dr. Robert Scott (bio available on request), noted physician and HIV/AIDS specialist is the keynote speaker for NNPA s annual Public Health Luncheon held this
Quality Improvement Goal of AHRQ-Supported Research in the June 13 Issue Of the Journal of the American Medical Association: PRNewswire - June 12, 2001; ROCKVILLE, Md., June 12 /PRNewswire/ -- Thousands of Medicare patients with diabetes mellitus or atrial fibrillation -- a rapid, erratic heart beat - - could benefit from two new quality improvement tools developed with the support of the Agency for Healthcare Research and Quality (AHRQ). The test results for these too
National Minority AIDS Council Calls on Congress To Continue and Expand Minority HIV/AIDS Initiative: PRNewswire - June 12, 2001; WASHINGTON, June 12 /PRNewswire/ -- The Congressional Black Caucus, Congressional Hispanic Caucus and Congressional Asian Pacific American Caucus conducted a Special HIV/AIDS Hearing this morning on at 9:00 a.m., which focused on the activities carried out by the US Department of Health and Human Services to implement
Brazil Orders Two Million Female Condoms for Project Expansion; Female-Controlled Protection is Central to Prevention Strategy: PRNewswire - June 12, 2001; CHICAGO, June 12 /PRNewswire/ -- The Female Health Company (OTC Bulletin Board: FHCO) today announced that it signed a contract with the Ministry of Health of Brazil to provide two million Female Condoms over the next nine months for the Ministry s groundbreaking national AIDS program. The Brazilian AIDS program ha
African and Western Alliance to Build First Large-Scale AIDS Medical Training Facility in Africa; State-of-Art Center in Uganda Will Educate Health Providers for All Africa and Provide HIV/AIDS Patients With Advanced Care: PRNewswire - June 11, 2001; KAMPALA, Uganda -- A new alliance of African and Western infectious disease experts, the Academic Alliance for AIDS Care and Prevention in Africa, will soon break ground for the first large-scale HIV/AIDS clinic in Africa to train medical personnel from across the continent on the latest treatment options and bring the
GlaxoSmithKline Reaffirms Commitment to Fight Diseases Of the Developing World: PRNewswire - June 11, 2001; LONDON -- GlaxoSmithKline (NYSE: GSK) today announced publication of Facing the Challenge, a report summarizing the company s contribution and commitment to improving the health and well-being of people living in the developing world. The report articulates the company s product, pricing and partnership commitments to
AIDS Epidemic In the Caribbean Focus of South Florida Sun-Sentinel Special Section: PRNewswire - June 8, 2001; FORT LAUDERDALE, Fla. -- The AIDS epidemic in the Caribbean is the focus of a 24-page special section called Witness to an Epidemic/AIDS in the Caribbean that will be published in the South Florida Sun-Sentinel this Sunday, June 10. The section will also be featured online with both narrative and interactive versions i
Black Leaders Ask Bush Administration Support For HIV/AIDS Action Plan Leaders Also Pledge to Expand Their Efforts to Combat HIV/AIDS State Of Emergency in Black America: PRNewswire - June 8, 2001; ATLANTA -- While simultaneously pledging to step up their own collaborative efforts to fight the HIV/AIDS epidemic in African- American communities, more than 100 Black leaders released a five-point action plan detailing the community s needs from the Bush Administration, and the demand for a declaration of a National
Black Churches Launch Second Annual HIV Testing National Awareness Campaign: PRNewswire - June 7, 2001; NEW YORK, June 7 /PRNewswire/ -- The Balm In Gilead s second annual Our Church Lights The Way: The Black Church HIV Testing Campaign, a national effort that empowers the power of the Black Church to encourage African Americans to get tested for HIV launches June 1st and will run the entire month. This campaign seeks to
Pfizer to Offer Diflucan Antifungal Medicine at No Charge To HIV/AIDS Patients in 50 Least Developed Countries Around the World: PRNewswire - June 6, 2001; NEW YORK, June 6 /PRNewswire/ -- Pfizer Inc said today that it will offer Diflucan(R) antifungal medicine at no charge to HIV/AIDS patients in 50 least-developed countries as identified by the United Nations where HIV/AIDS is most prevalent. The Diflucan Partnership was developed in cooperation with the United Nations
New Drug-Resistant HIV Strain Can Escape Detection: PRNewswire - June 6, 2001; Mutations Invisible to Most Assays Cause Resistance To Two of the Three Classes of AIDS Drugs SCOTTSDALE, Ariz., June 6 /PRNewswire/ -- A new study presented today at the 5th International Workshop on HIV Resistance and Treatment Strategies shows that a mutation in the genetic code of HIV (the virus that causes AIDS) c
Vertibrae's HIVresistanceWeb Launches First Comprehensive Online Resource for Drug Resistance Testing Information: PRNewswire - June 5, 2001; NEW YORK, June 5 /PRNewswire/ -- HIVresistanceWeb (http://www.HIVresistanceWeb.com), one of the online medical communities developed by Vertibrae, today announced that for the first time ever, comprehensive, up-to-date information about HIV drug resistance assays and assay providers is now available online. Created for
Progenics' Published Study Maps Cellular Attachment Site of HIV; Peptide Decoy Thwarts Viral Docking: PRNewswire - June 5, 2001; TARRYTOWN, N.Y., June 5 /PRNewswire/ -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) announced the publication of a scientific article describing how researchers designed a novel anti-HIV (human immunodeficiency virus) therapeutic candidate that mimics a cell-surface structure used by the virus to infect cells. This
Conference on Honduras 2001 to Focus on AIDS, Orphans, and Education: PRNewswire - June 4, 2001; WASHINGTON, June 4 /PRNewswire/ -- projecthonduras.com today announced that its second annual Conference on Honduras will take place in Washington, DC, on October 12-13, 2001. The event will bring together individuals and organizations engaged in projects to help Honduras in the areas of education and health care.
Femi Kuti's New York Concert to Usher In United Nations Special Session on HIV/AIDS: PRNewswire - June 4, 2001; NEW YORK, June 4 /PRNewswire/ -- World-renowned Nigerian musician Femi Kuti will continue his efforts to combat the devastating African AIDS epidemic when he performs Friday, June 22 in New York City just prior to the opening of the United Nations Special Session of HIV/AIDS. The concert, to be held at Irving Plaza, wi
Bike-a-Thon for AIDS Kicks Off in Central Park; Young Adult Group's 'Cycle for Humanity' Donates Proceeds to CMMB: PRNewswire - June 4, 2001; NEW YORK, June 4 /PRNewswire/ -- Hundreds of bikers throughout the metropolitan area will join the 18-mile, Cycle for Humanity bike-a-thon on Saturday, June 16 to raise $50,000 for an innovative AIDS initiative in Kenya supported by Catholic Medical Mission Board (CMMB). Organized by Contemporary Roman Catholics (CRC),
'AIDS At 20: Can This Man Find A Vaccine?': PRNewswire - June 3, 2001; If You Were To Ask Me About The Future, I Would Tell You That I Am Very Despondent About It, Says Dying Aids Activist Larry Kramer Dr. Seth Berkley Spearheads Efforts to Develop AIDS Vaccine; Says Goal is to Have 8-12 Vaccines in Development By 2007 NEW YORK, June 3 /PRNewswire/ -- Playwright, author and one of the ol
Virologic Announces New Data Demonstrating Growing Need for HIV Drug Resistance Testing; Data Strongly Support Resistance Testing for the 40,000 Individuals Infected Each Year in United States: PRNewswire - June 6, 2001; SCOTTSDALE, Ariz. -- Virologic, Inc. (Nasdaq: VLGC) announced today that the spread of drug-resistant HIV has accelerated rapidly over the past two years and that resistance testing can play an important role in patient treatment and new drug development, according to research presented at the 5th Annual International
UNICEF Mourns Nkosi Johnson 'A Courageous Boy Who Moved A Continent': PRNewswire - June 1, 2001; NEW YORK, June 1 /PRNewswire/ -- Calling him a courageous boy who moved a continent, the United Nations Children s Fund (UNICEF) today mourned the death of Nkosi Johnson, the 12-year-old South African who helped break the silence about HIV and AIDS. My heart goes out to Gayle Johnson, his loving mother and caregiver,
Recent Research Points to Success of Abstinence Education, Medical Institute for Sexual Health Points Out, Questioning National Campaign's Teen Pregnancy Study: PRNewswire - June 1, 2001; AUSTIN, Texas, June 1 /PRNewswire/ -- Abstinence education as a public health approach to teen pregnancy and sexually transmitted diseases is proving much more effective than the widely reported study by the National Campaign to Prevent Teen Pregnancy suggests, The Medical Institute for Sexual Health said today. This i
ViroLogic Announces Conference Call to Review Research Presented at the 5th International Workshop on HIV Drug Resistance and Treatment Strategies: PRNewswire - June 1, 2001; SOUTH SAN FRANCISCO, Calif., June 1 /PRNewswire/ -- ViroLogic, Inc. (Nasdaq: VLGC) today announced that it will hold a conference call on Wednesday, June 6, 2001 at 4:00 p.m. (EDT) to review highlights of scientific studies presented at the 5th International Workshop on HIV Drug Resistance and Treatment Strategies in S
Doctors Don't Talk Sex With Their Lesbian and Gay Patients: Four Out of Ten Gays and Lesbians Surveyed Say Their Doctors Don't Ask Them About Their Sexual Practices: PRNewswire - May 30, 2001; NEW YORK, May 30 /PRNewswire/ -- Four out of ten health care providers don t ask their gay and lesbian patients about their sexual practices, according to the second annual GayHealth.com(TM) online survey. Avoiding the subject of sex puts these patients at risk for HIV, HPV (human papillomavirus) and other sexually tra
HIVresistanceWeb Publishes HIV Drug Resistance Pocket Guide: Print Companion to Online Mutation Matrices to be Distributed to 5,000 HIV Physicians Nationwide: PRNewswire - May 30, 2001; NEW YORK, May 30 /PRNewswire/ -- Vertibrae, the publisher of HIVresistanceWeb, announced today the publication of an HIV Drug Resistance Information At-A-Glance pocket guide, to be issued to more than 5,000 HIV physicians across the country. Derived from HIVresistanceWeb s online Drug and Mutation Data pages, the free
ViroLogic's PhenoSense(TM) HIV Used in First Study to Demonstrate Mother-To-Child Transmission of Multi-Drug-Resistant HIV: New Study in Journal of Infectious Diseases Indicates Resistance Testing May Help Physicians Avoid Mother-to-Child Transmission of Drug-Resistant HIV: PRNewswire - May 30, 2001; SOUTH SAN FRANCISCO, Calif., May 30 /PRNewswire/ -- ViroLogic, Inc. today announced that a new study documents for the first time transmission of multi-drug-resistant HIV from mother to child. According to the researchers, the study findings, which will be published in this week s issue of the Journal of Infectious Dis
VaxGen AIDS Vaccine May Produce Broader Immunity Than Previously Detected: PRNewswire - may 29, 2001; BRISBANE, Calif., May 29 /PRNewswire/ -- VaxGen , Inc. presented laboratory data last week at a scientific conference indicating that the company s HIV/AIDS vaccine induces immune responses capable of preventing infection from a broader array of HIV strains than previously detected. The finding represents new evidence
U.S. Provides $200 Million to Global AIDS Fund; South Africa Finishes Weeklong AIDS Candlelight Commemoration; U.S. Secretary of State Colin Powell in Africa to Discuss AIDS Epidemic & Prevention: Donner Corp. International Issues Morning Call Note on CytRx Corp.: PRNewswire - May 29, 2001; SANTA ANA, Calif., May 29 /PRNewswire/ -- Donner Corp. International, a broker/dealer specializing in investment banking, headquartered in Santa Ana, CA, today issued a Morning Call Note on CytRx Corp., (Nasdaq: CYTR), Norcross, Georgia . CytRx is a biotechnology company with a phase III product, FLOCOR(TM), under deve
Lessons Learned From 20 Years of HIV/AIDS: amfAR Offers Perspectives on the Past and Future of the AIDS Epidemic: PRNewswire - May 29, 2001; NEW YORK, May 29 /PRNewswire/ -- According to the Joint United Nations Programme on HIV/AIDS ( UNAIDS ), there are now over 36 million men, women, and children living with HIV/AIDS worldwide. If current trends remain unchanged, there will be over 62 million people living with HIV/AIDS by 2005, and more than 40 million
The Immune Response Corporation Announces Additional Published Data Further Suggest Treatment With REMUNE(TM) May Stimulate CD8+ T Cell 'Killer' Function Against HIV: PRNewswire - May 29, 2001; CARLSBAD, Calif., May 29 /PRNewswire/ -- The Immune Response Corporation announced today the publication of data from a 15-patient, open-label research study suggesting that treatment with REMUNE(TM) (HIV-1 Immunogen) may increase the frequency of CD8+ T cells, which are capable of killing virus-infected cells through
Study Sheds Light on Role of Gender Differences in The Risk of HIV Infection Among Injection Drug Users: High-Risk Sexual Activity Plays Key Role: PRNewswire - May 27, 2001; WASHINGTON, May 27 /PRNewswire/ -- HIV risk factors among injection drug users (IDUs) differ markedly by gender, according to a 10-year study funded by the National Institute on Drug Abuse (NIDA). A recent study by researchers at the Johns Hopkins University reported that while drug-related risk behaviors and homosexua
AnorMED discontinues clinical development program for AMD-3100 in HIV: PRNewswire - May 25, 2001; VANCOUVER, May 25 /PRNewswire/ - AnorMED Inc. (TSE:AOM) announced today that it will discontinue its dose escalation Phase Ia/IIb trial of AMD-3100 in HIV due in part to abnormal cardiac activity, referred to as premature ventricular beats, observed in two patients who each received different doses of AMD-3100 within t
GlaxoSmithKline's Novel Candidate HIV Vaccine Prevents AIDS in Pre-Clinical Trials; Candidate Vaccine Prevents Development of Disease In AIDS Virus-Infected Monkeys: PRNewswire - May 24, 2001; SAN JUAN, Puerto Rico -- GlaxoSmithKline (NYSE: GSK) announced today that their innovative recombinant adjuvanted candidate HIV vaccine showed protection from a highly pathogenic and partially heterologous virus, simian-human immunodeficiency virus (SHIV) in rhesus monkeys according to results presented at the 2nd Annu
Crompton and Biosyn Sign Licensing Agreement for Topical Microbicide Development for Prevention of AIDS; Companies Aim to Create `Effective Topical Defense Against HIV and Sexually Transmitted Diseases': PRNewswire - May 23, 2001; GREENWICH, Conn. and PHILADELPHIA -- Crompton Corporation (NYSE: CK) and Biosyn, Inc. today announced the signing of a worldwide exclusive licensing agreement for Biosyn to develop Crompton s UC781 compound as a topical microbicide targeted against the AIDS virus. There is a compelling need for an effective topical def
United Foundation for AIDS Selects VIDAFIT(TM) for Personalized Nutrition Made-to-Order Formulations Address the Unique Needs of Each Patient: PRNewswire - May 23, 2001; MIAMI LAKES, Fla. -- INI Health, a nutrition pharmacy that makes personalized nutrition products to order, today announced that United Foundation for AIDS (UFA) in Miami Beach s South Shore Hospital, has agreed to use VIDAFIT for its 900 HIV-AIDS patients. Nutritional deficiencies and weight loss are common among HIV-A
Chiron Licenses Its HIV-1 and HCV Intellectual Property for NAT Blood Screening to Roche; HIV-1 and HCV NAT Blood Screening Tests to be Supplied to Blood Bank Market By Both Chiron and Roche: PRNewswire - May 23, 2001; EMERYVILLE, Calif. -- Chiron Corporation (Nasdaq: CHIR) announced today that it has reached agreement on definitive licensing terms with F. Hoffmann-La Roche ( Roche ) under its human immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV) intellectual property for nucleic acid testing (NAT) to screen blood,
African First Ladies Commit to Action on AIDS at Summit; International AIDS Trust Optimistic About Progress -- Declaration Calls for Summit's Issues on Women and Children to be Included in Agenda for Upcoming UN General Assembly Special Session on AIDS: PRNewswire - May 22, 2001; KIGALI, Rwanda -- The First Ladies Summit on Children and HIV/AIDS closed today in Rwanda with the wives of African leaders and representatives of 16 sub-Saharan African nations reaching a consensus to push for strategies and resources needed to address the impact of the HIV/AIDS pandemic on the women, children and fam
New Study Combines ZADAXIN(R) Plus Alpha Interferon in Difficult-to-Treat Chronic Hepatitis B Patients: Data at AALSD Session of Digestive Disease Week (DDW) Meeting -: PRNewswire - May 21, 2001; SAN MATEO, Calif., May 21 /PRNewswire/ -- SciClone Pharmaceuticals announced that a new study presented today at the American Association for the Study of Liver Disease (AASLD) session at the Digestive Disease Week (DDW) meeting in Atlanta showed significantly greater sustained response rates in patients treated with t
Immunization With an HIV-1 Immunogen (REMUNE(TM)) Appears To Induce Allo-Responses and HIV-1 Specific Responses: Data Presented at the Federation of Clinical Immunology Societies (FOCIS) 1st Annual Meeting in Boston, Massachusetts May 4-7, 2001: PRNewswire - May 21, 2001; CARLSBAD, Calif., May 21 /PRNewswire/ -- The Immune Response Corporation announced today data from preliminary interim clinical results from an ongoing Phase II trial indicating that treatment with REMUNE(TM) (HIV-1 Immunogen), an investigational product, appears to induce both allo and HIV specific cell mediated immun
IAVI.org Creates Online Campaign to Mobilize Support to Help 'End AIDS for All Time': IAVI and Yahoo! Collaborate to Support AIDS Vaccine Development, Campaign Launches Online on May 18th, AIDS Vaccine Awareness Day: PRNewswire - May 18, 2001; NEW YORK -- The International AIDS Vaccine Initiative (IAVI) announced today the launch of a global online campaign to mobilize support for the development of an AIDS vaccine. With 15,000 new infections each day, we cannot afford to delay, said Seth Berkley, M.D., president and chief executive officer of IAVI. While a
HIV Vaccines - Hope on the horizon: PRNewswire - May 18, 2001; ATLANTA, May 18 /PRNewswire/ -- The following was released today by the International Medical Press and International AIDS Vaccine Initiative: Over 35 million people are infected with HIV, and with no sign of the pandemic abating the development of an affordable, preventive vaccine to stem the advance of the virus is n
Both Initiatives Limited to Faith-Based Providers: AJCongress Lawsuit Challenges California Charitable Choice Program Similar in Terms to Just-Announced Federal Program: PRNewswire - May 17, 2001; NEW YORK, May 17 /PRNewswire/ -- The American Jewish Congress will seek a permanent injunction against implementation of a state-funded job training program in California open only to faith-based providers, as an unconstitutional preference for religion. The significance of the suit against the charitable choice progra
National Survey Shows Marked Increase in Syringe Exchange Programs; amfAR Funds Survey: Programs Gain Momentum as Means for HIV Prevention: PRNewswire - May 17, 2001; ATLANTA, May 17 /PRNewswire/ -- According to a survey funded by the American Foundation for AIDS Research (amfAR) and published in this week s issue of the Centers for Disease Control and Prevention s Morbidity and Mortality Weekly Report (MMWR), the number of syringe exchange programs (SEPs) in the United St
Thousands of Brave People Honor HIV/AIDS Vaccine Awareness Day on May 18th By Participating In Pallotta TeamWorks' AIDS Vaccine Rides 2001(SM): PRNewswire - May 16, 2001; Los Angeles, May 16 /PRNewswire/ -- In May 1997, President Clinton challenged the nation and the world to find a vaccine to stop the AIDS pandemic and proclaimed May 18 HIV/AIDS Vaccine Awareness Day. This summer more than 6,000 brave men and women will challenge themselves by participating in the Pallotta TeamWorks AI
HIV Vaccine Awareness Day Reinforces Importance of Vaccines as Best Hope For Fighting AIDS: HIV Vaccine Trials Network Salutes Thousands of Volunteers Currently Participating in Vaccine Trials Across the Nation: PRNewswire - May 16, 2001; SEATTLE, May 16 /PRNewswire/ -- Four years after the inaugural HIV Vaccine Awareness Day, the momentum toward finding an effective vaccine continues to grow. An HIV vaccine is our best hope for beating AIDS, said Dr. Larry Corey, principal investigator at the HIV Vaccine Trials Network (HVTN) Close collaboration among
Methadone Promotes HIV Infection in Cell Culture Studies at The Children's Hospital of Philadelphia: PRNewswire - May 16, 2001; UTRECHT, Netherlands , May 16 /PRNewswire/ -- Methadone, the drug that is widely used in drug treatment centers to treat heroin addicts, stimulates HIV infection of human immune cells studied in cell cultures, according to immunology researchers from The Children s Hospital of Philadelphia. The researchers proposed
Black Men & HIV: Sexuality and Health Discussed on BET's TEEN: SUMMIT Saturday, May 19 (Live) & Saturday, June 30 * 1:00 p.m. Do You Know the Score? and The Naked Truth: PRNewswire - May 15, 2001; WASHINGTON, May 15 /PRNewswire/ -- Sex is the game. It s the black community versus HIV. On the floor for the community, we have men and women who aren t using condoms, intravenous drug users who share needles and/or trade sex for drugs, and individuals who have both heterosexual relationships and secret same sex partn
Fourth Annual HIV Vaccine Awareness Day Honors Volunteers for Their Selfless Contribution to HIV Research: A Day to Say Thank You to the Thousands of People Worldwide Who Have Volunteered for Studies to Develop HIV Vaccines, Vaccines Are the World's Best Hope for Ending the Aids Epidemic: PRNewswire - May 15, 2001; SEATTLE, May 15 /PRNewswire/ -- Friday, May 18 commemorates the Fourth Annual HIV Vaccine Awareness Day, which honors thousands of volunteers worldwide who have literally rolled up their sleeves to receive an experimental vaccine designed to prevent HIV infection in studies. HIV Vaccines Trials Network (HVTN) sites wor
Invirion, Inc., Announces Business Agreement With Esoterix, Inc. to Use Virotect -- A Groundbreaking New Technology That Identifies Changes in The Activity of HIV in Individuals Much Earlier Than Any Test Used Until Now -- Set to Be Utilized in an Upcoming: PRNewswire - May 15, 2001; CHICAGO, May 15 /PRNewswire/ -- Invirion, Inc. announced today that it has reached a business agreement to use its groundbreaking new HIV test in at least one major upcoming clinical trials conducted by Esoterix, Inc., a leading laboratory services company. The test, called the ViroTect In Cell HIV-1 Detection Kit, al
NMAC Calls on Bush Administration to Increase Global AIDS Fund Contribution: Flat Funding for Domestic AIDS Initiative an 'Abdication of Responsibility': PRNewswire - May 11, 2001; WASHINGTON, May 11 /PRNewswire/ -- The National Minority AIDS Council (NMAC), called on the Bush Administration to make a contribution to the United Nations Global AIDS Fund commensurate with the magnitude of the need in Sub- Saharan Africa and other developing countries. The Bush Administration s proposal to contribut
New HIV Vaccine Research: The Intertwining of Merck & Co., Emory University, And CytRx Corp. CytRx Featured in the Atlanta Constitution Newspaper, May 7, 2001: Donner Corp. International Issues Morning Call Notes on CytRx Corp.: PRNewswire - May 8, 2001; SANTA ANA, Calif., May 8 /PRNewswire/ -- Donner Corp. International, a broker/dealer headquartered in Santa Ana, CA., today issued a Morning Call Note on CytRx Corp., Norcross, Georgia (Nasdaq: CYTR). CytRx is a biotechnology company with a gene delivery technology called TRANZFECT, also known as CRL-1005, which is bei
France to Award AIDS Activist Albina du Boisrouvray Country's Top Honor: PRNewswire - May 7, 2001; PARIS, May 7 /PRNewswire/ -- The following press release was issued today by Association Francois-Xavier Bagnoud: French Delegate Minister of Health, Bernard Kouchner, will award the Insignia of Chevalier in the French National Order of the Legion d Honneur, to Madame Albina du Boisrouvray, on Wednesday 9 May 2001 at 6
ViroLogic Awarded Research Grant From National Institutes of Health For New HIV Assay Development: PRNewswire - May 2, 2001; SOUTH SAN FRANCISCO, Calif., May 2 /PRNewswire/ -- ViroLogic, Inc. (Nasdaq: VLGC) today announced that the company has been awarded a $600,000 research grant from the National Institutes of Health (NIH) to develop new technology to measure HIV resistance to entry inhibitors and evaluate HIV vaccine candidates. The gran
New HIV/AIDS Science Explains Origin and Chimpanzee Connection: PRNewswire - May 1, 2001; LONDON, May 1 /PRNewswire/ -- A new twist on the theory that vaccines may have triggered the AIDS pandemic is advanced in the May 2001 issue of the scientific journal of Medical Hypotheses by an independent investigator and author of a bestselling book on the subject, Dr. Leonard Horowitz. The report explains for the f
amfAR Study Shows Syringe Prescription May Help Prevent HIV Transmission New Strategy Highlights Decrease in Risk Behavior of Injection Drug Users: PRNewswire - April 30, 2001; PROVIDENCE, R.I., April 30 /PRNewswire/ -- A study published in the May 2001 issue of the American Journal of Public Health and funded by the American Foundation for AIDS Research (amFAR) shows that physician syringe prescription is an effective and acceptable tool among injection drug users to enhance compliance to pr
AIDS Conference for Black Churches at Tuskegee University May 22-24: Dr. David Satcher and Dr. Helene Gayle Honorary Co-Chairs: The Revs. James R. Forbes, Vashti M. McKenzie, Jeremiah A. Wright and Drs. H. Clifford Lane, Eric Goosby and Wilbur Jordan Tops List of High Profiled Speakers in Health and Religion: PRNewswire - April 30, 2001; NEW YORK, April 30 /PRNewswire/ -- As more and more churches are taking a more aggressive role in addressing the AIDS epidemic in Black communities, pastors and church members around the country are preparing to attend The 3rd Annual Black Church HIV/AIDS Training Institute at Tuskegee University, Tuskegee, AL, May 22-
CMMB Takes Lead in Africa With Programs to Prevent Mother-to-Child Transmission of HIV-AIDS: PRNewswire - April 30, 2001; NEW YORK, April 30 /PRNewswire/ -- Catholic Medical Mission Board (CMMB), the non-profit organization that provides healthcare assistance to developing nations, has launched four pilot programs in Africa for the prevention of mother-to-child transmission (MTCT) of HIV-AIDS. CMMB will provide
GlaxoSmithKline Announces Agreement With the Government of Burundi to Increase Access to HIV/AIDS Medicines: PRNewswire - April 29, 2001; LONDON, April 29 /PRNewswire/ -- GlaxoSmithKline (NYSE: GSK) today welcomed the announcement by the Government of Burundi of the agreement to increase access to HIV/AIDS medicines in partnership with the pharmaceutical industry and five UN agencies. Burundi is the seventh African country to sign an agreement of this k
Progenics Pharmaceuticals and Roche Renew Collaboration to Identify And Develop Novel HIV Therapeutics: Small Molecules are Designed to Block Virus before Infection Occurs -: PRNewswire - April 27, 2001; TARRYTOWN, N.Y., and BASEL, Switzerland , April 27 /PRNewswire/ -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) and Roche have announced the renewal of their research collaboration to discover and develop novel HIV (human immuno deficiency virus) therapeutics. The goal of the program is to identify drugs that target
EU, IAVI Strengthen Joint Efforts to Develop and Distribute AIDS Vaccines: PRNewswire - April 26, 2001; ABUJA, Nigeria , April 26 /PRNewswire/ -- The European Union (EU) and the International AIDS Vaccine Initiative (IAVI) are strengthening their joint efforts to promote the accelerated development of preventive vaccines for AIDS and assure they are available in developing countries as rapidly as possible. The announceme
ViroLogic Enters Tenth Pharmaceutical Company Agreement to Assess New Anti-HIV Drugs: PRNewswire - April 24, 2001; SOUTH SAN FRANCISCO, Calif., April 24 /PRNewswire Interactive News Release/ -- ViroLogic, Inc. (Nasdaq: VLGC) today announced an agreement with DuPont Pharmaceuticals Company to assist DuPont Pharmaceuticals in the evaluation of new anti-HIV agents in development. DuPont Pharmaceuticals will use ViroLogic s drug resist
The Immune Response Corporation Announces Publication of Study Suggesting That REMUNE(TM) Induces HIV-1 Specific T Helper Immune Responses That Correlate With Control of Virus: PRNewswire - April 23, 2001; CARLSBAD, Calif., April 23 /PRNewswire Interactive News Release/ -- The Immune Response Corporation announced the publication of data today that suggest REMUNE(TM) (HIV-1 Immunogen), an investigational immune-based therapy, induces HIV specific (T helper cells) immune responses that correlate with control of virus (vir
GlaxoSmithKline Welcomes the Settlement of Industry Association Litigation Against the South African Government: PRNewswire - April 19, 2001; PHILADELPHIA, April 19 /PRNewswire/ -- GlaxoSmithKline s Chief Executive Officer, Jean-Pierre Garnier, unreservedly welcomed today s announcement that a settlement has been reached in the court case involving the South African Pharmaceutical Manufacturers Association (PMA) and the Government of South Africa. This settl
Achillion Pharmaceuticals Collaborates With NCI and NIAID For the Discovery of a New Class of HIV Drugs: CRADA Uses Achillion's Zinc Finger Targeting Technology -: PRNewswire - April 19, 2001; NEW HAVEN, Conn., April 19 /PRNewswire/ -- Achillion Pharmaceuticals, a privately held biopharmaceutical company focused on the discovery, development and commercialization of innovative anti-infective agents, today announced the implementation of a Collaborative Research and Development Agreement (CRADA) with the Nati
Demegen Announces Plan to Initiate Phase I/II Clinical Trial for Oral Candidiasis: PRNewswire - April 19, 2001; PITTSBURGH, April 19 /PRNewswire/ -- Demegen, Inc. (OTC Bulletin Board: DBOT), a clinical stage biopharmaceutical company specializing in the development of peptides for the treatment of infectious diseases and oncology, announced today that it plans to initiate a Phase I/II clinical trial for treating oral candidiasis
Four Studies Examine Tolerability and Antiviral Activity of Once-Daily FORTOVASE(R) Plus Ritonavir - 'Boosted' Protease Inhibitor Regimen -: PRNewswire - April 18, 2001; NUTLEY, N.J., April 18 /PRNewswire/ -- Roche today announced preliminary clinical data from four ongoing studies examining tolerability and antiviral activity with once-daily dosing of its protease inhibitor FORTOVASE(R) (saquinavir) plus a mini-dose of another protease inhibitor, ritonavir . Th
New Survey Shows Most Americans Are 'Not At All' Concerned With Contracting Genital Herpes: Survey Reveals Nearly 80 Percent of People Do Not Realize Epidemic Proportions of Disease: PRNewswire - April 17, 2001; EAST HANOVER, N.J., April 17 /PRNewswire/ -- According to a nationwide survey released today, nearly 80 percent of Americans are unaware of how widespread genital herpes has become and 65 percent of people say that they are not at all concerned about contracting the disease. These new figures, which reaffirm the common
NewsRx.net Preferred Site for Cancer, Malaria, AIDS, Other Health Searches, Audience Measurement Shows: PRNewswire - April 17, 2001; ATLANTA, April 17 /PRNewswire/ -- NewsRx Network, Atlanta, the leading provider of life science databases and daily and weekly health news, announced today the results of March, 2001, audience measurements based on its report from GoTo.com. GoTo search term listings reach 75% of all Internet users on America Online, Ly
VaxGen AIDS Vaccine Trials Clear 5th Safety Review: PRNewswire - April 12, 2001; BRISBANE, Calif., April 12 /PRNewswire/ -- The independent organization that oversees the only final-stage clinical trials for a preventive HIV/AIDS vaccine has once again indicated that the vaccine appears safe and that the trials are being conducted appropriately, VaxGen , Inc. (Nasdaq: VXGN) announced today. Separa
Ives Health Company Makes Statement: PRNewswire - Thursday April 12, 2001; CLAREMORE, Okla., April 12 /PRNewswire/ -- Ives Health Company (IVEH) announced that a criminal complaint was filed against M. Keith Ives and the Company concerning alleged FDA compliance issues concerning T-Factor and alleged misrepresentations contained in Company press releases, website and other advertising. The Co
BET College Hip Hop Fest Is Back with a Fantastic Day of Activities and Performances to Benefit HIV/AIDS Awareness in the African-American Community: The Best Spring Break Party on the East Coast Returns for its Fourth Year: PRNewswire - April 11, 2001; WASHINGTON, April 11 /PRNewswire/ -- More than 20,000 students from historically Black colleges and universities will converge outside of Richmond, Virginia this weekend to participate in the best organized Black- college spring break event on the East Coast. The 4th Annual BET College Hip Hop Fest returns Saturday, Ap
DuPont Pharmaceuticals Reveals a Promising R&D Pipeline: PRNewswire April 11, 2001; NEW YORK, April 11 /PRNewswire/ -- DuPont Pharmaceuticals Company, a wholly owned subsidiary of DuPont (NYSE: DD), plans to launch new drugs to treat unmet medical needs every 12-18 months beginning in 2004, DuPont Pharmaceuticals Chairman and CEO Richard U. De Schutter told a group of investment analysts here today.
Panacos Pharmaceuticals and the National Cancer Institute Initiate Joint HIV Drug Discovery Program: Collaboration Will Utilize Panacos's Proprietary Drug Screening Technology To Identify HIV Fusion Inhibitors: PRNewswire - April 11, 2001; GAITHERSBURG, Md., April 11 /PRNewswire/ -- Panacos Pharmaceuticals, Inc. (Panacos) announced today that it has signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to discover drug candidates that block the initial step in HIV infection -- fusion of the virus to huma
GlaxoSmithKline Sponsors Vertibrae's HIVresistanceWeb: New Features Include Comprehensive Drug and Mutation Data For HIV Healthcare Providers: PRNewswire - April 11, 2001; NEW YORK, April 11 /PRNewswire/ -- Vertibrae announced today that HIV industry leader GlaxoSmithKline has become a sponsor of HIVresistanceWeb (http://www.HIVresistanceWeb.com), one of the online medical communities developed by Vertibrae. The unrestricted educational grant will help HIVresistanceWeb continue its missi
ARUP Laboratories Offers Antiretroviral Drug Resistance Testing for HIV-1: PRNewswire - April 10, 2001; SALT LAKE CITY, April 10 /PRNewswire/ -- ARUP Laboratories, Inc. , a national, specialty diagnostic reference laboratory, announced that it is now offering antiretroviral drug resistance testing for HIV-1 in partnership with Tibotec-Virco, an international biotechnology company specializing in drug discovery, molecular
Association Francois-Xavier Bagnoud (AFXB) AIDS Orphans Assistance Database (AOAD): Online Database Enabling Individuals and/or Organizations Assisting AIDS Orphans and Vulnerable Children to Find, Learn About and Contact One Another To Be Launched on April 9, 2001: PRNewswire - April 9, 2001; CAMBRIDGE, Mass., April 9 /PRNewswire/ -- A unique tool designed to build bridges between organizations and individuals in the developed world and community-based organizations in developing countries that are involved in assisting children orphaned or made vulnerable by HIV/AIDS will be formally launched today. The AF
GlaxoSmithKline Announces Agreement With the Government of Mali to Increase Access to HIV/AIDS Medicines: PRNewswire - April 9, 2001; LONDON, April 9 /PRNewswire/ -- GlaxoSmithKline (NYSE: GSK) signed an agreement on April 7, 2001, with another African government to increase access to its HIV/AIDS medicines. The agreement with the Government of Mali is the sixth agreement under the UNAIDS Accelerating Access Initi
Kaposi's Sarcoma-Associated Herpesvirus Causes No Negative Health Effects In HIV-Negative Individuals, Find University of Pittsburgh Researchers: PRNewswire - April 9, 2001; PITTSBURGH, April 9 /PRNewswire/ -- New research at the University of Pittsburgh shows that a recently discovered herpesvirus, which often leads to Kaposi s sarcoma in HIV-positive individuals, has no negative effect on healthy HIV-negative adults. The study is published in the April 15 issue of Blood, a journal of the
Progenics' Experimental Drug, PRO 140, Lowered Viral Loads to Undetectable Levels in Animal Model of HIV Infection: Monoclonal Antibody Inhibited Replication of HIV In Vivo By Blocking Viral Entry: PRNewswire - Aprl 9, 2001; SEATTLE, April 9 /PRNewswire/ -- Progenics Pharmaceuticals, Inc. announced that its experimental drug, PRO 140, reduced viral burdens to undetectable levels in a well-recognized animal model of HIV (human immunodeficiency virus) infection. In mice treated with PRO 140, initially high HIV concentrations became unde- tec
Department of Health Services Dedicates California Public Health Laboratory: State-of-the-Art Facility to Play Critical Role In Protecting the Public's Health: PRNewswire - April 7, 2001; RICHMOND, Calif., April 7 /PRNewswire/ -- Marking a milestone in the advancement of public health, the California Department of Health Services (CDHS) today formally dedicated its new state-of-the-art California Public Health Laboratory in Richmond. In an event attended by hundreds of state employees and their families
GAVI and GlaxoSmithKline Deliver First Vaccines to Africa In New Vaccine Initiative for the Developing World: The Global Alliance for Vaccines and Immunization Brings First Shipment of DTPw-HB Vaccine to Mozambique: PRNewswire - April 6, 2001; PHILADELPHIA, April 6 /PRNewswire/ -- Representatives of the Global Alliance for Vaccines and Immunizations (GAVI) today delivered GlaxoSmithKline TritanrixHB vaccine to Africa in a ceremony to mark the first vaccine to be purchased and delivered to the developing world through the Global Alliance for Children s Vaccin
Africa Receives First Delivery of GAVI/Global Fund Vaccines: Bill Gates Senior Helps Deliver Life-saving Vaccines to Mozambique: PRNewswire - April 6, 2001; MAPUTO, Mozambique , April 6 /PRNewswire/ -- In a major step towards saving the lives of millions of children around the world, the Global Alliance for Vaccines and Immunization and The Global Fund for Children s Vaccines began the first round of a global schedule of vaccine delivery, to Mozambique, the first to reach
HIV/AIDS Statement by Bill Gates, Bill & Melinda Gates Foundation; Tim Wirth, United Nations Foundation; and Gordon Conway, Rockefeller Foundation: PRNewswire - April 6, 2001; SEATTLE, April 6 /PRNewswire/ -- The following statement is being issued by Bill Gates, Bill & Melinda Gates Foundation; Tim Wirth, United Nations Foundation; and Gordon Conway, Rockefeller Foundation: We want to highlight our shared agreement that the world s efforts to combat HIV/AIDS must include a balanced appr
Dental Problems Go Unresolved in Many HIV Patients: PRNewswire - April 6, 2001; ROCKVILLE, Md., April 6 /PRNewswire/ -- Oral infections, mouth ulcers and other severe dental conditions associated with HIV infections go untreated more than twice as often as other health problems related to the disease, according to a new study supported by the U.S. Agency for Healthcare Research and Quality (AHRQ).
Vector Medical Technologies, Inc. Announces Met-enkephalin, Therapeutic Aids Vaccine: PRNewswire - April 5, 2001; BOCA RATON, Fla., April 5 /PRNewswire/ -- Vector Medical Technologies, Inc. ( Vector or The Company ), announced that on April 4, 2001, at a meeting of the American Association of Immunologists held in the Orlando Convention Center, Nicholas P. Plotnikoff, Ph.D., Professor of Pharmacology at the University of Illinois
Progenics Pharmaceuticals' Published Study Describes Benefits of Combining Two Investigational Drugs to Block HIV Infection: Progenics' Viral-entry Inhibitor Synergistic with Trimeris/Roche Compound in Vitro: PRNewswire - April 5, 2001; TARRYTOWN, N.Y., April 5 /PRNewswire/ -- Progenics Pharmaceuticals, Inc. announced the publication of a scientific article showing that the investigational drugs PRO 542 and T-20 significantly enhanced anti-HIV activity when used in combination in laboratory studies. Progenics scientists and researchers at the Albert E
nSight and the AIDS Action Committee Partner to Design and Produce WWW.AIDSWALKBOSTON.ORG: New Site Provides Simplified Online Registration Process For This Annual Fundraiser --: PRNewswire - April 4, 2001; CAMBRIDGE, Mass., April 4 /PRNewswire/ -- nSight, Inc., a recognized leader in print and interactive communications offering a unique combination of consulting, project management services, training, staffing, and the AIDS Action Committee (AAC), invite you to visit http://www.aidswalkboston.org. The AIDS Walk Boston W
Dupont Pharmaceuticals Submits New Drug Application for One Tablet, Once-Daily Formulation of Sustiva(TM): PRNewswire - April 4, 2001; WILMINGTON, Del., April 4 /PRNewswire/ -- DuPont Pharmaceuticals Company today announced it has submitted a new drug application to the U.S. Food and Drug Administration ( FDA ) for both a 600 and 300 mg tablet formulation of its anti-HIV drug Sustiva (TM) (
Advanced Viral Research Corp. Announces Agreement With Selikoff Center To Conduct Clinical Research Studies in Israel Using Product R: PRNewswire - April 3, 2001; YONKERS, N.Y., April 3 /PRNewswire/ -- Advanced Viral Research Corp. (OTC Bulletin Board: ADVR) today announced an agreement with the Selikoff Center for Environmental Health and Human Development in Ra anana, Israel to develop research and clinical trials using Product R. Beginning with clinical trials using Product R
Crucell's PER.C6 Cell-Line Used in Merck's HIV-1 Vaccines Research Program: PRNewswire - April 3, 2001; LEIDEN, The Netherlands , April 3 /PRNewswire/ -- Crucell N.V., a leading biotechnology company focused on the discovery of unique drug targets on disease associated cells and on the development of huMADE(TM) biopharmaceuticals, today announced that Merck & Co. , Inc is applying Crucell s PER.C6 technology in
Merck Confirms Use of Vical's Naked DNA Technology in HIV Vaccine Program: PRNewswire - April 2, 2001; KEYSTONE, Colo., April 2 /PRNewswire/ -- Vical Incorporated announced today that the company s collaborative partner, Merck and Co., Inc., highlighted the success to date of its HIV vaccine development program, which includes a vaccine based on Vical s patented naked DNA gene delivery technology. Merck presented precli
Significant Success in Maintaining Viral Suppression Seen When Sustiva(TM) Is Substituted for Protease Inhibitors: PRNewswire - April 2, 2001; ISTANBUL, Turkey , April 2 /PRNewswire/ -- Data presented today indicate that DuPont Pharmaceuticals anti-HIV drug Sustiva (TM) ( efavirenz ), when substituted for a protease inhibitor, successfully maintained viral load suppression (less than 50 copies/mL) in
Merck & Co. Presents Preclinical Data on HIV Vaccine Program Utilizing CytRx's TranzFect Technology: PRNewswire - April 2, 2001; ATLANTA, April 2 /PRNewswire/ -- CytRx Corporation today announced that scientists from Merck & Co. , Inc. presented data from extensive preclinical studies in their efforts to develop an HIV-1 vaccine, at the Keystone Symposium in Keystone, Colorado. In November 2000, Merck licensed from CytRx the right to use Cyt
Three-Year Durability of Response Data Shows Sustiva(TM) Provides Greater Viral Suppression Than Protease Inhibitor Therapy: PRNewswire - April 2, 2001; ISTANBUL, Turkey , April 2 /PRNewswire/ -- Data presented today, at the 11th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) meeting here, indicate that DuPont Pharmaceuticals anti-HIV drug Sustiva (TM) ( efavirenz ), which is in
Epimmune Scientists Report Positive Pre-Clinical Data on Vaccine Designed To Combat HIV's Ability to Mutate: Company on Track to Initiate Clinical Trials Late This Year or Early 2002 Of Epitope-Based Vaccine for the Prevention and Treatment of HIV: PRNewswire - April 2, 2001; KEYSTONE, Colo., April 2 /PRNewswire/ -- Epimmune Inc. today announced positive pre-clinical data on its HIV vaccine that is designed to directly address the problem of viral mutation. At the Keystone Symposium: AIDS Vaccines in the New Millennium on March 30, 2001 in Keystone, Colorado, Company scientists reported tha
Valcyte(TM) (Valganciclovir) Is Approved by U.S. Food and Drug Administration For Treatment of AIDS-Related CMV Retinitis: Oral Drug With IV Potency: PRNewswire - March 30, 2001; NUTLEY, N.J., March 30 /PRNewswire/ -- Hoffmann-La Roche today announced that the U.S. Food and Drug Administration ( FDA ) has approved Valcyte(TM) (valganciclovir) for the treatment of cytomegalovirus ( CMV ) retinitis in AIDS patients.
Ghana Orders One Million Female Condoms for Project Expansion: Order Continues Increased Availability for Protection for Women: PRNewswire - march 29, 2001; CHICAGO, March 29 /PRNewswire/ -- The Female Health Company (OTC Bulletin Board: FHCO) today announced that it received an order from the United Nations Population Fund (UNFPA) for one million Female Condoms for the Ministry of Health in Ghana , a country of 20 million people in West Africa. The Ministry of Health
Scientists Identify New Vaccine Targets for Cancer-Causing Strains of Human Papilloma Virus: New Vaccine Approach May Help Treat and Prevent Pre-cancerous Lesions and Cervical Cancer: PRNewswire - March 27, 2001; SAN DIEGO, March 27 /PRNewswire/ -- Epimmune Inc. (Nasdaq: EPMN) announced today that Company scientists, in collaboration with Loyola University, Chicago, IL, Leiden University Medical Center, The Netherlands , and University of Wales College of Medicine, Wales, UK, have identified new vaccine targets for cancer-causi
South Africa Expands Female Condom Program: Order Signifies Importance of Female-Controlled Methods to Prevent HIV And Other STDs: PRNewswire - March 27, 2001; CHICAGO, March 27 /PRNewswire/ -- The Female Health Company (OTC Bulletin Board: FHCO.OB) today announced that it received an order from the National Department of Health of South Africa for 1.4 million Female Condoms. Because it has the largest number of people living with HIV/AIDS in the world -- 4.7 million people,
Abbott Laboratories to Offer AIDS Drugs and Rapid Diagnostic Test at No Profit In Africa: Offer Includes Abbott's Protease Inhibitors Kaletra(TM) and Norvir(R), Determine(TM) Test: PRNewswire - March 27, 2001; ABBOTT PARK, Ill., March 27 /PRNewswire/ -- Abbott Laboratories today announced that it will offer its two antiretroviral medications for the treatment of HIV infection, Kaletra (TM) ( lopinavir / ritonavir ) and
Novel Compound Inhibits HIV Replication in Cell Cultures, Suggesting Possible New Type of AIDS Drug, Say Researchers at The Children's Hospital of Philadelphia: PRNewswire - March 26, 2001; PHILADELPHIA, March 26 /PRNewswire/ -- A compound that inhibits human immunodeficiency virus (HIV) in human immune system cells may eventually provide a new therapeutic approach against AIDS by blocking HIV infection at an early stage. It may also deny the virus a hiding place in the cells from which HIV infection comm
New Data Suggests Improved Tolerability Associated with VIDEX EC(R) (didanosine) Capsules - Patients report fewer GI side effects: PRNewswire - March 23, 2001; SAN FRANCISCO, March 23 /PRNewswire/ -- Results from a study demonstrate that switching from Videx (R) (didanosine) chewable tablets to Videx EC(R) capsules, (enteric coated beadlets of didanosine) may significantly reduce common gastrointestinal (GI) side effects associated with the earlier buffered formulations of Vi
The American Academy of HIV Medicine (AAHIVM) Sets Qualifications For HIV/AIDS Specialists: Interview Availability With Scott Hitt, MD, President and Interim Executive Director of AAHIVM: PRNewswire - March 23, 2001; LOS ANGELES, March 23 /PRNewswire/ -- The American Academy of HIV Medicine (AAHIVM) has established criteria defining what it means to be a specialist among physicians and other health care workers treating individuals with HIV/AIDS. The development of a definition of an HIV/AIDS specialist comes at a time when AIDS pa
Hollis-Eden Receives Clearance From South African Government to Initiate a Clinical Trial with Transmucosal (Buccal) Formulation of Investigational Drug HE2000: PRNewswire - March 21, 2001; SAN DIEGO, March 21 /PRNewswire/ -- Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH) today announced it has received clearance from the South African Medicines Control Council (MCC) to initiate testing of a new transmucosal (buccal) formulation of the Company s lead investigational drug candidate HE2000 in treatment na
Three Nations Seek AIDS Strategies: PRNewswire - March 21, 2001; WASHINGTON, March 21 /PRNewswire/ -- Researchers from the United States , Canada and the United Kingdom are collaborating to evaluate the best treatment strategies for HIV-infected patients for whom highly active antiretroviral therapy has failed. Representatives of the U.
IAVI and Therion Form Collaboration to Advance Preventative Vaccines for AIDS: Program Aimed at Fighting AIDS in Developing Countries: PRNewswire - March 20, 2001; NEW YORK and CAMBRIDGE, Mass., March 20 /PRNewswire/ -- In continuing efforts to curb the global spread of AIDS, The International AIDS Vaccine Initiative (IAVI) and Therion Biologics will collaborate as new partners to develop prophylactic AIDS vaccines for developing countries, specifically India . The uniq
AnorMED initiates new clinical study with AMD-3100: Investigating the role of AMD-3100 in the mobilization of white blood cells: PRNewswire - March 19, 2001; VANCOUVER, March 19 /PRNewswire/ - AnorMED announced today that it has initiated a new Phase I clinical trial in healthy volunteers to study the white blood cell count increasing effects of AMD-3100, an inhibitor of the CXCR4 chemokine receptor. White blood cells are an important component of the circulatory system and
Invirion, Inc. Announces Allowance of Patent Claims for the Use of LIF For The Prevention of HIV/AIDS: PRNewswire - March 14, 2001; CHICAGO, March 14 /PRNewswire/ -- Invirion Corporation announced today that its founder, Bruce K. Patterson, M.D., has received approval from the United States Trade and Patent Office for a patent on a gene which affects production of LIF, a protein that occurs naturally in the human body and dramatically inhibits repl
VaxGen to Present Perspective on AIDS Vaccine Development: PRNewswire - March 14, 2001; BRISBANE, Calif., March 14 /PRNewswire/ -- VaxGen , Inc. announced today that it will hold the second in a series of presentations next week about the development of its HIV/AIDS vaccine, AIDSVAX. The presentation, titled The Varied Path of Vaccine Development, will explain the significance of the scientific hurdles AI
MediChem Life Sciences Delivers Antiviral Agent to Achillion Pharmaceuticals For Phase I Studies: Strategic Drug Development Team Performs Method Development and cGMP Synthesis Of Hepatitis B Virus (HBV) and Human Immunodeficiency Virus (HIV) Agent: PRNewswire - March 14, 2001; CHICAGO, March 14 /PRNewswire/ -- MediChem Life Sciences, a Chicago-based drug discovery technology and services company, announced today that the scientists at its Lemont Development Center successfully delivered kilogram quantities of ACH-126,443 to Achillion Pharmaceuticals, a New Haven, Connecticut-based biopharmac
Bristol-Myers Squibb Announces Accelerated Program to Fight HIV/AIDS in Africa: PRNewswire - March 14, 2001; Highlights of Company s Four-Point Program: - AIDS Drugs Below Cost - Transparent Pricing for AIDS Drugs in Africa - $115 Million in `Secure the Future Philanthropy - Emergency Patent Relief NEW YORK, March 14 /PRNewswire/ -- Bristol-Myers Squibb (NYSE: BMY) today announced new initiatives to help fight the HIV/AIDS ep
HIV+ Individuals Having Problems Adhering to Drug Regimens -- Patients' AIDS Battle Fatigue Shown 20 Years After the Start of the Epidemic: PRNewswire - March 14, 2001; RESEARCH TRIANGLE PARK, N.C., March 14 /PRNewswire/ -- Twenty years after the start of the epidemic, patients AIDS Battle Fatigue is visible, with HIV+ individuals finding it difficult to comply with their drug regimens and looking to take fewer and better drugs, according to data from a survey conducted by Savitz Rese
Hollis-Eden Files Investigational New Drug Application For Immune Regulating Hormone HE2200: PRNewswire - March 13, 2001; SAN DIEGO, March 13 /PRNewswire/ -- Hollis-Eden Pharmaceuticals, Inc. today announced it has submitted an investigational new drug application (IND) with the United States Food and Drug Administration ( FDA ) to begin human clinical trials with HE2200, an immune regulating hormone drug candidate. HE2200 has been shown
The Immune Response Corporation Scientists Report Preliminary Results Of Structured Treatment Interruption Study in HIV-Positive Individuals: REMUNE(TM) Used to Treat Patients With Chronic HIV-1 Infection During Interruptions of Antiretroviral Drug Therapy: PRNewswire - March 13, 2001; CARLSBAD, Calif., March 13 /PRNewswire/ -- The Immune Response Corporation announced today preliminary data from an open-label study that suggest treatment with REMUNE(TM) (HIV-1 Immunogen) in addition to HAART (Highly Active Antiretroviral Therapy) may help HIV positive individuals maintain control of the AIDS virus d
The BLA for the Chiron Procleix(TM) HIV-1/HCV Assay Accepted for Review By the FDA: PRNewswire - March 12, 2001; EMERYVILLE, Calif., and SAN DIEGO, March 12 /PRNewswire/ -- Chiron Corporation and Gen-Probe Incorporated announced today that the Biologics License Application (BLA) for the Chiron Procleix(TM) HIV-1/HCV Assay for human immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV) has been accepted for review by t
UCSF HIV/AIDS Expert and International Women's Health Leader Insist HIV/AIDS Prevention Efforts Address Gender Inequity: PRNewswire - March 8, 2001; SAN FRANCISCO, March 8 /PRNewswire/ -- An international call to action asserting that HIV/AIDS prevention programs must include economic and educational initiatives for women is being issued by Nancy Padian, PhD, director of International Programs at UCSF s AIDS Research Institute and Geeta Rao Gupta, PhD, President of
New National Survey of Parents and Kids: Bullying, Discrimination and Sexual Pressures 'Big Problems' for Today's Tweens and Younger Kids: Parents Often Wait For Their Kids to Raise Tough Issues: PRNewswire - March 8, 2001; Nickelodeon Launches Public Information Partnership with Kaiser Family Foundation and Children Now to Get Kids and Parents Talking Together NEW YORK, March 8 /PRNewswire/ -- Large numbers of 8-11 year olds say teasing and bullying (74%), discrimination and disrespect (43%), and threats of violence (38%) occur at their
NIDA/NIAID Study Confirms Gender Differences In Progression From HIV to AIDS; Despite Differences in 'Viral Load,' Men and Women Develop AIDS at the Same Rate: PRNewswire - March 7, 2001; WASHINGTON, March 7 /PRNewswire/ -- During the first years of HIV infection, women have significantly lower amounts of the virus in their blood than do men, according to one of the largest studies ever to examine gender- specific differences of HIV infection. Despite their lower initial viral levels, women suffer the l
FDA Approves Investigational Device Exemption For Trinity Biotech's Uni-Gold(TM) HIV Test: PRNewswire - March 7, 2001; DUBLIN, Ireland , March 7 /PRNewswire/ -- Trinity Biotech plc (Nasdaq: TRIB) today announced that the U.S. Food & Drug Administration s Centre for Biologics Evaluation and Research (CBER) has granted an Investigational Device Exemption (IDE), for treatment use, for Trinity s Uni-Gold(TM) HIV Test.
Trials of First AIDS Vaccine Candidate Designed For Africa Officially Begin in Nairobi: PRNewswire - March 6, 2001; NEW YORK, March 6 /PRNewswire/ -- The first AIDS vaccine candidate designed specifically for Africa officially entered human trials in Nairobi today when Dr. Pamela Mandela Idenya of the Kenyatta National Hospital became one of the first volunteers to be inoculated in the Phase I trial. The preventive vaccine candidate
amfAR Awards Over $1 Million in Grants to Identify Viral and Cellular Targets For New AIDS Drugs: New Methods of Attacking HIV Are Sought: PRNewswire - March 6, 2001; NEW YORK, March 6 /PRNewswire/ -- The American Foundation for AIDS Research (amfAR) today announced basic research grant awards totaling $1,168,431 for 13 projects to identify potential cellular and viral targets for the development of novel anti-HIV drugs. The newly funded projects will examine genes and gene products
Statement by Craig E. Thompson, Executive Director of AIDS Project Los Angeles: Desperation Drives Dirty Politics, Proposition A Supporters Misrepresent AIDS Project Los Angeles Position in Effort to Sway Voters: PRNewswire - March 4, 2001; An Unrelated and Outdated APLA Letter Distributed by Supporters Of Proposition A to West Hollywood Residents Compares Apples to Oranges - The Distribution of This Letter is Just Dirty Politics! LOS ANGELES, March 4 /PRNewswire/ -- AIDS Project Los Angeles (APLA) has always opposed and continues to oppose Proposition A.
A Hair-Raising Question: Can Hair Loss Signal an Underlying Internal Disease?: PRNewswire - March 2, 2001; WASHINGTON, March 2 /PRNewswire/ -- Unexpected hair loss at any age can be devastating. Society places a high value on personal appearance, and hair is one of a person s most visible features. But while some people may initially view hair loss as a cosmetic problem, it could be a sign of a serious medical condition.
African-American Leaders and Providers Attend Historic Summit to Replicate Solutions to HIV/AIDS Epidemic: PRNewswire - March 2, 2001; ST. PETERSBURG, Fla., March 2 /PRNewswire/ -- African-American government leaders, health care practitioners, community service providers and leaders from the faith-based community were given a rare opportunity to exchange best practices to combat the HIV/AIDS epidemic at a summit held March 1-3, in St. Petersburg, Fla
Ventana Medical Systems Launches Menu of RNA and DNA Tests for Breast Cancer And Hard-To-Determine Viral Conditions: BenchMark(TM) Automated ISH Offers 'Seeing is Believing' Advantage Over Non-Tissue Based Tests: PRNewswire - February 28, 2001; TUCSON, Ariz., Feb. 28 /PRNewswire/ -- Ventana Medical Systems, Inc. a leading supplier of automated instrument reagent systems to histology and drug discovery labs worldwide, today announced the launch of a portfolio of in-situ hybridization (ISH) tests used to detect cancer and viruses with greater speed than is curr
New Grant to IPPF/WHR for Adolescent Reproductive Health: PRNewswire - February 28, 2001; NEW YORK, Feb. 28 /PRNewswire/ -- The William and Flora Hewlett Foundation recently approved a grant of $600,000 to IPPF/WHR for providing sexual and reproductive health services to adolescents in Brazil , Ecuador and
Name Based HIV Reporting in Pennsylvania: PRNewswire - February 28, 2001; PHILADELPHIA, Feb. 28 /PRNewswire/ -- The Board of Directors of The Philadelphia AIDS Consortium (TPAC), the Title II Ryan White Planning Council and Coalition for southeastern Pennsylvania, released its position on Names Reporting for persons living with HIV/AIDS. The Board took its action the evening before State Hea
FDA Advisory Committee Recommends Approval of Valganciclovir HCl For Treatment of AIDS-Related CMV Retinitis: PRNewswire - February 27, 2001; GAITHERSBURG, Md., Feb. 27 /PRNewswire/ -- Roche announced that the U.S. Food and Drug Administration ( FDA ) Anti-Viral Drugs Advisory Committee (AVAC) today unanimously recommended the use of valganciclovir HCl for maintenance therapy and issued a 12-1 recommendation for induction therapy for the treatment of
New Poll Reveals Americans' Concerns About Living With Chronic Conditions And Desire for Elected Officials to Take Action to Improve Care: Groundbreaking Partnership Launched to Explore Solutions: PRNewswire - February 26, 2001; WASHINGTON, Feb. 26 /PRNewswire/ -- An overwhelming majority of Americans worry that the 125 million people living with chronic conditions in the United States are often not getting the care they need and are calling on Washington to take action, according to a Harris Interactive survey released today at the launch of
PowderJect and GlaxoSmithKline Initiate DNA Vaccine Clinical Study In Field of Hepatitis B Immunotherapy: Clinical Study Supports Second Development Program in Strategic Alliance: PRNewswire - February 23, 2001; OXFORD, England and MADISON, Wis., Feb. 23 /PRNewswire/ -- PowderJect Pharmaceuticals Plc and its wholly owned subsidiary, PowderJect Vaccines Inc, today announced the initiation of a clinical trial designed to support the development of a DNA immunotherapeutic to treat hepatitis B. The study is sponsored by
Statement From AIDS Project Los Angeles Executive Director Craig Thompson on Proposition A: PRNewswire - February 22, 2001; The following is being issued by AIDS Project Los Angeles Executive Director, Craig Thompson, on Proposition A: LOS ANGELES, Feb. 22 /PRNewswire/ -- Why are we here? Frankly, why is Proposition A on the ballot. For we all share the same goal -- to promote safer sex and decrease HIV transmission. As a gay man living wit
Serono Initiates Clinical Trial of Serostim(R) For AIDS-Related Metabolic Complication: Study to Identify Potential Benefits of Recombinant Human Growth Hormone For HIV-Associated Adipose Redistribution Syndrome (HARS): PRNewswire - February 20, 2001; NORWELL, Mass., and GENEVA, Feb. 20 /PRNewswire/ -- Serono, Inc. today announced the initiation of the Serostim(R) for Treatment of Adipose Redistribution Syndrome (STARS) study. This double blind, placebo-controlled study will evaluate Serostim(R) [somatropin (rDNA origin) for injection], a recombinant human growth ho
Maxygen and the International AIDS Vaccine Initiative Enter Agreement To Develop Novel Vaccines Against HIV: PRNewswire - February 20, 2001; REDWOOD CITY, Calif. and NEW YORK, Feb. 20 /PRNewswire/ -- Maxygen, Inc. (Nasdaq: MAXY), the International AIDS Vaccine Initiative (IAVI) and DBLV, LLC, an entity established and funded by the Rockefeller Foundation, today announced the formation of a three-year collaboration to develop novel HIV vaccines using Maxygen
Love American Style: Early and Often: The 2001 Durex Global Sex Survey -- U.S. Report Reveals Sex at an Earlier Age, Increased Frequency, Higher Risks and Other Truths About Sexual Behavior Around the Nation: PRNewswire - February 14, 2001; ATLANTA, Feb. 14 /PRNewswire/ -- According to results released today from the 5th annual Durex(R) Global Sex Survey - U.S. Report, Americans are having more sex and at an earlier age than any other country. Of the U.S. teens surveyed, ages 16-20, more than half (54%) admitted to having had unprotected sex with a new pa
HIV, HBV/HCV, & Flu Highlights of Antiviral Drug Discovery Conference, March 28-29, Princeton, NJ: PRNewswire - February 13, 2001; PRINCETON, N.J., Feb. 13 /PRNewswire/ -- The 2nd International Antiviral Drug Discovery & Development Summit will feature papers on CCR5, non-nucleoside reverse transcriptase inhibitors, anti-HIV fusion inhibitors, second generation HIV protease inhibitors , and new HIV drug resistance data on March 28-29, in Princ
The M.A.C. AIDS Fund Announces Record-Breaking Success of the VIVA GLAM Initiative and Unveil New Ad Campaign With Music Superstars Mary J. Blige and Lil' Kim: In Just Six Short Years, the M.A.C AIDS Fund Has Raised $19 Million Globally to Help People Living with HIV and AIDS: PRNewswire - February 12, 2001; NEW YORK, Feb. 12 /PRNewswire/ -- International superstars Mary J. Blige and Lil Kim known for success on the music charts have broken a new record by helping the M.A.C AIDS Fund raise $4 million for people affected by HIV and AIDS in just 12 months, pushing the total raised by the Fund since its inception to almost $2
Ponoi and AIDS Action Announce Privacy Partnership: AIDS Action Gives Users Active Privacy Tool: PRNewswire - February 12, 2001; NEW YORK, Feb. 12 /PRNewswire/ -- Finally, individuals seeking information about HIV and AIDS online do not have to fear privacy invasion. Providing a new level of privacy and security on the Internet, Ponoi Corp., a privacy solution provider, announced today an alliance with HIV/AIDS advocacy group, AIDS Action, to gi
National Black HIV/AIDS Awareness and Information Day Slated for Feb 23, 2001: Black History Month Events Will Mobilize African American Communities Nationally in the Fight Against HIV/AIDS: PRNewswire - February 12, 2001; ATLANTA, Feb. 12 /PRNewswire/ -- The Community Capacity Building Coalition (CCBC) today announced the establishment of National Black HIV/AIDS Awareness and Information Day on February 23, 2001. The CCBC is sponsoring this activity that focuses on the current HIV/AIDS among African Americans. Local organizations in con
AbsoluteCare - 'The Future of HIV Care' Grows to Over 200 Patients In Two Months in Atlanta: PRNewswire - February 9, 2001; ATLANTA, Feb. 9 /PRNewswire/ -- Avesis Incorporated announced that its wholly-owned subsidiary, AbsoluteCare, Inc., which represents a new approach to HIV/Wellness care, has seen its patient base grow to 225 patients in two months. Its first medical center opened in Atlanta, Georgia (the first HIV Medical center to ope
VaxGen AIDS Vaccine Induces Broad Array of Antibodies: Study Shows Binding to Variety of HIV Subtypes; Experimental Adjuvant Boosts Immune Response: PRNewswire - February 9, 2001; CHICAGO, Feb. 9 /PRNewswire/ -- A new study presented here this week indicates the AIDS vaccines under development by VaxGen , Inc. (Nasdaq: VXGN) induce antibodies that bind to a broader variety of HIV subtypes than originally expected. Additionally, a second study indicates that a development-stage adjuvant led to a
Clinical Study Shows VirtualPhenotype(TM) is Superior to Genotyping: First Clinical Study Demonstrates That VirtualPhenotype(TM) is a Reliable, Independent Predictor of Clinical Outcome: PRNewswire - February 8, 2001; CHICAGO, Feb. 8 /PRNewswire/ -- Results presented today at the 8th Conference on Retroviruses and Opportunistic Infections demonstrate, for the first time, the superiority of the VirtualPhenotype(TM) over conventional genotyping tests. The results showed that this unique resistance test developed by Virco can reliably
Study Examines Lipoprotein Profile of Patients Taking VIRAMUNE-Based Antiretroviral Treatment Combination: PRNewswire - February 8, 2001; CHICAGO, Feb. 8 /PRNewswire/ -- Preliminary findings from the metabolic and lipodystrophy sub-study of the Atlantic trial indicate that patients who took an anti-HIV treatment regimen containing VIRAMUNE(R) ( nevirapine ), ddI and d4T , were observed to have an improved lipoprotein profi
AIDS Project Los Angeles Executive Director Craig E. Thompson Statement On President George W. Bush and the Office of National AIDS Policy: PRNewswire - February 7, 2001; LOS ANGELES, Feb. 7 /PRNewswire/ -- The Bush Administration took a step in the right direction today in the fight against HIV and AIDS by retaining the Office of National AIDS Policy (ONAP). This first step of retaining the Office is important. The next step, however, is crucial. To assure an effective response to this
Abbott Laboratories' Kaletra(TM) (Lopinavir/Ritonavir) Continues To Demonstrate Viral Suppression and Tolerability In HIV-Positive Children At 48 Weeks Of Therapy: PRNewswire - February 7, 2001; ABBOTT PARK, Ill., Feb. 7 /PRNewswire/ -- Data presented at a scientific meeting in Chicago show that at 48 weeks of treatment, Abbott Laboratories (NYSE: ABT) protease inhibitor (PI), Kaletra (TM) ( lopinavir / ritonavir ) (pronounced kuh-LEE-tra),
First Protease Inhibitor-Switch Study in HIV-Positive Children Suggests Switching to Sustiva(TM) Maintains Viral Load Suppression in HIV-Positive Patients: PRNewswire - February 7, 2001; CHICAGO, Feb. 7 /PRNewswire/ -- Preliminary data suggest that switching heavily pretreated children from a protease inhibitor (PI)-containing regimen to a combination regimen including DuPont Pharmaceuticals anti-HIV drug Sustiva (TM) ( efavirenz ) is safe and well-tolerated.
White House Office of AIDS Policy Needed Now More Than Ever: National Minority AIDS Council Applauds Bush Administration For Keeping White House Office of National AIDS Policy And Office on the President's Initiative for One America: PRNewswire - February 7, 2001; WASHINGTON, Feb. 7 /PRNewswire/ -- Today, the National Minority AIDS Council (NMAC) applauded the Bush Administration s decision to maintain the White House Office of National AIDS Policy (ONAP) and the Office on the President s Initiative for One America. NMAC stressed the importance of keeping this office as independ
Pilot Clinical Study Showed Crixivan(R) Combined with Ritonavir Once-Daily Produced Anti-Viral Response in Treatment-Naive Patients: PRNewswire - February 7, 2001; CHICAGO, Feb. 7 /PRNewswire/ -- Preliminary results from an open label study with Crixivan (R) ( indinavir sulfate) 1200 mg and ritonavir 200 mg dosed once-daily in treatment-naive patients showed viral suppression and increased CD4 c
Progenics to Develop New AIDS Drug to Inhibit Viral Entry and Infection; Lead Candidate Selected: In preclinical studies with another 'entry inhibitor,' HIV showed no signs of drug resistance: PRNewswire - February 7, 2001; CHICAGO, Feb. 7 /PRNewswire/ --Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today reported that it had selected for development a lead therapeutic drug candidate from a novel class of anti-HIV compounds known as sulfated CCR5 peptides. In laboratory experiments, sulfated CCR5 peptides blocked HIV (human immunodeficie
Encouraging 48-Week Protease Inhibitor Resistance Data Presented for Abbott Laboratories' Kaletra(TM) (Lopinavir/Ritonavir) in Patients Without Previous HIV Therapy: Additional Data in Protease-Inhibitor Experienced Patients Show That Despite Resistance to Lopinavir, HIV Susceptibility to Some Other Protease Inhibitors May Remain Intact: PRNewswire - February 7, 2001; ABBOTT PARK, Ill., Feb. 7 /PRNewswire/ -- Data presented at a scientific meeting in Chicago from a 48-week study of patients new to HIV therapy showed that of those who experienced viral rebound (HIV RNA >400 copies/mL), no patient (0/31) treated with a Kaletra-based regimen was found to have protease inhibitor-resista
Vertex Pharmaceuticals Reports Preliminary Data from Phase II Clinical Study of VX-175: PRNewswire - February 6, 2001; CHICAGO, Feb. 6 /PRNewswire/ -- Preliminary results from a 28-day Phase II clinical study of VX-175, a prodrug of the HIV protease inhibitor amprenavir , were presented today at a scientific meeting in Chicago. VX-175 is now being investigated in Phase III clinical trials, where the drug is being dosed as three pills,
Data Suggest Delay in Initiation of Antiretroviral Treatment Negatively Impacts Time to Virologic Failure: PRNewswire - February 6, 2001; CHICAGO, Feb. 6 /PRNewswire/ -- Data presented today at a major medical meeting in Chicago suggest that treatment should be initiated in naive HIV positive patients before their CD4 cell counts drop to below 200 cells/mm(3). Patients who initiated therapy when their CD4 cell count was less than 200 cells/mm(3) did not
VIDEX EC(R) (Didanosine) Demonstrates Improved Safety, Tolerability and Comparable Efficacy in 48 Week Study: PRNewswire - February 6, 2001; CHICAGO, Feb. 6 /PRNewswire/ -- Results from a 48-week study demonstrate that VIDEX EC (didanosine) capsules had similar efficacy and virologic response compared to VIDEX tablets. Improved safety and tolerability were also seen in patients taking the VIDEX EC treatment regimen. These results were presented today at the
Triangle Pharmaceuticals Reports on Laboratory And Pharmacokinetic Studies of DAPD: PRNewswire - February 6, 2001; DURHAM, N.C., Feb. 6 /PRNewswire/ -- Triangle Pharmaceuticals, Inc. (Nasdaq: VIRS) today announced that it will present two separate studies relating to DAPD. DAPD is a novel dioxolane guanosine reverse transcriptase inhibitor that is in Phase I/II development by Triangle for the treatment of HIV. We are encouraged to
New Data Highlight Potency and Tolerability of a Once-Daily Anti-HIV Combination Regimen With Sustiva(TM)+FTC +ddI: Additional Data Show Once-Daily Regimens Improve Complicated Treatment Schedules, Maintain Virologic Response: PRNewswire - February 6, 2001; CHICAGO, Feb. 6 /PRNewswire/ -- Data presented today at a major medical meeting in Chicago suggest that the once-daily protease inhibitor-sparing regimen of DuPont Pharmaceuticals Sustiva (TM) ( efavirenz ) combined with the investigational drug emtricitabine (FTC) and didanosine (ddI) has a pot
Community Colleges Lead Higher Ed Effort to Combat HIV: PRNewswire - February 6, 2001; WASHINGTON, Feb. 6 /PRNewswire/ -- Amid clear evidence that ignorance can be the biggest killer of all, educators and health experts are partnering to intensify efforts toward HIV awareness, prevention and treatment on the nation s campuses and in the communities they serve. In its second five-year cooperative agreemen
Chronimed Announces Acquisition of APP Pharmacy Retail Stores; Acquisition Strengthens StatScript Retail Position in HIV and Transplant Markets: PRNewswire - February 5, 2001; MINNEAPOLIS, Feb. 5 /PRNewswire/ -- Chronimed Inc. (Nasdaq: CHMD) announced today that it has acquired the retail pharmacies of American Prescription Providers, Inc. ( APP ). The four pharmacies, which are located in New York City, Miami Beach, Atlanta, and Philadelphia, will be renamed and integrated into Chronimed s
HIV Resistance Survey Shows Majority of Physicians Choose Single Protease Inhibitor as First-Line Combination Therapy: VIRACEPT(R) Most Frequently Selected Protease Inhibitor: PRNewswire - February 5, 2001; CHICAGO, Feb. 5 /PRNewswire/ -- In a new survey assessing physicians experience with HIV resistance, 71% of physicians who initiate therapy with a protease inhibitor (PI) chose a single PI over a dual PI, reserving use of dual PIs for future therapy. Among those choosing a single PI, 63% selected
Data on DuPont Pharmaceuticals' Second-Generation Protease Inhibitors Show In-Vitro Potency Against HIV Virus Resistant to Other PIs: PRNewswire - February 5, 2001; CHICAGO, Feb. 5 /PRNewswire/ -- At a scientific conference here today, DuPont Pharmaceuticals presented data from pre-clinical studies on two second- generation protease inhibitors (PIs) to treat HIV. The data show the two PIs are potent, selective inhibitors of wild type HIV-1 and resistant viral variants common among
Once-A-Day Coviracil(R) (Emtricitabine, FTC) Shows Promise in HIV-Infected Patients: PRNewswire - February 5, 2001; DURHAM, N.C., Feb. 5 /PRNewswire/ -- Triangle Pharmaceuticals, Inc. (Nasdaq: VIRS) announced that it is presenting data today from two Phase III, 48-week trials which included over 900 patients comparing once-daily Coviracil(R) (emtricitabine, FTC) to twice- daily lamivudine ( 3TC ) in HIV-infected pa
AcroMetrix Enters Into Hepatitis C and HIV Licensing Agreement With Chiron: PRNewswire - February 1, 2001; BERKELEY, Calif., Feb. 1 /PRNewswire/ -- AcroMetrix announced today that it has signed an agreement with Chiron Corporation under which Chiron has licensed to AcroMetrix its hepatitis C (HCV) and HIV patent rights for use in nucleic acid diagnostics. The worldwide, semi-exclusive license, which includes blood screening
Regulatory Approval Granted In Argentina for Visible Genetics' TRUGENE HIV-1 Genotyping Kit: PRNewswire - February 1, 2001; TORONTO, Feb. 1 /PRNewswire/ -- Visible Genetics Inc. (VGI) (Nasdaq: VGIN) reported today that it has been granted regulatory approval in Argentina for its TRUGENE(TM) HIV-1 Genotyping Kit and OpenGene(TM) automated DNA sequencing system by the Administacion Nacional de Medicamentos, Alimentos Y Tecnologia. Visible Gen
Biochem Pharma Issued US Patent Covering Lamivudine use in Combination Therapy: PRNewswire - January 31, 2001; LAVAL (Quebec), Jan. 31 /PRNewswire/ - BioChem Pharma Inc. announced today that it was issued a U.S. patent on lamivudine in combination with other antiviral agents, expiring in 2018. U.S. Patent No. 6,180,639 covers pharmaceutical compositions comprising lamivudine in combination with other antiviral agents, as well a
VaxGen to Hold Talks on AIDS Vaccine Development: PRNewswire - January 30, 2001; BRISBANE, Calif., Jan. 30 /PRNewswire/ -- VaxGen Inc. (Nasdaq: VXGN) today announced a series of presentations beginning this Thursday to provide a detailed understanding of how the company is developing HIV/AIDS vaccines. The presentations will take place via conference calls and web casts every four to six weeks thro
FDA Grants Marketing Clearance for Cancidas(R), A New Antifungal Medicine from Merck: PRNewswire - January 29, 2001; WEST POINT, Pa., Jan. 29 /PRNewswire/ -- Merck & Co. , Inc. (NYSE: MRK) announced today that the Food and Drug Administration has approved Cancidas(R) (caspofungin acetate) as the first in a new class of antifungals, called echinocandins or glucan synthesis inhibitors, introduced in more than a decade. This new me
VaxGen Awarded NIH Grant for Subtype C HIV Vaccine Development: Funding Advances Company's Goal of Developing Worldwide AIDS Vaccine: PRNewswire - January 29, 2001; BRISBANE, Calif., Jan. 29 /PRNewswire/ -- VaxGen , Inc. (Nasdaq: VXGN) today announced that it has been awarded a grant from the National Institutes of Health for the development of subtype C HIV vaccines. Subtype C is the most common type of HIV found in Africa, India and
Chiron HIV Patent Upheld in Europe: PRNewswire - January 28, 2001; EMERYVILLE, Calif., Jan. 28 /PRNewswire/ -- Chiron Corporation (Nasdaq: CHIR) announced today that the European Patent Office (EPO) Board of Technical Appeals upheld the validity of Chiron s European HIV Patent No. 0 181 150 (the 150 patent ). This brings to an end third-party challenges to the 150 patent in the EPO.
Yahoo! Pledges US$5 Million to Support AIDS Vaccine Development: Global Internet Leader Yahoo! is the First Major Corporate Supporter Of the International AIDS Vaccine Initiative (IAVI): PRNewswire - January 27, 2001; DAVOS, Switzerland and SANTA CLARA, Calif., Jan. 27 /PRNewswire/ -- Yahoo! Inc. (Nasdaq: YHOO), a global Internet commerce, communications and media company, today pledged US$5 million to support the International AIDS Vaccine Initiative s (IAVI) effort to mobilize global support for the organization and accelerate the
Bill & Melinda Gates Foundation Pledges US$100 Million Toward $550 Million AIDS Vaccine Goal: Seeking to Spur Global Effort to Develop and Deliver Preventive Vaccine, Donor Issues Challenge Grant to International AIDS Vaccine Initiative (IAVI): PRNewswire - January 27, 2001; DAVOS, Switzerland , Jan. 27 /PRNewswire/ -- The Bill & Melinda Gates Foundation has issued a US$100 million challenge grant to the International AIDS Vaccine Initiative (IAVI) in a bid to mobilize global support for the organization and its work to accelerate the development and delivery of a preventive AIDS vacci
Trials of First AIDS Vaccine Candidate Designed for Africa to Begin: PRNewswire - January 27, 2001; NAIROBI, Kenya , Jan. 27 /PRNewswire/ -- The first AIDS vaccine candidate designed specifically for Africa will enter clinical trials in Nairobi following an endorsement from the Government of Kenya. The trial was approved by Kenya s National Council on Science and Technology last month after being cleared by Kenyatta
Hearing AIDS in Africa; International Communications in the Presence of an Emerging Catastrophe: PRNewswire - January 25, 2001; WASHINGTON, Jan. 25 /PRNewswire/ -- The International Committee of PRSA s National Capital Chapter is pleased to present the upcoming professional seminar entitled, Hearing AIDS: International Communications in the Presence of an Emerging Catastrophe. The program will take place at the National Press Club on Wednesday,
Los Angeles County Health Department to Begin Innovative HIV Drug Resistance Testing: Public/Private Partnership Will Provide Genotypic Testing With Visible Genetics' TRUGENE(TM) HIV-1 Genotyping Technology Under Vigilance II Study: PRNewswire - January 23, 2001; TORONTO, Jan. 23 /PRNewswire/ -- Visible Genetics Inc. (VGI, Nasdaq: VGIN) reported today that the Los Angeles County Department of Health Services (DHS) will begin providing state-of-the-art genotypic testing for low-income County residents infected with HIV through a unique public-private collaboration with Visible G
Chiron Grants Organon Teknika License to HIV Assay Patents: PRNewswire - Thursday January 18, 2001; EMERYVILLE, Calif., and BOXTEL, the Netherlands , Jan. 18 /PRNewswire/ -- Chiron Corporation (Nasdaq: CHIR - news) and Organon Teknika BV, a subsidiary of Akzo Nobel NV, announced today that they have entered into a license agreement. Chiron has granted Organon Teknika a worldwide, semi-exclusive license under the comp
Syphilis Festers in Gay Community, States AIDS Project Los Angeles: Los Angeles County Health Officials, AIDS Service Providers And Other Community Health Partners Convene For Anatomy of a Syphilis Outbreak Response - Part Two: PRNewswire - January 17, 2001; LOS ANGELES, Jan. 17 /PRNewswire/ -- Syphilis, thought to be a disease of the past, is continuing to spread among gay men in Los Angeles County. On Thursday, January 18, 2001, almost a year to the day of the outbreak, Health officials in Los Angeles will provide data obtained during Anatomy of a Syphilis Outbreak Respo
Scientists Report Breakthrough in Developing Vaccines To Treat Chronic Infection and Cancer: Epimmune and Scripps Researchers Discover How to Overcome Problem of Immune System Tolerance to Chronic Hepatitis B Virus in Animal Model: PRNewswire - January 17, 2001; SAN DIEGO, Jan. 17 /PRNewswire/ -- Scientists at Epimmune Inc. (Nasdaq: EPMN) and at The Scripps Research Institute, La Jolla, reported today in the Journal of Immunology that a new epitope-based vaccine approach can overcome the problem of immune tolerance to chronic hepatitis B virus in an animal model. Immune tolera
Genzyme Molecular Oncology Announces HIV Antigen Discovery Collaboration with Dr. Bruce Walker of Massachusetts General Hospital: PRNewswire - Wednesday January 10, 2001; FRAMINGHAM, Mass., Jan. 10 /PRNewswire/ --Genzyme Molecular Oncology (Nasdaq: GZMO - news) today announced it has entered into an HIV antigen discovery and research collaboration with Bruce Walker, M.D., director of the Partners AIDS Research Center at Massachusetts General Hospital. Dr. Walker is a highly regarded lea
Quest Diagnostics to Offer Virco's VirtualPhenotype(TM) Test To Predict Resistance to HIV Therapy: PRNewswire - Tuesday January 9, 2000; BALTIMORE, and TETERBORO, N.J., Jan. 9 /PRNewswire/ -- Virco, an international biotechnology group and pioneer in HIV pharmacogenomics and Quest Diagnostics Incorporated (NYSE: DGX - news), the leading provider of diagnostic laboratory testing, information and services in the United States , today announced an agree
Progenics Reports Publication of Encouraging Antiviral Studies of Novel HIV Therapy PRO 140: PRnewswire - Tuesday January 9, 2000; TARRYTOWN, N.Y., Jan. 9 /PRNewswire/ -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX - news) today announced the publication of a scientific article describing PRO 140, a novel inhibitor of HIV entry, which demonstrates broad and potent antiviral activity in preclinical models of HIV infection. PRO 140 is a monoclonal
Dallas Community Health Initiative Wins Monroe E. Trout Premier Cares Award: PRNewswire - Tuesday January 9, 2000; SAN DIEGO, Jan. 9 /PRNewswire/ -- Presbyterian Healthcare System s Vickery Meadow Healthy Community Initiative has won the Ninth Annual Monroe E. Trout Premier Cares Award for its efforts to improve the health of people living in a troubled neighborhood of Dallas, Texas. The Premier Cares Award recognizes exemplary eff
Antiviral Drug Discovery & Development Summit to Focus on Anti-HIV, HBV/HCV, And Influenza on March 28-29, 2001 in Princeton, New Jersey: PRNewswire - Monday January 8, 2001; PRINCETON, N.J., Jan. 8 /PRNewswire/ -- New pre-clinical and clinical data on compounds to target viral diseases will be the focus of the ``2nd International Antiviral Drug Discovery & Development Summit in Princeton, NJ, on March 28-29, 2001, announces Strategic Research Institute. The industry-oriented conference
BioChem Pharma Inc. - Trizivir approved in the European Union: PRNewswire - January 4, 2000; LAVAL (Quebec) Canada , Jan. 4 /PRNewswire/ - BioChem Pharma Inc. (NASDAQ: BCHE; TSE: BCH) announced today that its partner, GlaxoSmithKline plc, has received approval from the European Commission to market Trizivir , the new triple combination tablet, for the treatment of HIV-infected a

This information is designed to support, not replace, the relationship that exists between you and your doctor.
©1980, 2001. AEGiS.